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Abstract 
Drug induced liver injury is a major problem for the pharmaceutical industry and 
health services.  Yet 30-40 % of human hepatotoxins go undetected during in vitro 
studies.  Hence, more predictive in vitro liver models are a critical requirement for 
preclinical screening of compounds demonstrating hepatotoxic liability.  3D liver 
spheroids show promise as a novel model to investigate drug-induced liver injury 
with preliminary studies indicating the ability of spheroids to detect hepatotoxins as 
well as displaying an enhanced functional lifespan compared to 2D monocultures.   
The aim of this thesis was to develop an improved in vitro model to investigate drug-
induced liver injury.  A viable C3A spheroid model with a lifespan of 32 days was 
successfully optimised.  A characterisation of the spheroid model was performed, 
revealing direct cell-cell contacts, 3D morphology and cellular polarisation, hence 
recapitulating corresponding features of human liver tissue.  Subsequently, liver-
specific functions were investigated in the C3A spheroids and were found to display 
zonation, functional transporters, CYP enzyme activity, albumin production, urea 
synthesis and functional mitochondria.  After validating the biology of the model, the 
ability of the spheroids to detect hepatotoxins was examined.  The C3A spheroid 
model correctly identified 66.6 % of hepatotoxins to have a risk of liver injury, a 
higher predictive value than a 2D model. 
As hepatocytes only represent 60 % of the cells in the liver it was predicted that 
including non-parenchymal cells in the C3A spheroid model would cause increased 
sensitivity to hepatotoxins.  Indeed when C3A spheroids were co-cultured with 
endothelial cells or immune cells they correctly predicted more compounds to have 
a risk of human hepatotoxicity, improving their predictivity to 91.6 % and 83.3 % 
respectively.   
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It has been established that novel biomarkers of liver injury HMGB1, keratin 18 and 
miR-122 have enhanced sensitivity when compared to current clinical diagnostic 
markers, however they have not been extensively analysed in vitro.  It was 
determined that keratin 18 could be quantified from the C3A spheroid model and 
provides important mechanistic insight into the mechanism of cell injury occurring.   
Mitochondrial damage is implicated in up to 50 % of human hepatotoxins.  It was 
hypothesised that by analysing mitochondrial function in more detail one could 
reveal the mechanism of action by which a compound might be causing toxicity.  
Mitochondrial dysfunction could be successfully analysed in the C3A spheroids, 
which were found to be more sensitive to mitochondrial toxins than 2D cells.  
To conclude; C3A spheroids act as a human-relevant in vitro model with the 
potential to be incorporated into an initial drug safety screen, replacing 2D models 
with poor sensitivity and specificity.  Results suggest that the inclusion of non-
parenchymal cells may be advantageous to liver models.  Furthermore the analysis 
of endpoints including clinical biomarkers and mitochondrial function may improve 
the sensitivity of the drug screen.  
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1.1 Introduction 
Adverse drug reactions (ADR) are a constant major concern for pharmaceutical 
industries, regulatory authorities, as well as the patients themselves.  Type A, dose-
related ADR are common, predictable and caused by the primary pharmacology of 
the drug.  Type B-F reactions are rarer but much more complicated.  Type B ADR 
are less common and unrelated to the therapeutic drug action, making them harder 
to predict and treat.  Chronic ADR, type C, are both time and dose-related, whereas 
type D ADR are mainly time-related with a delayed onset.  Drug reactions can also 
occur after withdrawal of a compound, known as type E reactions.  The final type of 
ADR is type F, where an unexpected failure of therapy is observed, most frequently 
due to interactions with other drugs (Edwards and Aronson 2000).  Drug-induced 
liver injury (DILI) remains a prominent cause of ADR (Olsen and Whalen 2009; 
Russo et al. 2004; Sgro et al. 2002).  Lack of understanding of the mechanisms of 
human DILI could be a reason for this.  Predictive and relevant in vitro models of 
human DILI may help researchers identify the key events and mechanisms initiating 
DILI, along with aiding drug screening. 
This thesis describes the development and analysis of a novel in vitro liver model 
through the use of 3D cell culture techniques as well as investigating the 
toxicological predictivity of the model. 
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1.2 Drug-induced liver injury 
Drug side-effects are a major cause of liver damage, with 52 % of acute liver failure 
cases attributed to DILI (Norris et al. 2008; Ostapowicz et al. 2002).  Exposure to 
hepatotoxic compounds have varying severities, including mild asymptomatic 
changes, symptoms similar to acute or chronic liver diseases, or can result in liver 
failure, usually requiring a liver transplant (Navarro and Senior 2006).  However, 
liver transplants are not a sustainable treatment for liver injury as not only is it a 
complicated procedure but donor tissue is limited.  In addition 20-25 % of patients 
die before a liver becomes available for transplantation (Liou and Larson 2008; 
Norris et al. 2008; Reuben et al. 2010).  
Many therapeutic compounds can cause DILI.  This is often unrelated to the 
therapeutic mechanism of action, hence more complicated to diagnose and treat.  
The mechanism of toxicity of hepatotoxic drugs varies from compound to compound 
and the exact mechanism by which a drug causes injury being often disputed or 
unconfirmed.  Some drugs have been shown to cause toxicity by the formation of a 
reactive metabolite, such as paracetamol (acetaminophen) (James et al. 2003; 
Srivastava et al. 2010).  Cytochrome P450 (CYP) enzymes convert acetaminophen 
to the toxic metabolite, NAPQI (N-acetyl-p-benzoquinone imine), once other 
metabolic pathways are saturated.  NAPQI further depletes the antioxidant 
glutathione in hepatocytes leading to the formation of reactive oxygen species 
(ROS), mitochondrial damage, covalent binding and cytokine release (James et al. 
2003).  All of these mechanisms contribute to hepatocyte injury and liver damage; 
however the complete mechanism is still debated.  Other compounds have been 
suggested to cause DILI by primarily immune mediated mechanisms.  Diclofenac 
has been shown to cause immuno-allergic reactions, including clinical observations 
of hypersensitivity, production of antibodies and liver failure upon re-challenge 
(Boelsterli 2003).  Reactive metabolites, 5-OHdic and N,5-dihydroxydiclofenac, are 
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also produced with this compound, resulting in mitochondrial dysfunction, NADPH 
consumption and oxidative stress (Boelsterli 2003; Bort et al. 1999).  Fialuridine is 
another compound with as yet unconfirmed toxicological mechanisms.  The majority 
of evidence suggests that the damage caused by fialuridine is due to mitochondrial 
toxicity, with substantial research pursuing this investigation into mitochondrial 
damage (Honkoop et al. 1997; McKenzie et al. 1995).  Trovafloxacin is another 
compound which causes idiosyncratic DILI, potentially through immune mediated 
inflammatory stress mechanisms (Beggs et al. 2014; Shaw et al. 2010).  More 
research into elucidating the mechanism by which compounds cause DILI could 
help pharmaceutical companies to design out these liabilities in the future and 
consequently creating safer compounds. 
After initiation of liver injury, the liver attempts to repair damaged tissue. The liver 
has a high regenerative capacity in comparison to other human organs 
(Michalopoulos 2007).  After DILI, an inflammatory response occurs, as immune 
cells infiltrate to remove debris, followed by the regenerative response where the 
hepatocytes proliferate until the original number of cells are present, often within 1-2 
days, with full re-establishment of liver mass within 8- 15 days (Michalopoulos 
2007).  During this period, communication between multiple liver cell types is crucial 
for efficient regeneration. 
DILI is the leading cause for drug attrition during pre-clinical evaluation and the main 
reason for drug withdrawal from the market, which is extremely costly for 
pharmaceutical companies (Bell and Chalasani 2009; Lasser et al. 2002; Watkins 
2005).  Predictive in vitro and in vivo liver models are essential during initial drug 
screening in order to detect ADR early in the drug discovery process.  Nonetheless, 
current models have poor sensitivity to human hepatotoxins, with only 60-70 % of 
hepatotoxins detected in gold standard in vitro models (Gomez-Lechon et al. 2004; 
Xu et al. 2008) and approximately 50 % detected in animal models (Olsen and 
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Whalen 2009).  Hence more predictive liver models are required in order to reduce 
the number of toxic compounds making it into humans. 
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1.4 Human liver physiology and function 
The liver is a vital organ, situated below the diaphragm in the abdominal-pelvis 
region and in humans consists of four lobules, weighing approximately 1.5 kg in total 
(Bacon. B. R. et al. 2006; Cotran 2005).  The liver is connected to the hepatic artery 
carrying blood from the aorta, and the portal vein carrying blood from the 
gastrointestinal tract, spleen and pancreas.  Bile canaliculi collect bile produced from 
the liver which drains via the bile ducts into either the duodenum or the gall bladder 
(Bacon. B. R. et al. 2006).  The portal triad is a group of structures, including the 
hepatic artery, portal vein, bile duct, lymphatic vessels and vagus nerve which sits at 
the edge of the liver lobule.  Each liver lobe is made up of around one million 
lobules, around 1 mm by 2 mm, which are hexagonal in shape with the central vein 
at the core (Figure 1.1).  This arrangement leads to zonation of each lobule; the 
periportal region (zone 1) closest to the vasculature and therefore supplied with 
highly oxygenated blood and nutrients, perivenous region (zone 3) nearest to the 
central vein, with lower oxygen and nutrient supply, and the transitional region (zone 
2) in between the two (Bacon. B. R. et al. 2006; Godoy et al. 2013).  The 
consequence of this is functional zonation, whereby hepatocytes in different zones 
of the lobule express different liver functions.   
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Figure 1.1. Illustration of the liver lobule.  The liver lobule is arranged with the 
central vein in the middle and the portal triad (hepatic artery, portal vein, bile duct, 
lymphatic vessels and vagus nerve) on the periphery.  This leads to zonation of the 
liver acinus (zone 1 closest to the oxygenated blood supply, zone 2 intermediately 
and zone 3 nearest to the central vein). 
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The liver has a multitude of important functions.  Firstly, bile formation is a key 
function of the liver involving the hepatocytes excreting electrolytes and solutes from 
the plasma, then transporting them into the bile canaliculi (Bacon. B. R. et al. 2006).  
Metabolism of compounds is another key liver function.  This includes the 
metabolism of xenobiotics, bilirubin, cholesterol, lipoproteins, ammonia, 
carbohydrate and fatty acids (Bacon. B. R. et al. 2006).   In addition, the liver 
functions to store glycogen and vitamins, produces various hormones and urea and 
albumin synthesis (Bacon. B. R. et al. 2006; Cotran 2005). 
Figure 1.2.  Illustration of the liver sinusoid.  The liver sinusoid is composed of 
multiple cell types and structures.  Hepatocytes make up the majority of cells in the 
sinusoid and produce bile.  Bile canaliculi form between adjacent hepatocytes and take 
waste products into the bile ducts.  Endothelial cells line the blood vessels and possess 
fenestrations to monitor the passage of molecules and cells.  Kupffer cells and infiltrating 
macrophages circulate in the blood stream with the ability to migrate throughout the 
sinusoid.  Stellate cells inhabit the space of Disse between the sinusoid and the 
hepatocytes. 
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1.4.1 Role of hepatocytes in the liver 
The main functioning cell type in the liver is the hepatocyte, occupying 80 % of the 
liver volume and 60 % of the total cell number (Bacon. B. R. et al. 2006).  The 
hepatocytes sit in a plate along the lobule and are exposed to capillaries on either 
side, also known as the liver sinusoids, allowing a consistent supply of blood (Figure 
1.2) (Bacon. B. R. et al. 2006).  Adjacent hepatocytes are connected with tight-
junctions and form bile canalicular structures which run perpendicular to the 
capillaries (Gissen and Arias 2015).  Hepatocytes are functionally polarised cells, 
with specific transporters localised to the basolateral (sinusoidal) membrane or the 
apical (canalicular) membrane, allowing specific molecules to be taken up or 
secreted from the cells.  The structural and functional polarity of hepatocytes go 
hand-in-hand for efficient liver function; for example some substances may be taken 
up by hepatocyte transporters from the capillaries and must be secreted by a 
different transporter into the bile, or metabolised and transported back into the blood 
stream (Bacon. B. R. et al. 2006; Gissen and Arias 2015; Godoy et al. 2013).  As the 
homeostasis of many molecules are controlled by hepatocytes, multiple enzymes, 
such as those involved phase I and II metabolism, must be expressed in order to 
perform these important physiological functions.  Hepatocytes also express many 
plasma proteins, including albumin, protease inhibitors, transporters and 
inflammatory modulators (Bacon. B. R. et al. 2006; Lippincott. J. B 1993).   
 
1.4.2 Role of non-parenchymal cells in the liver 
Non-parenchymal cells (NPC) reside alongside hepatocytes in the liver and 
contribute 40 % of the total cell number (Bacon. B. R. et al. 2006).  These cell types 
play an important part in maintaining liver structure and correct functionality. 
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Furthermore, the phenotype and function of NPC dramatically changes once the 
liver is damaged, contributing significantly to the liver’s recovery process as well as 
potentially furthering insult to the tissue (Godoy et al., 2013).  The second largest 
cell population in the liver, comprising 19 % of the cells, are the sinusoidal 
endothelial cells (LSEC) which function to line the capillaries in the liver.  This allows 
the regulation of substances between the circulation and the liver (Kmiec 2001).  
These cells have large fenestrations to allow molecules such as hormones, toxins, 
nutrients and plasma proteins to flow freely between the plasma and the liver, with 
the ability to prevent larger molecules entering.  LSEC have additional roles within 
the liver including scavenger functions and clearance of endotoxins and bacteria by 
receptor mediated mechanisms, playing a role in both immunological tolerance and 
liver regeneration (Anderson 2015; Ding et al. 2010; Limmer and Knolle 2001).  
During liver injury LSEC alter their function and morphology, enlarging their 
fenestrae, secreting IL-1, detecting DAMPs (damage-associated molecular pattern 
molecules) and enhanced tethering to leukocytes in order to allow for liver repair 
and regeneration (Godoy et al. 2013; Michalopoulos 2007).  
 
Kupffer cells make up 15 % of the cells in the liver and are the resident macrophage 
in this organ, residing within the capillaries (Bouwens et al. 1986; Kmiec 2001).  Like 
all macrophages, the Kupffer cells migrate around the liver and function to engulf 
infiltrating bacteria and cell debris, recruit neutrophils and encourage liver repair.  In 
addition to this, during liver injury Kupffer cells release pro-inflammatory cytokines 
such as IL-1β, TNFα and IL-6 (Wheeler 2003).  Kupffer cells additionally have an 
important role in regulating liver regeneration (Michalopoulos 2007).  This is 
accomplished by releasing anti-inflammatory cytokines alongside the ability to 
recruit other cells to the liver, including neutrophils, natural killer cells and 
monocytes (Godoy et al. 2013; Kolios et al. 2006). 
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Stellate cells (also known as perisinusoidal cells or Ito cells) are pericytes located 
between the sinusoid and hepatocytes in the perisinusoidal space of Disse and 
comprise of 6 % of the population of cells in the liver (Bacon. B. R. et al. 2006).  
Once activated, the main function of the stellate cell is the formation of scar tissue 
during liver fibrosis.  This involves chemotaxis, chemokine secretion, contractility 
and proliferation of stellate cells.  This cell type can also detect DAMPs and can be 
activated by the release of cytokines from Kupffer cells, aiding liver regeneration 
(Godoy et al. 2013; Michalopoulos 2007).  However, in a healthy liver, stellate cells 
are inactivated and in a quiescent state.  At this point their main function is storing 
vitamin A and displaying neuronal and neuroendocrine markers (Kordes et al. 2008; 
Kordes et al. 2009; Kordes et al. 2007).  
Other cell types in the liver include fibroblasts, which function to maintain the 
structural integrity of connective tissue when in their inactive state, producing 
collagen, fibres and other substances found in the extracellular matrix (ECM). 
Fibroblasts are activated in response to tissue damage, leading to excessive 
production of ECM components, which can lead to liver fibrosis and eventually 
cirrhosis (Guyot et al. 2006).  Neutrophils and macrophages can also both migrate 
into the liver during injury (Mantovani et al. 2011).  Neutrophils have increased 
tethering to LSEC and produce ROS during liver damage and infiltrating 
macrophages are alternately activated and produce TNFα, IL-1, IL1RA, TGFβ and 
IL-10 and act pro-apoptotic towards neutrophils (Godoy et al. 2013).  
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1.5 Current liver models used to investigate DILI 
There are numerous models in which one can investigate human DILI.  The most 
relevant option is to study the in vivo situation, for example through conducting 
clinical trials.  This would give the most accurate and relevant representation of 
human DILI.  However, this is not always possible, has broad ethical implications, 
and many rare toxicities are still undetected in clinical trials.  Therefore researchers 
must find different ‘models’ in which to investigate DILI.  Figure 1.3 lists some of the 
most common systems used to recapitulate a human liver, highlighting the main 
drawbacks of each technique. 
Animal models are legally required for safety and efficacy testing of all new 
pharmaceuticals.  In general, in vivo studies are highly predictive of organ toxicity 
and essential in order to ascertain a full organism response to a chemical 
(Research. 2004).  However, species, environmental and genetic differences 
between animals and humans can result in dangerous chemicals going undetected 
in vivo.  Liver injury is particularly hard to predict, with only 50 % of human 
hepatotoxins detected in animal models and poor concordance between animal and 
human toxicity data (Olsen and Whalen 2009; Olson et al. 2000a).  Many 
compounds cause rare idiosyncratic reactions and these often can’t be detected in 
the small number of genetically similar animals used to test for toxicity (Lee 2003), 
as well as many compounds going undetected in clinical trials due to the rarity of the 
toxicity (Stricker 1992).  Furthermore, there are ethical restrictions to the use of 
animals, as well as rules against certain experiments or procedures being performed 
in vivo (Krewski et al. 2010).   
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Figure 1.3. The increasing complexity of liver models.  Numerous liver models 
are available for the investigation of DILI.  These models range from the closest 
resemblance to humans with highest complexity to the most ethically accepted and 
easy to manipulate systems.  Clinical trials and animal’ studies are legally required 
and provide whole organisms responses to drug compounds, however they bare 
ethical restrictions as to what and how many experiments can be performed.  Liver 
slices can be studied in more detail ex vivo, however they can’t be sustained for 
prolonged periods.  Complex 3D models, also known as microphysiological 
systems, recapitulate the liver microenvironment with the ability to include multiple 
cell types and microfluidics, however this comes at the cost of high expense and 
difficult set-up and analysis.  Spheroids display 3D cell structures and can include 
multiple cell types but have yet to be validated for key parameters and biological 
characteristics.  Varies cell types can be cultured in a simple 2D model, including 
human hepatocytes or immortalised cell lines, which are easy to manipulate and 
analyse, yet this leads to lower functionality and altered morphology.  The most 
simplistic in vitro models include subcellular fractions or liver enzymes, which 
although useful, provide limited information on the whole cell response. 
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For this reason, human-relevant in vitro liver models are essential during initial drug 
screening in order to detect ADR early in the drug discovery process.  In vitro liver 
models range from liver slices taken from an animal or human, to reconstituted liver 
enzymes.  These models differ in their likeness to human liver, complexity and 
ethical acceptance.  For instance, liver slices contain all of the primary cells and 
structures of an in vivo animal liver and can be analysed in detail with little 
restrictions.  Conversely, they have a short lifespan and can be complicated to 
manipulate and analyse.  Reconstituted liver enzymes might reflect the metabolic 
functions of a human liver but are simple, giving little insight into other important liver 
parameters (such as cellular dysfunction or drug transporter effects).  The majority 
of in vitro liver models focus on hepatocytes or their immortalised alternatives, as 
not only are they the most common cell type in the liver but are also responsible for 
the majority of the liver-specific functions, such as the endogenous and xenobiotic 
metabolism, synthesis and secretion of substances and bile production (Godoy et al. 
2013; Lippincott. J. B 1993).  However, the liver is a complicated tissue with a 
diverse structure and multiple cell types.  NPC constitute up to 40 % of the total cell 
number in the liver, contributing significantly to the intricate liver structure as well as 
having an important role in correct liver function (Bacon. B. R. et al. 2006).  Hence a 
co-culture liver model may better represent the human liver.  Increasingly complex 
cell culture techniques are becoming available and are beginning to be incorporated 
into drug screens. 
Currently 30-40 % of hepatotoxic drugs still remain undetected during in vitro drug 
screening, despite efforts to increase the sensitivity of these models, leading to 
potentially dangerous compounds being continued throughout development 
(Garside et al. 2014; O'Brien et al. 2006; Xu et al. 2008).  Hence novel, appropriate, 
human-relevant, in vitro liver models are a necessity in order to identify human 
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toxins before they reach animal or clinical trials.  Commonly used in vitro models, 
their limitations and potential improvements are discussed in detail below. 
 
1.5.1 In vitro liver models used to investigate DILI: Primary human 
hepatocytes 
Hepatocytes can be isolated from human liver biopsies and cultured as a 2D 
monolayer in vitro; they are still considered by many to be the gold standard in vitro 
model for assessing DILI (Gomez-Lechon et al. 2004).  Animal hepatocytes are 
more freely available and less costly, resulting in an array of research using rodent, 
canine or even porcine hepatocytes.  However, species differences, such as 
variations in metabolism and pharmacokinetics of compounds, impact the 
predictivity of the model potentially rendering animal hepatocytes inappropriate for 
detecting human hepatotoxins (Olson et al. 2000b).  Primary human hepatocytes 
when isolated and cultured correctly, show phase I and II metabolic enzyme activity, 
glucose metabolism, ammonia detoxification, albumin secretion and other functional 
markers for up to 72 hours in culture (Knobeloch et al. 2012).  Cultured human 
hepatocytes thus act as a valuable model for drug metabolism and acute toxicity 
studies (Donato et al. 2008).   
Nonetheless, there are disadvantages of using this cell type as a liver model.  
Firstly, not only is the availability of human liver tissue sometimes limited, especially 
for the amounts required for pharmaceutical drug testing, but often that which is 
available is from a damaged liver which has been removed because of a cancer and 
may have other existing pathologies or previous damage (Godoy et al. 2013).  
Consequently, the quality of the hepatocytes isolated is dependent on the quality of 
the donor tissue.  Additionally, there is a large variation between donors when using 
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human liver tissue, as some hepatocytes are more susceptible to toxicity or more 
metabolically competent than others, thus the variation in responses of the cells can 
be large and unpredictable (Donato et al. 2008; LeCluyse et al. 2005).  Pooling 
hepatocytes from multiple donors may help to overcome this issue, however this is 
not always an option.  Another complication is the isolation procedure itself, with the 
technique of isolating hepatocytes from both human and animal liver being fairly 
complex and requiring advanced skills and techniques, where multiple problems and 
limitations can arise (Godoy et al. 2013; LeCluyse et al. 2005).  Once isolated, 
hepatocytes rapidly lose their phenotype and function in 2D cultures in vitro, typified 
by a decrease in phase I and II enzyme activity, decreased glucose metabolism and 
ammonia detoxification and lower albumin secretion, as well as morphological and 
structural changes (Godoy et al. 2013; Gomez-Lechon et al. 2004; Khetani et al. 
2015b).  This reduction in liver-specific function and phenotype limits the use of 
primary hepatocytes to no more than 72 hours in 2D culture, meaning that only 
acute testing can be performed (Godoy et al. 2013).   
 
1.5.2 In vitro liver models used to investigate DILI:  Immortalised human liver 
cell lines 
An alternative to using primary hepatocytes are immortalised cell lines, mainly 
derived from human hepatocellular carcinomas which overcomes any species 
differences associated with using animal derived cells.  The main advantages of 
using liver cell lines over primary human hepatocytes are the higher proliferative 
capability and therefore long lifespan, ease of availability, stable phenotype, easy 
handling and the absence of any donor variations (Donato et al. 2008; Gerets et al. 
2012; LeCluyse et al. 2012; O'Brien et al. 2006).  In spite of this, the lower liver-
specific functions displayed by these cell types are their main downfall, as many 
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human hepatocarcinoma cell lines do not express all of the metabolizing enzymes 
seen in vivo, or have levels of enzymes which are not physiologically relevant (Guo 
et al. 2011; Khetani et al. 2015b; LeCluyse et al. 2012).   
HepG2 cells are the most commonly used human liver cell line and therefore the 
best characterised.  These cells are derived from a hepatocellular carcinoma and 
are epithelial-like and non-tumorigenic (LeCluyse et al. 2012).  This cell line can 
biotransform numerous xenobiotic compounds and is able to secrete typical liver 
plasma proteins including albumin, fibrinogen and transferrin.  However, gene 
expression levels of phase I and II biotransformation enzymes of these cells cultured 
in 2D are substantially lower than those found in primary human hepatocytes 
(LeCluyse et al. 2012).  This lack of enzyme function indicates that the HepG2 
model is not fully representative of the phenotype of a human hepatocyte and is 
therefore unlikely to accurately detect human hepatotoxins that require metabolic 
activation.  Further research has revealed that HepG2 cells have a sensitivity of 80 
% to hepatotoxins, yet a specificity of 40 % when using non-liver toxins (Atienzar et 
al. 2014).  This may be an improvement on other screening techniques; however, 
one cannot be confident in this model due to the lower functional profile of these 
cells.  HepG2 cells have been studied in detail as an attempt to improve their 
toxicological predictivity and function.  In order to express increased levels of 
specific enzymes, HepG2 cells have been transfected with different CYPs and used 
for specific drug metabolism studies (Vermeir et al. 2005).   
C3A cells were selected as a clonal derivative of HepG2 cells with some 
advantages, chosen for their strong contact-inhibited growth characteristics, as well 
as high-albumin production, alpha fetoprotein and transferrin synthesis and are able 
to grow in glucose deficient media (LeCluyse et al. 2012; Nibourg et al. 2012).  This 
derivative of HepG2 cells appears to better represent a primary hepatocyte, 
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however, more research is required on these C3A cells in order to elucidate their 
potential as a liver model.   
Another liver cell line under investigation is HepaRG, a terminally differentiated 
human hepatocellular carcinoma cell.  These cells produce both hepatocyte-like  or 
cholangiocyte-like cells and can then be differentiated into mature hepatocyte-like or 
biliary-like cells using dimethyl sulfoxide (DMSO) (LeCluyse et al. 2012; Nibourg et 
al. 2012).  HepaRG cells have been shown to express phase I and II enzymes, 
including specific CYPs, with high drug metabolising potential (Guillouzo et al. 
2007).  The cells additionally produce albumin, urea and lactate and have been 
shown to have functional transporters (Guillouzo et al. 2007; Nibourg et al. 2012).  
Nevertheless, these increases in enzyme expression are artificial in that they are 
strongly dependant on the high concentrations of DMSO in the cell culture media 
(LeCluyse et al. 2012).   
More recently stem cell research has shown potential for in vitro liver modelling, 
including mesenchymal, fibroblast, embryonic and induced pluripotent stem cells, 
which can be differentiated into human hepatocytes.  These cells show many 
morphological and functional features of hepatocytes, including drug metabolising 
activity, albumin secretion, drug transportation, glycogen storage (Godoy et al. 
2013).  However some functions are still suboptimal and there is question over 
whether these cells are truly differentiated into mature hepatocyte-like cells 
(Guguen-Guillouzo et al. 2010); nonetheless research is ongoing (Nibourg et al. 
2012).  Other immortalised cells, including Huh7, FLC-4/5/7, FA2N-4, have similar 
advantages and disadvantages which have been reviewed (Godoy et al. 2013; 
Nibourg et al. 2012). 
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1.5.3 In vitro liver models used to investigate DILI: NPC co-culture models 
It may be essential to include all relevant cell types for complete recapitulation of the 
liver in vitro and in order to improve the predictive value of these models.  There is 
evidence to suggest that including NPC in in vitro liver models can produce a more 
in vivo-like microenvironment, with enhanced liver functions.  It has been found that 
including LSEC in primary rat hepatocyte culture models resulted in CYP function 
being maintained for up to 48 days, with hepatocyte differentiation markers, such as 
albumin, transferrin and hepatocyte nuclear factor-4, present up to day 37 and 
consistent urea synthesis for 28 days (Kang et al. 2013).  Similar results have been 
observed with HepG2 cell culture, where the addition of endothelial cells caused 
CYP enzymes to be induced to a higher degree than in a monoculture (Ohno et al. 
2009).  This indicates that endothelial cells help to regulate CYP enzymes and 
transporter gene pathways.  This research provides evidence that the presence of 
endothelial cells increases and maintains hepatocyte function in vitro.  Interestingly, 
the reverse is also seen, as hepatocytes improve and regulate endothelial cell 
function.  Hepatocytes are able to signal to LSEC to regulate the expression of 
adhesion receptors, allowing the increase or decrease of lymphocyte adhesion, 
hence aiding the repair of the liver after injury (Adams et al. 2010).  Few studies 
have investigated the effects of endothelial cell co-culture on sensitivity of a model 
to hepatotoxins and further research is essential to elucidate the role of these cells 
in DILI. 
Kupffer cells have been found to influence hepatocyte function, for example when 
included in a hepatocyte culture system metabolic functions were increased (Yagi et 
al. 1998).  Additionally, it has been revealed that co-culturing Kupffer cells with 
hepatocytes alters the hepatocyte function in response to an inflammatory stimulus 
that would otherwise have no effect on the hepatocytes alone (West et al. 1986).  
Kupffer cells can also detect and respond to hepatocyte stress and damage from 
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hepatotoxins in vitro, with increased activity of Kupffer cells and release of cytokines 
(Kegel et al. 2015).  The production of these inflammatory factors would not occur in 
a monoculture liver model, therefore the inclusion of Kupffer cells may increase the 
ability of the model to detect certain hepatotoxins.  Other immune cells have been 
investigated in liver models, for example monocytic cell line THP-1 cells.  Huh-7 liver 
cells were co-cultured with THP-1 cells and produced an increase in pro-
inflammatory and stress-related gene expression after treatment with the 
hepatotoxin troglitazone, as well as increased drug metabolism and sensitivity when 
compared to a Huh-7 monoculture (Edling et al. 2009).   
Additionally, stellate cells have an important role in liver homeostasis.  One study by 
Kasuya et al. describes the essential role of stellate cells in the communication 
between hepatocytes and endothelial cells (Kasuya et al. 2011).  Kostadinova et al. 
2013 studied a co-culture model including hepatocytes, Kupffer cells, endothelial 
cells and stellate cells which revealed that liver function can be maintained for up to 
3 months (Kostadinova et al. 2013).  This included increased albumin, transferrin 
and fibrinogen production, increased urea synthesis and increased CYP inducibility 
when compared to a monolayer culture of hepatocytes alone.  The co-culture model 
also responded to inflammatory stimuli, likely due to the inclusion of Kupffer cells in 
the model.  Moreover, the co-cultured cells displayed a toxic response to 
hepatotoxins, whereas monolayer cultures of hepatocytes did not (Kostadinova et al. 
2013) indicating that the inclusion of NPC is necessary to improve the predictive 
value of the model.  Hence, there is building evidence that the inclusion of NPC in 
an in vitro liver model may more realistically recapitulate liver structure, function and 
response to toxins. 
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1.5.4 In vitro liver models used to investigate DILI:  3D liver models 
There remains a need for more sophisticated in vitro liver models to better 
recapitulate liver physiology.  One suggestion for how to achieve this is by 
enhancing the cells microenvironment to be more in vivo-like.  The main 
disadvantage of standard in vitro liver models is that cells have a completely 
different morphology and structural arrangement than in vivo.  In the human liver, 
cells have a 3D morphology and structural organisation, with direct cell-cell contacts 
to neighbouring cells which is important for cell signalling.  Hepatocytes have both 
structural and functional polarity, with a polygonal 3D morphology, specific 
orientation and localised transporter functions (Gissen and Arias 2015).  When 
cultured in 2D, hepatocytes flatten and spread out, losing their 3D cell-cell contacts 
and limiting signalling pathways.  Additionally 2D hepatocytes have an altered 
phenotype as the cells dedifferentiate and lack polarisation, resulting in cellular 
proliferation and a loss of many crucial functions (Gomez-Lechon et al. 1998; 
Semler et al. 2000; Wells 2008).   
The ECM is an important factor to consider when culturing cells, as this acts as a 
scaffold for the adhesion of cells, as well as a signalling platform (Gissen and Arias 
2015).   The stiffness of the ECM in the liver alters the function of multiple cell types 
and can result in changes to albumin production, migration and flattening of cells 
(Semler et al. 2000; Wells 2008).  Consequently many research groups have 
investigated the effects of culturing cells in a 3D environment free of artificial ECM in 
order to more accurately model the liver microenvironment.   
There are multiple ways in which cells can be cultured in 3D.  A frequently used 
culture technique is sandwich culture, where hepatocytes are placed between layers 
of ECM components such as collagen or Matrigel.  This technique is not a complete 
3D organization of cells but has been shown to promote a more in vivo-like 
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hepatocyte morphology with less flattening, cell-cell contacts, increased polarisation, 
prolonged viability and functionality (Dunn et al. 1991).  Multiple cell types can be 
applied to the sandwich culture technique to allow diffusion of cellular signals 
between cell types but with no direct cell-cell contact.  However, a key disadvantage 
of this model is the variation in ECM components such as Matrigel and the effects 
these products have on cell phenotype. 
One of the most common ways for cells to be cultured in full 3D orientation is by 
using scaffolds.  Various types of scaffolds exist, one of which are hydrogel 
scaffolds which hepatocytes can be embedded within.  These hydrogels have been 
shown to improve function further than sandwich culture (Moghe et al. 1997).  Cells 
can also be seeded into 3D scaffolds made of natural or artificial ECM, allowing cells 
to migrate into these structures and form 3D tissues.  For example, scaffolds in the 
form of ‘sponges’ can be used; cells can be seeded into the sponge matrix, forming 
small 3D aggregates within the pores of the scaffold (Godoy et al. 2013).  
Micropatterning has emerged as a technique allowing modification of cell and ECM 
interactions and accurate placement of cells, thereby controlling their 
microenvironment.  This technique has shown potential at improving and prolonging 
hepatocyte function (Gerlach et al. 2003; Zinchenko et al. 2006).  A very novel 
culture technique involves the use of 3D printing, where cells and biological 
materials can be automatically printed into a certain design in order to create 
tissues, accurately controlling the placement of multiple cell types and structures 
(Murphy and Atala 2014).  The difficulty with all of these scaffold-based techniques 
are as follows:  (1) developing the correct material for cells to adhere to and (2) 
ensuring that the size and shape of the structures are appropriate for optimal cell 
function, the diffusion of signalling molecules, waste products, nutrients and oxygen.  
Moreover these techniques are often practically difficult to set up, with a complicated 
harvesting and analysis of cells not to mention costly and variable in their output.  A 
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more high-throughput and readily available 3D culture technique would be desired 
from a drug screening perspective. 
1.5.5 In vitro liver models used to investigate DILI: Liver spheroids 
Spheroids, also known as microtissues or organoids, are small, round 3D clusters of 
cells.  Molds or scaffolds can be used to facilitate the formation of spheroids (Wong 
et al. 2011), or they can form naturally as the cells self-assemble to form a 3D 
spherical structure.  Figure 1.4 illustrates some of the different techniques commonly 
used to create spheroids (Lee et al. 2013; Materne et al. 2015; Ramachandran et al. 
2015; van Zijl and Mikulits 2010).  All of these methods have been used to create 
spheroids, however as with most 3D culture techniques, reproducibility is a problem, 
with variation in spheroid size, shape, viability, proliferation and functionality 
(Friedrich et al. 2009; van Zijl and Mikulits 2010).  In addition some of these 
techniques are more complex than others, requiring specialist equipment and often 
spheroids must be harvested before performing any analyses.  Scaffold-free 
methods for creating spheroids include the hanging-droplet technique, low adherent 
round-bottomed cell culture plates and rocked or stirred cultures which allow cells to 
self-assemble and form tissue aggregates.  Spheroids produced by these methods 
form extensive direct cell-cell contacts and produce their own ECM, which may 
overcome the negative effects seen with other 2D and 3D liver models.  Moreover, 
these spheroids display an in vivo-like liver structure, including cuboidal cell 
morphology, polarised hepatocytes and structural similarities such as bile canaliculi 
formation (Peshwa et al. 1996).  Evidence clearly suggests that spheroids cultured 
using a scaffold-free method better represent human liver morphology and function 
compared to a 2D monolayer culture (Peshwa et al. 1996; Wong et al. 2011).  Plate-
based methods, such as the hanging-drop technique and low adherent round 
bottom plates offer the advantage of producing one aggregate per well, removing 
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the need to harvest spheroids after formation, as well as making drug treatment 
much easier. 
Spheroids can be formed from primary hepatocytes or liver cell-lines and research 
shows that both have been shown to display enhanced, more in vivo-like 
functionality and a longer lifespan compared to 2D monolayer cultures.  Primary 
human hepatocytes survive and are functional in spheroids for up to 4 weeks, 
sustaining phase I and II enzyme expression, albumin and urea synthesis alongside 
expression of liver-specific markers.  Additionally bile canaliculi structures can be 
visualised in the spheroids, indicating polarisation of hepatocytes and the 
expression of hepatic transporters (Messner et al. 2013; Tostoes et al. 2012).   
Figure 1.4. An illustration of the different approaches used to create 3D 
spheroids.  The techniques used to create spheroids vary in complexity and include 
the use of rotatory or rocked culture, as well as low adherent surfaces, matrices and 
hanging-drop techniques in order to stimulate cells to aggregate in clusters.   
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Furthermore, spheroids produced from numerous different liver cell lines have 
shown enhanced function when cultured in 3D, overcoming the main inadequacies 
of using immortalised hepatocarcinoma cell lines in 2D.  For example Huh7 cells can 
be cultured in spheroids and show expression of phase I and II enzymes as well as 
polarisation of various receptors (Sainz et al. 2009).  Investigations into HepG2 cell 
spheroids revealed that they have higher albumin production and metabolic activity 
as well as over-expression of genes involved in xenobiotic and lipid metabolism and 
more liver-like structures when compared to 2D cultures (Chang and Hughes-
Fulford 2009; Mueller et al. 2011).  Additionally, studies have been performed on 
C3A spheroids showing increases in liver-specific functions and potential enhanced 
sensitivity to hepatotoxins than 2D cultures (Fey and Wrzesinski 2012; Wrzesinski 
and Fey 2013; Wrzesinski et al. 2013), however multiple parameters still need to be 
elucidated.  HepaRG cells have been cultured as spheroids and show a significant 
improvement in albumin and AboB production, increases in liver specific gene 
expression and activity, and induction of CYP enzymes when compared to 2D 
cultured cells (Takahashi et al. 2015; Wang et al. 2015).  Hence the spheroid model 
overcomes many limitations of 2D cell culture, is extremely adaptable and can be 
used with a wide variety of different cell types. 
Spheroids can be created with multiple cell types, often referred to as organoids as 
they better recapitulate an in vivo organ.  Hepatocytes have been co-cultured with 
hepatic stellate cells, showing the same morphological and structural changes as 
with monoculture spheroids but superior CYP function and expression, up to 30 % 
increases in albumin production sustained for 2 months (Riccalton-Banks et al. 
2003; Thomas et al. 2005; Wong et al. 2011).  Hepatocytes have also been co-
cultured with Kupffer cells and endothelial cells in spheroids, showing viability for 35 
days, expression of transporters and sensitivity to some hepatotoxins (Messner et 
al. 2013).  The location of different cell types can be studied in spheroids in order to 
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establish the reorganisation of multiple cell types over time (Dorst et al. 2014; Godoy 
et al. 2013).  Despite the fact NPC have been included in many liver spheroid 
models, little research has gone into investigating the specific effects or roles of the 
NPC in the system compared to monocultures.   
Cells cultured in spheroids are viable for a longer period than in 2D cultures, 
allowing for long-term cultures with the possibility of repeated-dose toxicity studies 
(Godoy et al. 2013).  In addition, the quick and simple culture technique requires 
limited expertise and allows for high-throughput analysis, all of which are major 
advantages for a pharmaceutical drug screen.  Furthermore, the in vivo-like 
phenotype, structure and functionality could result in spheroids being more 
predictive of human hepatotoxins and result in a useful model for the investigation of 
liver injury (Fey and Wrzesinski 2012; Godoy et al. 2013; Tostoes et al. 2012). 
  
Figure 1.5.  A diagram illustrating oxygen and nutrient gradients throughout a 
spheroid.  The outer layer of the spheroid has normal oxygen and nutrient 
concentrations.  Further into the spheroid, oxygen and nutrient concentrations 
decrease, with necrosis occurring in the spheroid core. 
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Nonetheless, like most in vitro models there are some disadvantages and 
unresolved issues when it comes to culturing spheroids.  Spheroids can develop 
hypoxic cores, where the central cells undergo necrosis (Figure 1.5).  This is due to 
the lack of diffusion of oxygen and nutrients into the spheroid core and build-up of 
cell debris and waste products in the centre.  It has been reported that oxygen can 
diffuse 100 - 150 μm through tissue, suggesting that spheroids under 200 - 300 µm 
radius would have a healthy core (Asthana and Kisaalita 2012; Curcio et al. 2007; 
Olive et al. 1992).  In addition to this, oxygen concentrations effect hepatocyte 
functionality as the demand for oxygen in these cells is 10 times higher than other 
cell types, and studies have shown that increased oxygen uptake rates can lead to 
increased liver-specific functions (Cho et al. 2007).   
A different theory states that a lack of nutrients to cells is the cause of apoptotic cell 
death and that this occurs whilst oxygen is present (Funatsu et al. 2001; Grimes et 
al. 2014; Kasinskas et al. 2014).  However, little research has thoroughly 
investigated the essential parameters required in order to avoid necrotic core 
formation, which could be influenced by culture technique, cell type, cell number and 
culture duration.  Furthermore, few studies on liver spheroids have confirmed cell 
viability or oxygen concentrations over a prolonged period and throughout the 
spheroid core.  It is essential to avoid a necrotic core in a liver model as this would 
distort any toxicity data collected from the spheroid model if pre-existing cell damage 
was present.  Conversely, this gradient may be advantageous, as oxygen and 
nutrient gradients exist throughout the liver sinusoid, leading to zonation of the 
lobule.  Hence it is important that these factors are investigated thoroughly during 
validation of a spheroid culture system.   
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1.5.6 In vitro liver models used to investigate DILI: Microfluidic liver systems 
One of the disadvantages of in vitro models is the artificial way in which medium is 
sequentially renewed and drug treatment acutely added.  This results in non-steady 
state conditions, depletion of substrate and accumulation of product (Gebhardt et al. 
2003).  Microfluidics systems are a way to overcome some of these issues, with 
continuous perfusion of medium through the cell culture (Bhatia and Ingber 2014).  
There is also suggestion that the shear stress created by the flow of medium is 
complimentary to the cells and their phenotype (Lee et al. 2013).  Moreover, 
evidence has revealed that microfluidics causes maintenance of more in vivo-like 
system as the consistent low concentrations of nutrients, oxygen and metabolites 
has been shown to improve liver-specific functions in hepatocytes as well as 
improve cell viability in these systems (Esch et al. 2015; Gebhardt et al. 2003; Lee 
et al. 2013; Tostoes et al. 2012).   
Research on C3A hepatoma cells cultured in a microfluidic device showed liver-
specific functions, including gluconeogenesis, ureagenesis and albumin synthesis,  
with almost comparable levels to primary hepatocytes (Filippi et al. 2004).  These 
systems can now be created in microchip size, resulting in a more practical sized 
device.  The HepaTox Chip is a microfluidic device with multiple channels 
representing the microvessels and allowing the maintenance of hepatocyte functions 
and more realistic dosing strategies (Toh et al. 2009).  Some research groups have 
combined 3D culture with microfluidics and show promising results with 
maintenance of a liver-specific phenotype for weeks (Domansky et al. 2010; Esch et 
al. 2015; Lee et al. 2013; Tostoes et al. 2012).  More sophisticated culture systems 
such as complex hollow-fibre bioreactors are being developed, consisting of a 
complex scaffold onto which cells are seeded, with a flow of media through the 
system (Gerlach et al. 2003; Williams D et al. 2012).  
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Some limitations to these complex models are also apparent.  The perfusion of 
media can result in the loss or disaggregation of cells from the system, especially as 
the cells proliferate and can become over confluent.  Therefore, the use of 
microfluidics devices for long-term culture may not be appropriate.  Moreover the 
effect of shear stress on the cells has yet to be fully elucidated and could be 
potentially damaging to the system (Lee et al. 2013).  Little investigation has gone 
into confirming the sensitivity of microphysiological systems such as liver-on-a-chip 
devices, with some evidence suggesting poor detection of human hepatotoxins (Toh 
et al. 2009).  Major drawbacks of all perfusion models are the complicated and 
costly set-up and maintenance of the system, difficult analysis and extraction of 
data, large number of cells required and low throughput nature.  This means that the 
model is often not amenable to high-throughput or long-term drug screening.  
Despite potential for these complex 3D liver models to more accurately recapitulate 
in vivo liver tissue, this kind of system may not be appropriate as an in vitro liver 
model for drug screening. 
 
In conclusion, numerous in vitro liver models are available, ranging in complexity 
and each of which has promises and drawbacks to their use for investigating DILI.  
A summary of the advantages and disadvantages of some of the currently available 
in vitro liver models are shown in in Table 1.1.   
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In vitro model Advantages Disadvantages 
Primary human 
hepatocytes 
• Most liver-like cell 
• Liver-specific functions 
• Enzyme activity 
• Well established 
• Limited availability 
• Large variability 
• Short lifespan 
Immortalised 
human liver cell 
lines 
• Unlimited lifespan 
• Inexpensive 
• Little variability 
• Easy to culture 
• Well established 
• Limited enzyme activity 
• Poor liver-specific function 
• Low specificity  
NPC co-cultures 
• Includes more relevant 
cell types 
• Increased liver-specific 
functions 
• Increase CYP enzyme 
activity 
• Limited availability of 
primary cells 
• Limited lifespan 
• More complex to create 
Spheroids 
• In vivo-like cell 
morphology 
• Liver-specific functions 
• Prolonged lifespan 
• High-throughput 
• Multiple cell types 
available 
• Necrotic core formation 
• Variability in spheroid size 
and formation 
• Difficult analysis 
Complex 3D 
models 
• In vivo-like cell 
morphology 
• Multiple cell types 
available 
• Low-throughput 
• Expensive 
• High variability 
• Difficult analysis 
• Complex to set up 
• Large number of cells 
required 
Microfluidics 
devices 
• In vivo-like 
microenvironment 
• Liver-specific functions 
• Low-throughput 
• Expensive 
• Difficult analysis 
• Need further investigation 
• Complex to set up 
Table 1.1 Advantages and disadvantages of commonly used in vitro liver models.   
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1.3 Biomarkers of DILI 
Clinical trials are legally required in order to determine the safety and efficacy of a 
compound in human subjects.  Early diagnosis of DILI can be troublesome and often 
requires an invasive liver biopsy.  Serum biomarkers are often utilised for a simpler, 
non-invasive diagnosis of liver injury.  Appropriate, sensitive biomarkers of DILI are 
needed not only to monitor liver function and potential injury during clinical trials but 
also in order to aid patient diagnosis and treatment of DILI.  A biomarker is a 
characteristic objectively measured as an indicator of a normal biological, 
pathological or pharmacological process.  To screen for liver injury, blood or serum 
can be analysed for biomarkers, as any biomolecules released by the liver will enter 
the circulation.  Biomarkers of liver injury can include metabolites, proteins or RNAs.  
Protein biomarkers released from the liver during injury include aminotransferases, 
such as alanine transaminase (ALT), aspartate aminotransferase (AST), glutamate 
dehydrogenases (GGT) and alkaline phosphates (AP), with the first two proteins 
indicating hepatocellular injury and the latter indicating cholestatic injury (Laverty et 
al. 2010).  The degree of liver injury occurring can be estimated from the degree of 
activity or concentration of these enzymes in the blood stream.  
 
1.3.1 Current clinical biomarkers of DILI 
ALT is the most commonly utilised biomarker analysed by pharmaceutical 
companies and regulatory agencies for the detection of DILI (Dufour et al. 2000), 
with an elevation over twice the upper limit of normal (40 IU/L) indicating liver 
damage (Antoine et al. 2009a; Benichou 1990).  Additionally, total bilirubin levels 
(TBL) can be analysed as a measure of liver function with elevations indicating a 
decline in liver function.  ALT elevations are often seen before changes in TBL, 
however even ALT cannot predict liver injury at an early time point, as once these 
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biomarkers are significantly raised in the serum severe liver damage may have 
already ensued.   
Other problems exist with the currently used clinical biomarkers.  First, elevations of 
these molecules in serum could often indicate conditions other than DILI, as these 
markers are not organ specific.  An example of this would be that ALT and AST 
could be raised due to damage to another organ system such as the heart, as well 
as indicating non-related liver diseases including fatty liver disease or viral hepatitis 
(Antoine et al. 2013; Antoine et al. 2012; Antoine et al. 2009a; Ozer et al. 2008; 
Zhou et al. 2013).  In addition, even if the biomarkers do reveal DILI in a patient, the 
elevation of ALT doesn’t always correlate with the extent of injury and levels can 
vary between patients (Ozer et al. 2008).  The currently used biomarkers are also 
relatively insensitive, being unable to detect mild or early liver injury.  The lack of 
translatable biomarkers may be the cause of the poor concordance between animal 
and human toxicity data, leading to only 50 % of hepatotoxins being detected in vivo 
(Olson et al. 2000b).  It is clear that the criteria for diagnosing DILI must be 
improved and novel methods of detecting liver injury investigated.  Research into 
finding novel biomarkers of DILI is underway in order to potentially overcome the 
problems with current clinical biomarkers of DILI.  A perfect biomarker would be 
organ specific, have a higher sensitivity and earlier serum detection, as well as 
giving insight into the mechanism or cause of injury and the severity of the condition.  
Figure 1.6 shows a selection of clinical and novel biomarkers, their mechanistic 
insight and the time at which they are released after onset of DILI.  Some of these 
novel biomarkers are discussed below. 
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1.3.2 Novel biomarkers of DILI: HMGB1 
One novel biomarker that has been identified as a possible indicator of liver injury is 
high mobility group box-1 (HMGB1).  HMGB1 is a component of all nucleated cells; 
it is essential for life and is usually found in the nucleus where it binds to DNA and 
regulates transcription (Bianchi and Beltrame 1998; Calogero et al. 1999).  This 
protein also has additional functions which are thought to be stimulated by 
modification of its structure.  Once reduced HMGB1 acts as a chemoattractant; 
partially oxidised HMGB1 has pro-inflammatory cytokine activity whereas terminal 
oxidation of the protein abrogates these functions (Janko et al. 2013; Kazama et al. 
2008; Venereau et al. 2012; Yang et al. 2012).  Extracellularly, HMGB1 can 
modulate the immune response as it aids the regeneration of damaged tissue, 
secretes cytokines, recruits neutrophils as well as controlling inflammation of the 
surrounding area (Scaffidi et al. 2002; Wang et al. 1999; Yamada and Maruyama 
2007).   
This extracellular release of HMGB1 occurs in two phases. Firstly, hypoacetylated-
HMGB1 is passively released from both apoptotic and necrotic cells, which occurs 
early on during liver injury (Antoine et al. 2009b; Bell et al. 2006; Evankovich et al. 
2010; Nystrom et al. 2012).  A delayed release of oxidised HMGB1 occurs via 
release from activated immune cells such as macrophages, which triggers the 
release of hyperacetylated HMGB1 as an immune response to the injury.  
Consequently HMGB1 has been investigated as a mechanistic biomarker of liver 
injury, as it is released into serum post liver injury and the different isoforms 
distinguish between early and late liver injury and liver regeneration.  Research has 
revealed that levels of HMGB1 are increased in the serum of patients following 
acetaminophen overdose and concentrations correlate with the extent of necrosis 
occurring in the liver (Antoine et al. 2012; Antoine et al. 2009b).  When compared to 
ALT analysis, HMGB1 was able to predict the extent of liver injury and likelihood of 
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survival more accurately and at an earlier time point (Antoine et al. 2013; Antoine et 
al. 2012; Antoine et al. 2009b).  Thus, there is potential for HMGB1 to be used as a 
clinical serum biomarker to predict the extent of liver injury (Andersson and Rauvala 
2011; Yamada and Maruyama 2007). 
 
1.3.3 Novel biomarkers of DILI: Keratin-18 
Another protein that has been investigated as a potential biomarker of DILI is keratin 
18.  Keratins are highly expressed by epithelial cells such as hepatocytes, and are 
responsible for cell structure and integrity (Ku et al. 2007; Omary et al. 2002).   
Keratin 18 is specifically expressed by hepatocytes and research has found that the 
full length protein (fk18) is passively released by necrotic cells, whereas caspase-
cleaved keratin 18 (ck18) is released as a result of apoptotic cell death (Biven et al. 
2003; Cummings et al. 2006).  These proteins have been found to be released into 
the serum early on during DILI and their levels correlate well with histological data 
on the extent of injury (Antoine et al. 2009b).  Keratin 18 was found to be a more 
sensitive biomarker of liver injury than ALT (Antoine et al. 2013) and was more 
accurate at predicting the severity and outcome of DILI, as well as being specifically 
released from the liver (Antoine et al. 2012).  An additional advantage of this protein 
is the ability to distinguish between different modes of cell death, thus giving 
mechanistic insight to the type of liver damage occurring, as well as being 
hepatocyte-specific (Antoine et al. 2009b). 
 
1.3.4 Novel biomarkers of DILI: miR-122  
Specific microRNAs (miR) also have potential to act as biomarkers of DILI.  miR 
consist of single stranded non-coding regulatory RNA, which are typically very small 
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at approximately 20 nucleotides.  Some miR have been shown to be stable 
extracellularly in body fluids such as blood and urine (Szabo and Bala 2013; Zhou et 
al. 2013).  Hence these molecules have the potential to be used as biomarkers of 
various conditions as their levels correlate with injury occurring from specific origins.  
miR-122 functions to maintain homeostasis of hepatic cholesterol and lipid 
metabolism (Castoldi et al. 2011; Krutzfeldt and Stoffel 2006).  There is also 
evidence that miR-122 acts as a tumour suppressor gene (Bai et al. 2009; Kutay et 
al. 2006).  miR-122 was found to be elevated in the serum of patients with various 
different liver diseases (Cermelli et al. 2011; Xu et al. 2011) and further research 
revealed miR-122 as a hepatocyte-specific marker of DILI, with levels in plasma 
correlating well with the extent of liver injury after treatment with various 
hepatotoxins (Antoine et al. 2013; Harrill et al. 2012; Starkey Lewis et al. 2011; 
Zhang et al. 2010).  miR-122 is released into the bloodstream very early on after 
initiation of liver injury.   When compared to using ALT levels to predict DILI, miR-
122 had a higher sensitivity and specificity (Starkey Lewis et al. 2011; Zhang et al. 
2010) and moreover was found to be highly enriched in the human liver, therefore 
acting as a tissue-specific biomarker (Liu et al. 2009; Sempere et al. 2004).  As an 
additional advantage miR-122 is conserved across multiple species, meaning that it 
could be measured in preclinical in vivo models and extrapolated to clinical studies 
(Chang et al. 2004). 
A major caveat with all clinical biomarkers of DILI is that these molecules tend not to 
be, or have difficulty being, assessed in vitro.  Only few biomarkers, such as ALT, 
are analysed in animal studies and show correlations with clinical data (Lea et al. 
2016), however the current lack of translatable biomarkers is a problem which needs 
addressing in order to fully understand the causes and mechanisms of DILI.  If 
clinical DILI biomarkers could be assessed more easily in vitro, this may aid the drug 
screening process and prevent ADR further along in the drug development process.  
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1.6 Aims and Objectives 
The overall aim of this thesis was to create a more representative in vitro liver model 
in order to investigate DILI.  In order to achieve this, six objectives were created. 
 
Aim 1:  To develop a novel in vitro liver spheroid model, optimising key parameters 
and characterising essential liver-specific structural and morphological components. 
In order to investigate DILI an appropriate in vitro model, representative of a human 
liver, is essential.  The aim was to overcome some of the numerous disadvantages 
of current liver models and in turn create a more realistic, human-relevant in vitro 
model.  Lack of liver-like structures was identified to be a key downfall of current 
liver models, alongside the short lifespan, unavailability and large variation of 
primary liver cells.  The plan was to use a 3D cell culture technique with an 
immortalised liver cell line to create a liver model.  Key parameters investigated 
included viability and lifespan, cellular morphology, 3D structure and proliferation. 
 
Aim 2:  To confirm liver-specific functionality in the liver spheroid model and 
compare this to other liver models. 
The second aim was to overcome another major caveat of current in vitro liver 
models:  functionality.  Liver cell lines are known for their poor representation of 
human liver function, yet evidence suggests that 3D cell culture could improve upon 
this.  By investigating key liver-specific functions, such as zonation, metabolic 
activity, synthesis of compounds and bile transport, the project intended to confirm 
liver-like functioning of the liver spheroid model and compare this to 2D cell cultures. 
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Aim 3:  To investigate the ability of the liver spheroid model to detect human 
hepatotoxins and compare this to other liver models. 
The ability of a liver model to detect hepatotoxicity is the most important determinant 
of whether the model is appropriate to investigate DILI.  Current in vitro liver models 
have poor sensitivity and many hepatotoxic compounds go undetected.  Therefore 
the third aim was to reveal the ability of the liver spheroid model to detect a range of 
compounds with a risk of DILI.  The sensitivity of this spheroid model could then be 
compared with other 2D and 3D in vitro liver models. 
 
Aim 4:  To determine whether the inclusion of NPC alters the sensitivity or 
specificity of the liver spheroid model to hepatotoxins. 
The majority of in vitro models used to investigate DILI rely solely on hepatocytes or 
their immortalised alternatives, yet 40 % of the liver is populated by NPC.  Previous 
research indicates that co-culturing hepatocytes with NPC can create a model with 
more liver-like functionality.  How these cells affect sensitivity of a liver model to 
hepatotoxins, however, has not been elucidated.  The fourth aim of this thesis was 
to create a co-culture spheroid model and investigate how the addition of NPC alters 
the ability of the liver model to detect hepatotoxicity. 
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Aim 5:  To elucidate whether the measurement of novel biomarkers is possible from 
the in vitro liver spheroid model and if this can provide additional information about 
the mechanism of hepatotoxicity.  
Current clinical diagnostic biomarkers of DILI have weaknesses and research 
indicates that novel alternatives provide organ-specific and mechanistic information 
about the injury occurring.  Despite this, biomarkers of liver injury are not commonly 
quantified from in vitro liver models.  It was investigated whether novel biomarkers of 
DILI could be quantified from cell-based liver models and whether this could provide 
additional mechanistic information into the type of cell damage occurring and 
potentially increase the sensitivity of the liver spheroid model to hepatotoxins. 
 
Aim 6:  To confirm whether mitochondrial dysfunction caused by hepatotoxins can 
be detected in the liver spheroid model.  
DILI is thought to occur by an array of different mechanisms and 50 % of 
hepatotoxins cause injury through mitochondrial dysfunction (Begriche et al. 2011; 
Boelsterli and Lim 2007).  Mitochondria are integral to cell survival, hence the ability 
to detect mitochondrial liabilities in an in vitro model could greatly reduce the 
number of toxic compounds making it to clinic.  The final aim was to determine 
whether mitochondrial liabilities could be correctly identified in the liver spheroids 
and whether this may give mechanistic insight into how some common hepatotoxins 
are causing liver injury. 
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2.1 Introduction 
Predictive in vitro liver models are essential during initial drug screening in order to 
conduct an accurate risk assessment leading to better candidate selection early in 
the drug discovery and development process.  Current drug safety screens only 
detect 60-70 % of hepatotoxins (Xu et al. 2008).  The rapid decline in function and 
viability of human hepatocytes ex vivo and inter-donor variability is a major limitation 
of their use (Donato et al. 2008; Gomez-Lechon et al. 2004; Khetani et al. 2015b; 
LeCluyse et al. 2005).  Furthermore immortalised hepatocarcinoma cell lines, such 
as HepG2, C3A, Huh7 and HepaRG, demonstrate low functionality and an altered 
phenotype compared to human hepatocytes in vivo (Godoy et al. 2013; Guo et al. 
2011; LeCluyse et al. 2012).  Hence investigations into developing novel in vitro liver 
models are underway. 
 
Figure 2.1.  Illustration of the polarisation of hepatocytes. Tight junctions and 
desmosomes form on the apical membrane between adjacent hepatocytes and the 
membrane of each hepatocyte distorts to form a bile canaliculi structure. 
Transporters are localised to specific membranes in order for efficient transport.  
For example MRP1, SLCO3A1 and SLC28A3 are localised to the basolateral 
membrane whereas MRP2, Pgp and BSEP are expressed on the canalicular 
membrane and export compounds into the bile. 
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A key disadvantage of commonly used in vitro models is a lack of 3D structure, 
which has a significant effect on the hepatocyte morphology, function, phenotype, 
signalling and toxicological response (Gomez-Lechon et al. 1998; Semler et al. 
2000; Wells 2008).  Figure 2.1 illustrates the polarisation of hepatocytes in vivo 
along with the formation of desmosomes and tight junctions, creating bile canaliculi 
between the apical membranes and localised expression of hepatic transporters.  
For example MRP2 and Pgp are transporters localised to the canalicular membrane 
of hepatocytes and transport organic anions and efflux lipophilic cations from the cell 
respectively (Esteller 2008).  The microenvironment, secondary structures and 
specific polarisation of hepatocytes is vitally important to their function (Godoy et al. 
2013).  It is possible that in order to create a more relevant liver model, one must 
recapitulate these 3D structural characteristics. 
A simple, inexpensive and high-throughput method of culturing cells in 3D is by 
creating spheroids (Friedrich et al. 2009; Godoy et al. 2013; van Zijl and Mikulits 
2010; Wong et al. 2011).  The use of spheroids as a model for screening of 
hepatotoxins is fairly novel, in contrast to other areas of research where spheroids 
are a well-established 3D cell culture technique (van Zijl and Mikulits 2010).  
Preliminary research into liver spheroids has shown promising results.  For instance, 
hepatocarcinoma cell lines when cultured in 3D spheroids display more liver-like 
structures and functions than monolayer cultures (Chang and Hughes-Fulford 2009; 
Fey and Wrzesinski 2012; Mueller et al. 2011; Sainz et al. 2009; Takahashi et al. 
2015).  C3A cells are a subclone of HepG2 cells selected for their strong contact-
inhibited growth characteristics, as well as high-albumin production and transferrin 
synthesis and are able to grow in glucose deficient media (Nibourg et al. 2012).  
This cell line may therefore have advantages over other hepatocarcinoma cells 
when cultured in spheroids, with their reduced proliferation rate which is more 
representative of the in vivo situation and potentially allowing the cells to be cultured 
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for longer periods (Wrzesinski et al. 2013).  Previous studies of C3A spheroids have 
revealed superior function over 2D cultures, including increased cholesterol and 
urea release, as well as glycogen synthesis (Fey and Wrzesinski 2012; Wrzesinski 
and Fey 2013; Wrzesinski et al. 2013).  Despite the increasing interest and use of 
3D liver models, little research has gone into determining the most reliable method 
of spheroid formation and culture, as well as optimisation of key parameters such as 
spheroid size, proliferation, viability, cellular morphology and internal structure 
(Asthana and Kisaalita 2012; Curcio et al. 2007; Olive et al. 1992).  Additionally, 
further investigation into the liver-specific functionality and sensitivity of this model is 
necessary before it can be considered for drug screening purposes. 
The aim of this work was to develop and optimise a liver spheroid model and 
perform an initial characterisation.  C3A cells were chosen in order to create 
spheroids with the advantages of being human derived, easy to obtain and culture, 
little variability and reduced proliferation rate once in 3D.  Scaffold-free techniques 
were adopted to create spheroids for their ease, reproducibility, high-throughput 
nature and to avoid the detrimental effects of scaffolds or ECM.  
Hypothesis 1: C3A cells cultured in 3D spheroids would be viable for a prolonged 
period of time, with a reduced proliferation rate. 
Hypothesis 2: C3A spheroids will display a more in vivo-like internal structure 
including 3D morphology, direct cell-cell contacts and polarisation characteristics 
leading to an overall increased likeness to human liver tissue. 
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2.2 Materials and Methods 
Agarose type V high gelling temperature (A3768), agarose low electroendosmosis 
(EEO) (A9539), fetal bovine serum (FBS), penicillin-streptomycin, 1 x phosphate 
buffered saline (PBS), paraformaldehyde (PFA), Triton X-100, Tween20, Tris, 
bovine serum albumin (BSA), DMSO, doxorubicin were purchased from Sigma 
Aldrich, Missouri, USA.  C3A cells and Eagle's minimal essential medium (EMEM) 
were purchased from LGC standards, Middlesex, UK.  Ultra-Low Adherence (ULA) 
plates were purchased from Corning, NY, USA.  Cell Titer-Glo assay was purchased 
from Promega, Madison, USA.  MRP2 (ab3373), MRP1 (ab24102), SLC22A3, 
SLC03A1 and Pgp (ab8189) antibodies were purchased from Abcam, Cambridge, 
UK. Prolong Gold (P36930), Hoechst (H3570) and Alexa Fluor 568 phalloidin 
(A12380) were purchased from Life Technologies, Carlsbad, CA, USA.  Alexa Fluor 
488 Donkey Anti-Mouse (R37114) was purchased from Invitrogen, Carlsbad, CA, 
USA. M65 and M30 ELISA kits were purchased from Peviva, Stockholm, Sweden.  
BSEP antibody was purchased from ThermoFisher Scientific, MA, USA. 
2.2.1 Spheroid formation and cell culture 
C3A cells were maintained in EMEM supplemented with 10 % FBS and 1 % 
penicillin-streptomycin under standard cell culture conditions.  C3A cells were used 
between passage 5 and 15 for all experiments.  C3A cells were not mycoplasma 
tested or characterised before use.  For 2D monolayer experiments 40,000 C3A 
cells/well  were seeded, left to adhere for 24 hours and confirmed to be 100 % 
confluent before analysis. 
Spheroids were created using two techniques, the liquid-overlay technique (LOT) 
and ULA plates.  The LOT was performed as previously described (Yuhas et al., 
1977).  100 µL of molten sterile 1.5 % Agarose (high gelling temperature) dissolved 
in EMEM was added per well to flat-bottomed 96-well cell culture plates and left to 
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set to form a low-adherence surface (Figure 2.2).  C3A cells were seeded onto 
either LOT or ULA plates at different cell densities (500 - 2500 cells/well) in 100 µL 
media, centrifuged for 5 min at 1000 rpm and left for 72 hours to form spheroids.  
The outer 36 wells of the plate were not used due to inconsistencies occurring from 
differences in oxygen and humidity (Figure 2.3).  50 % of the media was renewed 
twice weekly and spheroids were cultured for up to 32 days.  Cell numbers were 
counted by trypsining cells in spheroids (pool of 3 spheroids) and counting cell 
number using a haemocytometer. 
  
Figure 2.2.  Illustration of spheroid formation using the LOT and ULA 
plates.  Both (A) the LOT and (B) ULA plates were investigated.  For the LOT 
agarose was added to each well of a flat-bottom 96-well plate and left to set. 
Cells were then seeded into the wells and after approximately 72 hours the cells 
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2.2.2 Phase contrast microscopy to measure spheroid morphology and 
diameter 
Spheroid diameter and morphology was analysed by light microscopy using a 
phase-contrast microscope (ECLIPSE TS100/100-F, Nikon).  Photographs were 
captured using a digital camera head (DS-Vi1, Nikon) and a stand-alone controller 
and display unit (DS-L3, Nikon).  Spheroid diameter was measured from these 
images (n=9) (where not symmetrical the maximum diameter was measured).  
2.2.3 Histological analysis for the analysis of cell morphology and 
proliferation. 
Spheroids were washed in PBS, fixed for 1 hour in 4 % PFA and embedded in 2 % 
Agarose (low EEO) in 4 % PFA then paraffin embedded.  Tissue sections were cut 
and stained with haematoxylin and eosin (H&E) or immunostained for Ki-67 as 
previously described (Colley et al., 2011).  Briefly tissue sections had wax removed 
Figure 2.3.  Spheroid and cell culture plate layout. When culturing spheroids or 
cells in monolayer on 96-well plates, only the inner 60 wells were used, as the 
outer 36 wells has inconsistencies in spheroid formation and cell density.  
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with Histoclear, were hydrated in decreasing concentrations of ethanol, stained with 
haematoxylin, then eosin and next dehydrated in increasing concentrations of 
ethanol and cleared using Histoclear.  Immunostaining for Ki-67 was carried out by 
Julie Haigh at the Department of Veterinary Pathology, Leahurst Campus, University 
of Liverpool, UK. 
2.2.5 Keratin 18 cell death quantification by ELISA 
Total keratin 18 and ck18 in pooled spheroid supernatant (10 wells) were quantified 
using M65 and M30 ELISA kits respectively, according to the manufacturer’s 
protocol. All incubations were performed at room temperature (RT).  Samples were 
diluted as appropriate and 25 µL of standard and sample added to the pre-coated 
ELISA plate, followed by 75 µL M65 or M30 conjugate and incubated on a plate 
shaker at 60 rpm for 2 or 4 hours respectively.   The wells were washed 5 times with 
250 µL Wash Buffer and incubated for 20 min with 200 µL TMB substrate in the 
dark. 50 µL stop solution was added, the plate shaken for 10 seconds, then after 5 
min the absorbance read at 450 nm using a microplate reader (Thermo Scientific 
Varioskan Flash).  Apoptotic cell death was represented by the ck18 concentration, 
total cell death represented by total keratin 18, and necrotic cell death calculated 
from the total cell death minus apoptotic cell death. 
2.2.6 Transmission electron microscopy 
Spheroids were pooled (10 wells) and fixed at day 10 of culture and processed for 
electron microscopy (EM).  Transmission EM was performed by Alison J Beckett, 
Biomedical EM Unit, School of Biomedical Sciences, University of Liverpool and 
images taken using FEI Tecnai G2 Spirit 120KV bioTWIN. 
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2.2.7 Immunofluorescent analysis of spheroids 
Spheroids were transferred to ULA plates, washed three times in PBS and fixed with 
4 % PFA for 1 hour at 4 °C.  Spheroids were washed again then permeabilized with 
0.5 % Triton X-100 in Tris-Buffered Saline with 0.05 % Tween20 (TBST) overnight at 
4 °C and next blocked with 0.1 % Triton X-100/3% BSA in TBST for 2 hours at RT.  
Primary antibody diluted in 0.1 % Triton X-100 /1 % BSA in TBST were then 
incubated with the spheroids overnight at 4 °C.  Multidrug resistance protein-2 
(MRP2) and P-glycoprotein (Pgp) antibodies were used at a 1:20 dilution.  Other 
transporters MRP1, BSEP, SLCO3A1 and SLC28A3 were analysed, but could not 
be optimised for use with spheroids.  Spheroids underwent three 1 hour washes with 
1 % Triton X-100 in TBST then incubated with secondary Alexa Fluor 488 Donkey 
Anti-Mouse antibody diluted at 1:1000, Hoechst diluted at 1:5000 and phalloidin 
diluted at 1:250 in 0.1 % Triton X-100 /1 % BSA in TBST overnight at 4 °C.  
Spheroids were washed for 1 hour and finally mounted with Prolong Gold onto a 
glass microscope slide.  Maximum intensity projection images of spheroids were 
taken on Zeiss microscope using 40 × oil objective. 
2.2.8 Immunofluorescent analysis of 2D monolayers 
Cells were washed in PBS for 30 min at 4 °C then fixed with 2 % PFA for 30 min at 4 
°C.  Cells were permeabilized with two 15 min washes in 0.2 % Tween-20/ 0.5 % 
Triton X-100 in PBS at 4 °C and blocked for 30 min in 5 % BSA/ 0.2 % Tween-20/ 
0.5 % Triton X-100 in PBS at RT.  The primary antibody was diluted in 5 % BSA/ 0.2 
% Tween-20/ 0.5 % Triton X-100 in PBS and incubated with cells overnight at 4 °C.  
Cells underwent three 15 min washes in 0.2 % Tween-20/ 0.5 % Triton X-100 in 
PBS then incubated with secondary Alexa Fluor 488 Donkey Anti-Mouse antibody 
diluted at 1:1000, Hoechst diluted at 1:5000 and phalloidin at diluted 1:250 in 5 % 
BSA/ 0.2 % Tween-20/ 0.5 % Triton X-100 in PBS for 1 hour at RT.  Cells underwent 
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three 15 min washes in PBS and finally were mounted with Prolong gold onto a 
glass microscope slide. Images were taken on Zeiss microscope using 40 × 
magnification with oil objective. 
2.2.9 Statistical analysis 
Data are representative of at least three independent experiments (n=3) and 
expressed as mean ± SEM. Graphs and statistical analyses were performed using 
GraphPad Prism 5.  A Shapiro-Wilk normality test was performed on all data sets. 
Data which passed normality tests underwent analysis by a two-way ANOVA, those 
which did not underwent a non-parametric Kruskal-Wallis test.  Significance was 
determined from a p value < 0.05. **** p<0.0001, *** p< 0.001 ** p<0.01, * p< 0.05. 
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2.3 Results 
2.3.1 Comparison of spheroid formation techniques 
C3A cells with a seeding density of 2500 cells/well successfully created spheroids 
using both the LOT and ULA plates, with the cells in each well aggregating to form a 
single spheroid (see Figure 2.2). 
Spheroids created by LOT were generally more spherical and uniform in shape 
compared to those created on ULA plates which had a more irregular structure with 
a less defined outer perimeter throughout the culture period (Figure 2.4A).  The 
diameter of the spheroids gradually increased over the culture period of 25 days, 
with very similar growth curves from both techniques (Figure 2.4B).  Due to a more 
consistent, spherical morphology all further spheroids were generated using the 
LOT.  
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Figure 2.4.  Comparison of spheroid formation techniques.  (A) Phase-contrast 
images of representative spheroids cultured from 2500 cells on LOT or ULA plates 
over 25 days. Scale bar = 100 µm. (B) Growth curve of spheroids cultured by 
liquid-overlay technique (black circle) or ULA plates (clear triangle).  Spheroid 
diameter (µm) was plotted against culture time (days). Data are represented as 
mean ± SEM (n=3 in triplicate). 
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2.3.2 Optimisation of spheroid starting cell number 
Next, the effect of different starting cell numbers on spheroid formation, size and 
shape over time was investigated.  Spheroids were formed by LOT from 500, 750, 
1000, 1500, 2000 or 2500 C3A cells and cultured for 32 days.  Brightfield 
microscopy was used to measure spheroid diameter and morphology every 2-3 
days (Figure 2.5A).  Spheroid size versus time for each cell number is plotted in 
Figure 2.5B.  
All starting cell numbers resulted in the formation of spheroids with varying sizes 
and morphology.  Spheroids created from 500 cells gradually increased in diameter 
over 32 days from 237.0 ± 14.3 µm to 432.9 ± 111.4 µm in diameter, however these 
spheroids were less uniform and less stable in shape, resulting in disaggregation of 
some cells (Figure 2.5A and 2.5B).  Spheroids with a starting cell number of 750 or 
1000 cells steadily grew over 32 days, starting with a diameter of 289.4 ± 26.5 µm 
and 343.2 ± 73.3 µm at day 4 and increasing to 407.7 ± 92.3 µm and 539.5 ± 39.5 
µm at day 32 respectively, and maintained a uniform spherical shape over the 
course of the culture.  Spheroids created from higher starting cell numbers, 1500, 
2000 or 2500 cells, increased in size more rapidly, reaching much larger diameters 
of 624.5 ± 59.5 µm, 730.0 ± 112.0 µm and 759.1 ± 83.5 µm, as well as becoming 
irregular in shape (Figure 2.5A and 2.5B).  From this data, 750 to 1000 cells was 
determined to be an optimal range of cell number, as these spheroids remained 
uniform in shape over the 32 days, with little variation in post establishment size and 
the smallest diameter. However 2500 cell spheroids have also been subsequently 
used in the analysis as a comparison. 
Next, cell numbers were counted in the optimised 1000 cell spheroids over 32 days 
(Figure 2.6).  Cell number can be seen to increase over time, with a typical 
sigmoidal pattern, reaching a plateau around day 21 of culture, indicating reduced 
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proliferation and senescence.  The 1000 cell spheroids reached a maximum of just 
over 60,000 cells at the end of the culture period.  
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Figure 2.5.  Effect of starting cell number on spheroid size and morphology.  
Spheroids were created from 500, 750, 1000, 1500, 2000 and 2500 C3A cells and 
cultured for 32 days. (A) Phase-contrast images of representative spheroids, 
images taken at day 7, 11, 14, 18, 21, 25, 28, 32. Scale bar  = 100 µm. (B) Growth 
curve of spheroids over 32 days.  Spheroid diameter (µm) was plotted against 
culture time (days).  Data are represented as mean ± SEM (n=3 from 5 repeats).  
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2.3.3 Internal spheroid structure 
In order to analyse the internal structure of the C3A spheroids and to visualise cell 
morphology and arrangement over 32 days, H&E staining was performed (Figure 
2.7).  Staining of spheroids with a starting cell number 750 cells revealed a compact, 
uniform structure, with a defined outer perimeter (Figure 2.7).  Cells within these 
spheroids had a cuboidal 3D morphology with direct cell-cell contacts, as seen in the 
liver in vivo (Krishna 2013).  Correlating with cell growth data (Figure 2.5), the 750 
cell spheroids are seen to increase in size and stay uniformly spherical throughout 
the culture period with only very small amounts of apoptosis visible on the H&E 
staining at later stages of culture past day 18.  On the other hand in the larger 2500 
cell spheroids small patches of cell death started to occur around day 14 and, by 
day 18, a necrotic core had formed.  Additionally, by day 25 the 2500 cell spheroids 
became misshapen and their growth started to rapidly increase, resulting in the 
spheroids disaggregating and losing structural integrity (Figure 2.7).  
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Figure 2.6.  Spheroid cell count. Spheroids were created from 1000 C3A cells and 
cultured for 32 days and cell number counted per spheroid.  Spheroid cell number is 
plotted against culture time (days).  Data are represented as mean ± SEM (n=3 in 
triplicate).  
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EM was performed and cell microstructures analysed.  Figure 2.8 A-C shows 
images taken throughout the spheroids.  Spheroids were observed to be viable, with 
a defined cell membrane and numerous mitochondria, an intact nuclear membrane 
and Golgi.  It is clear that the cells are in a 3D morphology and numerous direct cell-
cell contacts were visible.  Overall the cell morphology was comparable to that of 
liver tissue (Figure 2.8 D and E).  It was also possible to identify multiple bile 
canalicular structures throughout the spheroids (Figure 2.8 C), which can be 
confirmed by the formation of tight junctions and desmosomes at either end of a 
deformation in the cell membrane between adjacent cells (Farquhar and Palade 
1963), as schematically illustrated in Figure 2.1.    
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C 
Figure 2.8.  Electron microscopy of C3A spheroids. Spheroids were created by LOT 
and for transmission electron microscopy.  (A) shows a section of a typical C3A 
spheroid and (B) at a higher magnification, indicating the nucleus (N), mitochondria 
(M), nuclear membrane (white arrow) and plasma membrane (black arrow). (C) and (D) 
are images of human liver tissue for comparison taken from (Dutkowski et al. 2006) and 
Dr R C Wagner, University of Delaware.  (E) shows an example of the formation of bile 
canalicular structures (star) indicated by a space between adjacent cells connected by 
desmosomes (black arrow) and tight junctions (white arrow) at either end.  Images of 
spheroid were taken using an electron microscope. Scale bars = 10 µm, 2 µm and 1 
µm respectively.  
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B A 
C D 
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2.3.4 Cell death analysis in spheroids 
The release of cell death biomarkers was quantified from spheroids of different sizes 
(Figure 2.9).  Keratin 18 was analysed to distinguish between apoptotic and necrotic 
cell death in the spheroids.  It was revealed that significantly higher levels of 
necrosis in the larger 2500 cell spheroids compared to the 1000 cell controls.  
3485.5 ± 133.1 U/L of necrotic keratin 18 was detected in spheroids created from 
2500 cells and cultured for 24 days, whereas over 10 times less, 243.7 ± 80.9 U/L, 
was detected in 1000 cell spheroids cultured for 10 days.  There was however no 
significant difference in the levels of apoptosis in the different culture conditions, 
staying in the range 241.3 to 945.8 U/L (Figure 2.9A).  In addition to this, necrosis 
appears to be the leading mechanism of cell death in the larger and older spheroids, 
supporting the histology data which appears to show a necrotic core only in the 
larger 2500 cell spheroids (Figure 2.7, bottom row).  The amount of cell death was 
also compared against the corresponding spheroid diameter for each culture 
condition (Figure 2.9B).  Necrosis was observed to significantly increase once 
spheroids reach a critical diameter of around 700 µm, correlating with histology 
which shows necrotic core formation once spheroids reach 700 µm.  Extending the 
culture time to 24 days increased necrosis further in the larger spheroids (Figure 
2.9B).    
Next the cumulative basal levels of cell death in 1000 cell spheroids were 
determined over a culture period of 33 days (Figure 2.10).  The levels of apoptotic 
and necrotic biomarker release did not change significantly over a 32 day period.  
Slightly higher levels of necrosis were detected at day 3 of culture 0.27 ± 0.19 
U/L/cell, with apoptosis at 0.063 ± 0.007 U/L/cell.  For the remainder of the culture 
period the levels of necrosis decreased and apoptosis increased until day 33 at 0.21 
± 0.05 U/L/cell and 0.06 ± 0.05 U/L/cell respectively.   
D 
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Culture 
condition 
Spheroid 
diameter (μm) 
Apoptosis 
(U/L) 
Necrosis 
(U/L) 
Total cell death 
(U/L) 
1000 cell Day 10 354.9 557.3 243.7 801.0 
2500 cell Day 18 709.89 545.6 1667.7 *** 2213.3 
2500 cell Day 24 683.86 945.8 3485.5 **** 4431.3 
2D control 24 hr - 241.3 2174.4 **** 2415.7 
A 
B 
Figure 2.9.  Comparison of basal cell death in spheroids of different sizes. 
Biomarkers of apoptosis (ck18) and total cell death (total keratin 18) were analysed by 
ELISA in supernatants of spheroids of different sizes and culture times, and compared 
to a 2D monolayer control. (A) Total cell death (U/L), split into apoptotic (white) and 
necrotic (black) are plotted against culture condition; (B) Table showing cell death 
values obtained compared to culture condition and corresponding spheroid diameter 
(µm) Data are represented as mean ±  SEM (n=3 using 20 replicates). **** p<0.0001, 
*** p< 0.001 for necrotic keratin 18 compared to 1000 cell day 10. 
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2.3.5 Spheroid proliferation rate 
Proliferation of the cells in the spheroids was analysed over the first 18 days of 
culture using Ki-67 staining in spheroids created from 750 or 2500 cells.  Nuclei 
stain blue with haematoxylin and proliferating cells appear brown, stained with Ki-67.  
A reduction in the amount of proliferating cells can be seen in Figure 2.11A, with 
those that are proliferating mainly located to the periphery of the spheroids.  At day 
4, 59.50 ± 3.5 % and 50.60 ± 2.3 % of the cells in the spheroids were proliferating 
for spheroids created from 750 and 2500 cells respectively (Figure 2.11B).  At day 
11 significantly less proliferation was occurring and after 18 days in culture only 
32.43 ± 6.1 % and 7.40 ± 1.3 % of cells were proliferating in 750 and 2500 cell 
spheroids respectively (Figure 2.11B).  This correlates with the cell number data in 
Figure 2.6, as cells initially have a higher proliferation rate as cell number rapidly 
increases, this then decreases by around day 18 as the cell number levels off and 
proliferation rate decreases. 
Figure 2.10.  Keratin 18 release from spheroids over time.  Biomarkers of 
apoptosis (cleaved keratin 18) and total cell death (full-length keratin 18) were 
analysed in supernatants of spheroids over a 33 day culture period.  Total cell 
death, split into apoptotic (white) and necrotic (black) are plotted against culture 
condition.  Data are represented as mean ± SEM (n=3 using 20 replicates). 
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Figure 2.11.  Proliferation of cells within the spheroids. Spheroids were 
created by LOT from 750 or 2500 C3A cells and fixed at day 4, 11 and 18 of 
culture, paraffin embedded, sectioned and stained with ki67 (brown) to stain 
proliferating cells, and haematoxylin (blue) to stain the nuclei. (A) Images of 
spheroid mid-sections.  Scale bar =100 µm; (B) Graph showing proliferating cells 
(%) plotted against culture time (days). Data are represented as mean ± SEM 
(n=3), **** p<0.0001, *** p< 0.001, * p<0.05 compared to day 4. 
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2.3.6 Polarisation of C3A cells in spheroids 
One of the key features of hepatocytes is their ability to polarise.  This involves the 
formation of bile canaliculi between adjacent cells, as well as the polarisation of key 
transporters to either the apical or basolateral membranes (see Figure 2.1 for 
schematic) (Gissen and Arias 2015; Godoy et al. 2013).  Immunofluorescence was 
used to analyse the internal structure of the spheroids over time.  Spheroids were 
fixed and stained with Hoechst (blue) to stain the nuclei and phalloidin (red) to 
visualise F-actin structures, then imaged by confocal microscopy (Figure 2.12).  
After 4 days in culture, actin filaments were observed forming between cells within 
the spheroid (Figure 2.12A).  After 11 days in culture, these actin structures could be 
seen joining together to create an interconnected network of secondary structures 
throughout the spheroid (Figure 2.12B). 
  
Figure 2.12.  Secondary structure formation in spheroids. Spheroids were cultured 
by LOT, fixed and stained with Hoechst (blue) to stain the nuclei and phalloidin (red) to 
stain F-actin. Maximum intensity projection images were taken using a Zeiss Axio 
Observer microscope at 10 × (4 day old spheroids) and 40 × (11 day old spheroids) 
magnification respectively.  Scale bars = 100 µm and 50 µm respectively. 
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The expression of MRP2 and Pgp transporters was used to confirm whether the 
actin structures observed were the result of cellular polarisation and the formation of 
bile canaliculi, and whether or not culture time or spheroid size affected this process.  
Spheroids of different starting cell numbers were analysed over 18 days for MRP2 
and Pgp expression.  Figure 2.13 shows the expression of MRP2 and Figure 2.14 
the expression of Pgp in spheroids created from 750, 1500 or 2000 cells.  The 
staining pattern of these transporters emulated the F-actin structures seen 
previously (Figure 2.12).  The secondary structures could be seen forming after 4 
days of culture regardless of the starting cell number, and appeared to elongate and 
join together over time, forming an interconnected network of canalicular-like 
structures (Figure 2.13 and 2.14).  The same staining pattern for MRP2 and Pgp 
were not observed in the corresponding 2D monolayer culture (Figure 2.13 and 
2.14, bottom row). 
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Figure 2.13.  MRP2 transporter location in spheroids. Spheroids were created from 
750, 1500, 2000 C3A cells by LOT or C3A cells were cultured in a 2D monolayer and  fixed 
at day 4, 11 and 18 of culture.  Immunofluorescent staining was performed for the 
canalicular transporter MRP2 (green) and Hoechst (blue) to stain the nuclei.  Maximum 
intensity projection images were taken using a Zeiss Axio Observer microscope at 40 × 
magnification.  Scale bars = 50 µm. 
 
  Chapter 2     
67 
 
  
Figure 2.14.  Pgp transporter localisation in spheroids. Spheroids were created from 
750, 1500, 2000 C3A cells by LOT or C3A cells were cultured in a 2D monolayer and  fixed 
at day 4, 11 and 18 of culture.  Immunofluorescent staining was performed for the 
canalicular transporter Pgp (green) and Hoechst (blue) to stain the nuclei.   Maximum 
intensity projection images were taken using a Zeiss Axio Observer microscope at 40 × 
magnification.  Scale bars = 50 µm.  Some of the day 18 spheroids were unable to be 
mounted onto a microscope slide due to increased size. 
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2.4 Discussion 
3D in vitro models are becoming more widely used when investigating drug toxicity.  
Multiple companies now offer spheroids to be shipped ready for use in drug toxicity 
testing, such as InSphero (InSphero 2016).  Research has shown the potential for 
liver spheroid models to be more predictive for hepatotoxicity than commonly used 
2D liver models, as well as being more amenable to high-throughput screening and 
long-term repeat dose studies (Fey and Wrzesinski 2013; Godoy et al. 2013; Mueller 
et al. 2011; Tostoes et al. 2012).  However many parameters had not been 
thoroughly investigated in spheroid models and there were relatively few direct 
comparisons between liver spheroids and other 2D models. 
In this chapter a technique for creating liver spheroids from the C3A cell line was 
developed and optimised.  C3A cells, a derivative of HepG2 cells, were chosen for 
this model as they exhibit strong contact-inhibited growth characteristics, 
consequently when cultured in a spheroid these cells do not proliferate to the same 
extent as other hepatocarcinoma cell lines (Wrzesinski and Fey 2013).  This also 
better emulates primary cells which bear limited proliferation capacity.  As with other 
liver cell lines cultured in 2D, C3A cells have disadvantages including limited 
expression of metabolizing enzymes and lack of liver-specific functions (Guo et al. 
2011; LeCluyse et al. 2012), however the advantages over primary cells include 
unlimited replication potential, stable phenotype, absence of donor variation as well 
as ease of availability (Donato et al. 2008; LeCluyse et al. 2012).   
In this study, C3A spheroids were created and characterised and found to be 
uniform and reproducible using the LOT, which has not been previously reported to 
have been used with this cell type.  The LOT is a well-established technique and 
has been used to create spheroids from numerous different cell types in the past 
(Dorst et al. 2014; Herzog et al. 2015).  Creating spheroids by this method was rapid 
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and demonstrated a high degree of reproducibility (coefficient of variation 0.53 or 
less for spheroid diameter); also it does not require an extensive tissue engineering 
background, making this model far more user-friendly.  The cost-effectiveness of the 
model and amenability to both high-throughput and repeat-dose studies makes it a 
promising model for toxicological studies (Godoy et al. 2013).  The optimised 
spheroids remained viable for 32 days of culture with a maximum diameter of 407.8 
± 92.3 µm, and uniform in shape and size.  Histological and EM analysis revealed 
cuboidal cell morphology within the spheroids, with direct cell-cell contacts similar to 
the in vivo liver structure, hence overcoming the multitude of structural and 
phenotypic problems with culturing cells in 2D (Gomez-Lechon et al. 1998; Semler 
et al. 2000; Wells 2008).  The C3A spheroid model therefore recapitulates the 
human liver more so than the corresponding 2D cell models. 
One disadvantage of using spheroids for drug testing is that necrosis can occur 
within the spheroid core, distorting toxicity data. Despite this problem, few 
researchers have analysed the extent of necrosis when using liver spheroids.  It has 
been estimated that oxygen and nutrients can diffuse through approximately 100 - 
150 µm of tissue (Asthana and Kisaalita 2012; Curcio et al. 2007; Olive et al. 1992), 
however the size or time at which liver spheroids develop necrosis at the core has 
not been specifically determined.  To complicate things further, factors such as cell 
type, cell number, culture time, culture technique and scaffold interactions may all 
have an impact on the development of necrosis in a spheroid model.  The data 
generated in this chapter optimised starting cell number to create uniform 
reproducible spheroids, and after culture for 32 days the optimised spheroids do not 
possess a necrotic core, with only very low degree of apoptosis and necrosis 
detected over a 32 day culture period.  It was determined that once the C3A 
spheroids exceed approximately 700 µm in diameter a necrotic core can be seen to 
have developed and there were significantly increased detectable levels of necrotic 
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biomarker.  Therefore, C3A spheroids exceeding this critical size were deemed 
unusable to accurately determine the toxicological effect of a compound since they 
are likely to be structurally unstable, with pre-existing necrosis at the core. 
In vivo, hepatocytes are structurally and functionally polarised (Gissen and Arias 
2015; Godoy et al. 2013).  The formation of bile canaliculi structures between cells 
in the C3A spheroids confirms the structural polarity of the spheroids, and was 
confirmed using EM and immunofluorescence.  It was also identified that the 
spheroids displayed functional polarity, as MRP2 and Pgp - transporters known to 
be localised to the canalicular membrane of hepatocytes in vivo – were found to be 
expressed on the canalicular membrane (Esteller 2008; Wrzesinski et al. 2014).  
These polarisation features were not reproduced in 2D monolayers.  The expression 
of these transporters is important, as not only do they have vital roles in liver 
homeostasis, but are also involved in the transport of drugs into, and export from, 
hepatocytes (Jedlitschky et al. 2006; Sharom 2011).  Dysfunction of these transports 
can lead liver damage and cholestasis.  Other basolateral and canalicular 
transporters were analysed, however the method used could not be optimised.  
Analysis of other hepatic uptake and export transporters would be valuable to this 
research. 
Other studies have used C3A cells to create spheroids, such as Wrzesinski’s group, 
who created C3A spheroids on AggreWell plates and transferred them into a 
microgravity bioreactor for culture (Fey and Wrzesinski 2012; Wrzesinski and Fey 
2013; Wrzesinski et al. 2013).  Characterisation was performed on their spheroids, 
such as analysis of spheroid size and viability (Wrzesinski and Fey 2013; Wrzesinski 
et al. 2013).  More recently the same group have investigated the changes which 
occur once cells are cultured in 3D, finding key differences in cell architecture, 
metabolism and compound synthesis, growth and genetics (Wrzesinski et al. 2014).  
The C3A spheroids created in this chapter displayed similar overall characteristics to 
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those created by Wrzesinski’s group, including similar growth curves and 
comparative structural similarities.  A scaffold free approach for creating spheroids 
was also adopted in this thesis in order create direct cell-cell contacts and to reduce 
any ECM effects (Gomez-Lechon et al., 1998; Semler et al., 2000; Wells, 2008), 
however the LOT was much simpler than that used by Wrzesinski’s group.   
2.4.1 Conclusion 
Spheroids show promise as a novel in vitro liver model, including a prolonged 
lifespan, structural similarities with the liver in vivo, good reproducibility and 
amenability to high-throughput screening.  A reproducible technique for creating 
uniform C3A spheroids was developed.  The optimised spheroids were created from 
750-1000 C3A cells and were viable for 32 days, displaying a reduced proliferation 
rate, an in vivo-like cell morphology as well as 3D direct cell-cell contacts, polarised 
cells, bile canaliculi formation and localised hepatic transporters.    
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3.1 Introduction 
The liver is a vitally important organ, with multiple functions essential for human 
survival.  The main function of the liver is the metabolism of compounds, including 
hormones, xenobiotics, carbohydrates, lipids as well as the production of albumin, 
urea, amino acids, lipoprotein and cholesterol (Cotran 2005; Lippincott. J. B 1993).  
The expression and function of key metabolic enzymes is essential in order for 
hepatocytes to metabolise and synthesise compounds.   Additionally, functional 
transporters are needed for the liver to exocytose and endocytose important 
molecules (Cotran 2005; Godoy et al. 2013).  Many of these metabolites or by-
products need excreting hence hepatocytes have transporters to secrete bile into 
the canaliculi and bile ducts in order to remove these substances from the liver 
(Gissen and Arias 2015).  Mitochondrial integrity is crucial to ensure correct 
functioning of hepatocytes, as these organelles are responsible for respiration and 
producing energy through metabolism (Cooper 2000).  Some of these functions 
occur in specific zones of the liver, as the liver displays functional heterogeneity due 
to zonation of the liver lobule.  Some of these key functions of the liver are 
summarised in Figure 3.1. 
 Figure 3.1.  The functional roles of hepatocytes.  An illustration of the key 
functions of hepatocytes including the synthesis of substrates and compounds, 
enzymatic metabolism, secretion of important molecules, excretion of substances 
into bile canaliculi and efficient energy production through mitochondrial respiration. 
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Expression of liver-specific markers, albumin and urea synthesis, metabolic enzyme 
expression, increased enzyme function and transporter function, have been 
determined to be increased in 3D liver models  (Chang and Hughes-Fulford 2009; 
Sainz et al. 2009; Tostoes et al. 2012).  This may overcome one of the key 
disadvantages of liver cell lines in that they display reduced liver function in 2D 
culture (Guo et al. 2011; LeCluyse et al. 2012). A more accurate liver model 
displaying increased liver-specific functions may help to broaden one’s 
understanding of the mechanisms of liver injury and potential toxic drug targets, 
allowing researchers to create more efficacious drugs whilst designing-out toxicities.  
Hence, determining the functionality of in vitro liver models has become a priority in 
the aim to create more human-relevant drug screening systems.  Despite the 
increased research into this area there is still much more to investigate in 3D liver 
models, and the functionality of C3A spheroids has yet to be fully determined or 
compared to current 2D liver models. 
In the previous chapter a technique for creating spheroids using C3A hepatoma 
cells was developed and optimised.  This work next planned to elucidate the liver-
specific functionality and phenotype of the C3A spheroids and compare this with a 
corresponding 2D culture model.   
Hypothesis: C3A spheroids will display liver-like functions which will be an 
improvement upon corresponding 2D culture model. 
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3.2 Materials and Methods 
L-glutamine, sodium pyruvate, 1 x PBS, PFA, Triton X-100, Tween20, Tris, BSA, 
DMSO and glucose were purchased from Sigma Aldrich, Missouri, USA.  C3A cells 
and EMEM were purchased from LGC standards, Middlesex, UK.  Cell-Tak was 
purchased from Corning, NY, USA.  GS, CPS1, CYP2E1, CYP3A4 and GAPDH 
antibodies, Albumin Human ELISA Kit (ab108788) and Urea Assay Kit (ab83362) 
were purchased from Abcam, Cambridge, UK. Prolong Gold (P36930), Hoechst 
(H3570), Alexa Fluor 568 phalloidin (A12380) and Cell Tracker 5-
chloromethylfluorescein diacetate (CMFDA) (C7025) were purchased from Life 
Technologies, Carlsbad, CA, USA.  M65 and M30 ELISA kits were purchased from 
Peviva, Stockholm, Sweden.  XFe96 cell culture microplates, spheroid microplates, 
extracellular flux assay kits, calibrant and base medium minimal DMEM were all 
purchased from Seahorse Bioscience, Massachusetts USA.  Bradford reagent was 
purchased from Bio-Rad, Hertfordshire, UK. 
3.2.1 Spheroid formation and cell culture 
C3A cells were maintained and cultured in monolayers as previously described 
(Section 2.2.1).  Spheroids were created using the LOT from 1000 C3A cells as 
described previously (Section 2.2.1).   
3.2.2 Analysis of MRP2 and Pgp transporter function 
Spheroids and monolayers were incubated with 5 µM CMFDA with or without 25 µM 
MK571 (MRP inhibitor) and 12.5 µM PSC833 (Pgp inhibitor) in EMEM for 30 min at 
37 °C.  CMFDA is membrane permeable until it enters the cells and is converted to 
glutathione-methylfluorescein (GSMF), a cell impermeable substrate for MRP2 and 
Pgp.  Cells and spheroids were washed in PBS and prepared for 
immunofluorescence analysis as previously described (Section 2.2.7). 
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3.2.3 Preparation of cell lysates 
Supernatant samples were stored at -80 °C.  Monolayer cells were lysed using 100 
µL lysis buffer made up of 250 mM sucrose, 50 mM Tris-HCl pH 7.4, 5 mM MgCl2, 1 
mM β-mercaptoethanol, 1 % Triton X-100.  Spheroids were pooled (20 wells), 
washed in PBS, and lysed using 100 µL lysis buffer with 1 % Triton X-100, and 
stored at -80 °C.  Samples were sonicated before analysis to ensure thorough lysis 
of spheroids.  
3.2.4 Bradford assay for quantification of protein content 
Standards in the range 0 - 0.5 mg/mL BSA were added to a 96-well plate. Samples 
were diluted as appropriate in dH20.  200 µL Bradford Reagent was added per well 
and the absorbance measured at 570 nm.  Protein concentrations were calculated 
using values obtained from the standard curve.   
3.2.5 Western blot analysis for the expression of zonation and hepatocyte 
markers 
50 µg of each sample was denatured at 80 °C before being analysed by SDS-PAGE 
on a 10 % acrylamide gel. The proteins were then transferred to a nitrocellulose 
blotting membrane then blocked using 10 % non-fat milk in Tween-Tris Buffered 
Saline (TBST).  Membranes were probed with primary antibodies 
carbamoylphosphate synthetase I (CPS1), glutamine synthetase (GS), CYP3A4 and 
GAPDH at 1:1000 dilutions overnight in 10 % non-fat milk in TBST.  Membranes 
were washed in TBST and bound antibody detected using secondary antibodies 
anti-rabbit IgG-peroxidase (1:10000), anti-mouse IgG-peroxidase (1:10000) 
incubated for 2 hours. Protein bands were visualised by enhanced 
chemiluminescence on X-ray developer film.  GAPDH was analysed to ensure even 
loading of samples. 
  Chapter 3     
78 
 
 
3.2.6 Histological analysis of functional zonation and hepatocyte markers 
Spheroids were fixed, sectioned and stained with haematoxylin and CYP2E1 or 
CPS1 as previously described (Section 2.2.3).   Immunohistochemistry was carried 
out by Julie Haigh at the Department of Veterinary Pathology, Leahurst Campus, 
University of Liverpool, UK. 
3.2.7 Measurement of CYP activity by quantification of metabolites using Mass 
Spectrometry 
Spheroids and 2D monolayer cells were washed twice in Williams E phenol-red free 
medium.  Cells were treated with 1 mM testosterone and 0.25 mM 
dextromethorphan in Williams E medium for 24 hours.  Spheroids or cells were 
pooled (from 12 wells), cells were washed in Williams E medium then stored at – 80 
°C until analysis.  Quantification of metabolites 6β-OH-testosterone and 
Dextrorphan by Mass Spectrometry was performed by Rowena Sison-Young at the 
University of Liverpool, UK.  
3.2.8 Quantification of albumin release by ELISA 
Albumin release from spheroids and monolayers into supernatant was quantified 
using Albumin Human ELISA Kit (Abcam), according to the manufacturer’s protocol.  
Supernatant was pooled (4 wells) and collected 4 days after media change, twice 
weekly over 32 days and stored at -80 °C until analysis.  All incubations were 
performed at RT.  Albumin standards were prepared and 50 µL added to the wells of 
a pre-coated 96-well plate, along with samples for analysis, and incubated for 1 
hour.  The plate was washed 5 times with 200 µL wash buffer and incubated with 50 
µL biotinylated albumin antibody for 30 min.  The plate was washed as previously 
described and incubated with 50 µL SP conjugate for a further 30 min.  Again the 
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plate was washed and incubated with 50 µL Chromagen solution for 20 min then 50 
µL stop solution added.  The absorbance was read at 450 nm using a microplate 
reader (Thermo Scientific Varioskan Flash).  The albumin concentration in the 
samples was calculated using values obtained from the standard curve and 
normalised to average cell number.  
3.2.9 Quantification of urea release  
Urea release from spheroids and monolayers into supernatant was quantified using 
a Urea Assay Kit (Abcam), according to the manufacturer’s protocol.  Supernatant 
was pooled (4 wells) and collected 4 days after media change, twice weekly over 32 
days and stored at -80 °C until analysis.  Urea standards were prepared and 50 µL 
added to the wells of a 96-well plate, along with samples for analysis, and incubated 
with 50 µL urea reaction mix for 1 hour at 37 °C, protected from light.  The 
absorbance was read at 570 nm using a microplate reader (Thermo Scientific 
Varioskan Flash).  Urea concentration in the samples was calculated using values 
obtained from the standard curve and normalised to average cell number. 
3.2.10 Visualisation of mitochondrial location 
Mitochondria were visualised by incubating spheroids with 1 µM JC-1 
(tetraethylbenzimidazolylcarbocyanine iodide) for 1 hour, then washed in PBS, 
incubated with Hoechst for 10 min, then washed once again and mounted onto a 
microscope slide as previously described (Section 2.2.7) 
3.2.11 Analysis of mitochondrial function by oxygen consumption analysis 
Mitochondrial function was analysed using Seahorse XF technology.  For 2D 
monolayer experiments C3A cells were seeded onto Seahorse cell culture 
microplates at 40,000 cells/well 24 hours before experimentation. The sensor 
cartridge from the extracellular flux assay kit was hydrated in XF calibrant at 37 °C in 
  Chapter 3     
80 
 
a non-CO2 incubator overnight.  For experiments on spheroids, the Seahorse 
spheroid microplate was coated with Cell-Tak (200 µL in 2.8 mL 0.1 M sodium 
bicarbonate), incubated for 1 hour at 37 °C, washed twice with 200 µL sterile H2O 
and left to air-dry.  Seahorse medium was prepared using 25 mM glucose, 2 mM L-
glutamine and 1 mM in base medium minimal DMEM (Seahorse), pH adjusted to 7.4 
and heated to 37 °C.  The spheroid microplate was then filled with 175 µL Seahorse 
medium and one spheroid carefully transferred into the centre of each well.  The 
outer wells of the Seahorse culture plates were filled with 175 µL media only and 
used to calculate background values (see Figure 3.2).  2D monolayer cells were 
washed in Seahorse medium then 175 µL medium added to each well.  For 2D 
experiments final compound concentrations had been previously optimised as 1 µM 
oligomycin, 0.25 µM FCCP, 1 µM antimycin-A and 1 µM rotenone (data not shown).  
For spheroid experiments twelve different conditions were used (A-L) in order to 
optimise drug concentrations (Table 3.1).  Appropriate concentrations of each 
compound were made up in Seahorse medium.  25 µL each compound was added 
to the corresponding port on the sensor cartridge, A-D in the order of injection 
(Figure 3.2).  Cells and spheroids were incubated for 1 hour in a non-CO2 incubator 
before the experiment.  A Cell Mito Stress Test was then performed using Seahorse 
XFe96 Extracellular Flux Analyser and Wave software which analyses oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR).  Cells and 
spheroids were finally washed in PBS and lysed before performing a Bradford assay 
for protein quantification. Data was analysed using Seahorse XF Mito Stress Test 
Report Generator and data normalised to protein content.  6 wells of spheroids or 
2D monolayer wells were used for each experiment.  
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Condition 
Oligomycin 
concentration µM) 
FCCP concentration (µM) 
A 1 1.5 
B 1 2 
C 1 3 
D 1 3.5 
E 3 1.5 
F 3 2 
G 3 3 
H 3 3.5 
I 5 1.5 
J 5 2 
K 5 3 
L 5 3.5 
Table 3.1. Optimisation of Cell Mito Stress Test for spheroids.  Varying 
concentrations of oligomycin and FCCP were analysed using twelve conditions (A-L) 
in order to optimise the Mito Stress Test for use with C3A spheroids. 
Figure 3.1.  Seahorse sensor cartridge layout.   Each well contains 4 ports, A, B, C 
and D. Compounds are added to the following ports in order of injection; (A) oligomycin, 
(B) FCCP, (C) antimycin-A and rotenone. 
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Table 3.2.  Calculation of compound dilutions for Seahorse experiments.  
 
3.2.12 Statistical analysis 
Data are representative of at least three independent experiments (n=3) and 
expressed as mean ± SEM. Graphs and statistical analyses were performed using 
GraphPad Prism 5.  A Shapiro-Wilk normality test was performed on all data sets. 
Data which passed normality tests underwent analysis by a two-way ANOVA, those 
which did not underwent a non-parametric Kruskal-Wallis test.  Significance was 
determined from a p value < 0.05. **** p<0.0001, *** p< 0.001 ** p<0.01, * p< 0.05. 
  
Compound Port 
Injection 
volume (µL) 
Final volume in 
well (µL) 
Injection 
concentration 
Oligomycin A 25 200 8 × 
FCCP B 25 225 9 × 
Antimycin- A C 25 250 10 × 
Rotenone C 25 250 10 × 
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3.3 Results 
3.3.1 Confirmation of transporter function in spheroids 
Previously it was determined that key canalicular transporters were expressed in the 
spheroid model (Section 2.3.4), as MRP2 and Pgp polarise to the canalicular 
membrane in C3A spheroids, forming a bile canalicular network.  In this chapter it 
was investigated whether or not these transporters were functionally active.  MRP2 
and Pgp functionality was determined using fluorescently labelled CMFDA by 
immunofluorescence.  This compound is membrane permeable and can passively 
enter cells, however once inside cells it is converted to glutathione-methylfluorescein 
(GSMF), a membrane impermeable compound which can only be excreted from 
cells via transport through function MRP and Pgp transporters.  In the spheroids   
there was limited retention of CMFDA (green) within cell cytoplasm and an 
accumulation and co-localisation of the compound within secondary canalicular-like 
structures (red) (Figure 3.3A).  Blocking MRP and Pgp transporters resulted in 
CMFDA being retained in the cell cytoplasm (Figure 3.4).  This suggests that 
CMFDA was actively transported out of the cells by MRP2 and Pgp into the 
canalicular structures.  2D monolayer C3A cells retained CMFDA within the cell 
cytoplasm (Figure 3.3B) and no transport out of the cells was observed.  
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Figure 3.3.  Transporter inhibition in spheroids. Spheroids were incubated with 
(A) CMFDA (green) only; (B) CMFDA and MK571 (MRP inhibitor); (C) CMFDA and 
PSC833 (Pgp inhibitor); (D) CMFDA, MK571 and PSC833 for 30 min.  Spheroids 
were washed, fixed and stained with Hoechst (blue) to view the nuclei and phalloidin 
(red) to view F-actin. Snap images were taken using a Zeiss Axio Observer 
microscope at 40 × magnification.  Dotted line indicates an example of a cell where 
CMDFA is retained within the cell cytoplasm.  Arrow indicates the canalicular-like 
structures containing CMFDA.  Scale bars = 50 µm. 
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3.3.2 Functional zonation in spheroids 
Specific functional markers were probed for in order to assess liver zonation and 
functional heterogeneity.  Figure 3.5 indicates some of the zonated functions of the 
human liver which can be used as zonation markers.  CPS1 is an enzyme of the 
urea cycle which catalyses the metabolism of ammonia and bicarbonate to 
carbamoylphosphate and can be utilised as a marker for periportal and intermediate 
areas of the liver (Gebhardt 1992; Koenig et al. 2007; Poyck et al. 2008).  GS is 
involved in the conversion of ammonia and glutamate to glutamine and can be used 
as a marker of perivenous regions (Gebhardt 1992; Winkler et al. 2015).  Western 
blot was used to analyse the expression of these two zonation markers and it was 
found that they were both expressed in the C3A spheroids (Figure 3.6A).  Next the 
spheroids were stained for CPS1 and it was found to be expressed near the 
periphery of the spheroid, an area with the highest oxygen concentrations, similar to 
the periportal area of the liver lobule (Figure 3.6B).  
  
  Chapter 3     
87 
 
  
Figure 3.5.  Markers of liver zonation.  Due to the zonation of the liver, specific 
liver functions are carried out in particular zones, as illustrated in the above diagram.  
The zonated functional activity can be used to probe for markers of specific liver 
zones. 
Figure 3.4.  Functional heterogeneity in spheroids. (A) Spheroids and 2D 
monolayer C3A cells were analysed in duplicate by western blot for zonation 
markers CPS1 and GS.  (B) Spheroids were fixed at day 18 of culture, paraffin 
embedded, sectioned and stained with CPS1, a periportal marker (brown) and 
haematoxylin (blue) to stain the nuclei. Scale bar = 100 µm. 
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3.3.3 Expression of hepatocyte specific markers 
In order to determine the presence of key liver-specific enzymes involved in drug 
metabolism, expression of CYP3A4 and CYP2E1 was analysed.  A western blot was 
performed for CYP3A4 and Figure 3.7A shows clear expression of this enzyme in 
the spheroid cultures and 2D.  Subsequently the spheroids were stained for 
CYP2E1 using immunohistochemistry.  CYP2E1 was observed to be expressed in 
the spheroid, indicating that the spheroids express this liver-specific functional 
marker (Figure 3.7B). 
Keratin 18 is a hepatocyte-specific protein responsible for cell structure and integrity 
and is only expressed in liver cells (Ku et al. 2007; Omary et al. 2002)  The 
expression of keratin 18 was also analysed in C3A spheroids, which can be seen to 
be expressed in cells within the spheroid to a higher degree than 2D cultures (Figure 
3.7A). 
 
  
Figure 3.7.  Expression of hepatocyte-specific markers in spheroids.  (A) 
western blot for CYP3A4 and keratin 18 expression in spheroids and 2D monolayer 
cells in duplicate.   (B) Spheroids were fixed at day 11 of culture, paraffin 
embedded, sectioned and stained with CYP2E1 antibody (brown) and haematoxylin 
(blue) to stain the nuclei. Scale bar = 100 µm. 
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3.3.4 CYP enzyme activity 
The metabolic capacity of the C3A spheroids was next analysed.  Spheroids were 
treated with two compounds, testosterone and dextromethorphan, which are 
metabolised by CYP3A4 and 2D6 respectively.  The metabolites of these two 
compounds were quantified as an indication of the activity of these two CYP 
enzymes in spheroids and compared to 2D cultures (Figure 3.8).   The highest 
production of the CYP3A4 testosterone metabolite, 6β-OH-testosterone, was in C3A 
spheroids at day 3 of culture at 8.01 ± 2.1 nM/spheroid.  Likewise, day 3 spheroids 
also produced the highest quantities of Dextrorphan, the CYP2D6 
dextromethorphan metabolite, also, at 0.062 ± 0.01 nM/spheroid.  When normalised 
to cell number, the CYP activity in 2D monolayer C3A cells could be compared to 
spheroids (Figure 3.9).  2D monolayer cells had a lower CYP3A4 and 2D6 activity 
than day 3 spheroids.  Reported Dextrorphan values in human hepatocyte spheroids 
are around 11.6 nM, higher than the values observed in C3A spheroids (Bell et al. 
2016).  Reported CYP3A4 activity values from 2D primary hepatocytes range from 
around 5 – 350 pmol/mg, and CYP2D6 from 1- 60 pmol/mg, with equivalent values 
in C3A spheroids being 14,907 pmol/mg and 115 pmol/mg respectively (Hewitt et al. 
2007).  
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Figure 3. 8.  CYP enzyme activity in spheroids.  Spheroids were incubated with 
1 mM testosterone and 0.25 mM dextromethorphan hydrobromide for 24 hours.  
Supernatant and cell samples were collected and analysed by mass spectrometry 
for metabolite formation.  CYP2D6 and CYP3A4 enzyme activity were 
represented by the quantification of metabolites 6ß-OH-testosterone and 
Dextrorphan (nM/spheroid) respectively.  Data are represented as mean ± SEM 
(n=3 from 12 replicates). 
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Figure 3.9.  CYP enzyme activity is higher is spheroids than 2D cells.  
Spheroids and C3A cells cultured as a monolayer were incubated with 1 mM 
testosterone and 0.25 mM dextromethorphan hydrobromide for 24 hours.  
Supernatant and cell samples were collected and analysed by mass spectrometry 
for metabolite formation.  CYP2D6 and CYP3A4 enzyme activity were represented 
by the quantification of metabolites 6ß-OH-testosterone and Dextrorphan (μM/106 
cells) respectively.  Data are represented as mean ± SEM, **** p<0.0001 (n=3 from 
12 replicates).  
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3.3.5 Production of albumin and urea 
A major function of the liver is the metabolism and synthesis of vital substances, two 
of which are albumin and urea, commonly utilised to asses liver-specific function 
(Bacon. B. R. et al. 2006; Cotran 2005).  Albumin and urea production from 
spheroids was quantified over 32 days.  Albumin production increased over the 32 
day culture period to a maximum cumulative release of 9.14 ± 3.5 pg/cell (Figure 
3.10A).  This was compared to 2D monolayer cultured C3A cells which were seen to 
produce a maximum of 1.91 ± 0.42 pg/cell albumin after 8 days of culture, 
significantly less than in 3D culture.  Urea production from C3A spheroids peaked 
early on at day 4 with 0.46 ± 0.06 pmol/cell of urea released, with the production 
residing at around 0.2 pmol/cell for the remainder of the culture period (Figure 
3.10B).  Less urea was produced from monolayer cultured C3A cells, with a 
maximum of 0.016 ± 0.001 pmol/cell urea produced on day 4.  
A 
Figure 3.10.  Albumin and urea production in spheroids.  Supernatant samples 
from spheroids were analysed over 32 days, with 2D C3A cells used as a 
comparison.  (A) Albumin and (B) urea release were quantified in spheroid (black 
circle) and monolayer (black square) supernatant and plotted against culture time 
(days) . Data are represented as mean ± SEM, * p<0.05 (n=3 in triplicate). 
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3.3.6 Mitochondrial function in spheroids 
Firstly mitochondrial expression and location were analysed in C3A spheroids using 
immunofluorescence.  Figure 3.11 shows mitochondria (red) in relation to nuclei 
(blue) in the spheroids.   Mitochondria were observed to be distributed throughout 
the C3A cell cytoplasm and appeared to be in abundance.  Due to the 3D nature of 
the spheroids the staining could not be seen in all of the cells in the image due to 
limitation of cell penetration of the microscope which has a maximum depth of 20 
nm. 
 
In order to analyse the function of mitochondria in the spheroids mitochondrial 
respiration was measured using Seahorse technology and a Mito Stress Test.  This 
analysis works by calculating OCR and ECAR through measurement of oxygen and 
free proton concentrations present in the culture (Hill et al. 2012; 
SeahorseBioscience 2016). Figure 3.12 represents a typical OCR curve produced 
from a Mito Stress Test with the sequential addition of oligomycin, FCCP and 
antimycin A and rotenone.  These drugs each challenge the mitochondria 
Figure 3.11.  Mitochondrial location in spheroids.  Spheroids were incubated 
with 1 µM JC-1 mitochondrial stain (red) then nuclei stained (blue) and imaged by 
confocal microscopy at 40 × magnification and represented as snap images.  (A) 
shows a section throughout the spheroid; (B) shows a close-up of one cell.  Scale 
bars = 50 µm. 
B 
A 
B 
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complexes within the Electron Transport Chain (ETC) in order to calculate specific 
respiratory parameters and elucidate how the mitochondria are functioning.  
Oligomycin inhibits ATP synthase (mitochondrial complex V), therefore any 
decrease in OCR after its addition is estimated to be the amount of respiration linked 
to ATP production (Hill et al. 2012).  FCCP was added next, acting as a proton 
uncoupler as the mitochondrial membrane becomes permeable to protons, this OCR 
value allows one to calculate the maximal potential respiration of the system being 
tested (Hill et al. 2012).  Finally non-mitochondrial oxygen consumption can be 
analysed by adding rotenone and antimycin-A, mitochondrial complex I and III 
inhibitors respectively, to inhibit the respiratory chain (Hill et al. 2012).  Firstly 
concentrations of oligomycin and FCCP were optimised to ensure that the assay 
was appropriate for use with spheroids.  Table 3.1 shows the concentrations of each 
compound used in the optimising conditions.  Ideally, during the Mito Stress Test 
basal OCR would be clearly above 0, with a significant decrease after the addition of 
oligomycin and an increase back above the basal level after addition of FCCP, 
finally with antimycin-A and rotenone brining the OCR down below the previous 
values seen, resulting in a curve comparable to Figure 3.12.  Figure 3.13 shows the 
OCR curves produced in the Mito Stress Test in C3A spheroids under each 
condition tested.  From this data it seemed clear condition H produced the most 
informative OCR curve, thus these concentrations were used in future experiments 
on spheroids.  2D monolayer experiments had been previously optimised for the 
concentrations 1 µM oligomycin, 0.25 µM FCCP, 1 µM antimycin-A and 1 µM 
rotenone (Kamalian et al. 2015).   
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Figure 3.12.  Representative OCR curve from a Mito Stress Test.  A typical 
graph plotting OCR (pmol O2/min) against time (min) during a Mito Stress Test with 
the sequential addition of oligomycin, FCCP, antimycin-A and rotenone.  The 
calculation of basal respiration, proton leak, ATP-linked respiration, spare 
respiratory capacity and non-mitochondrial respiration are depicted.  Image taken 
from Seahorse Bioscience.  
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Figure 3.13.  Optimisation of spheroid Mito Stress test.  A Mito Stress test was 
performed on 10 day cultured spheroids using Seahorse technology using a range of 
conditions (A-L). Raw OCR values (pmol O2/min/µg protein) were plotted against 
time (min).  Data represent mean ± SEM (n=1, 6 replicates).  
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The experiment on spheroids was first carried out to establish a baseline of normal 
mitochondrial function.  The spheroids responded to the Mito Stress Test as 
expected, similar to the typical OCR curve in Figure 3.12.  OCR values for C3A 
spheroids and 2D monolayers are plotted in Figure 3.14.  Spheroids had slightly 
lower overall OCR than 2D monolayer cells, and spheroids had higher variation in 
OCR, however there was no significant difference between the two culture 
conditions.  Extracellular acidification rate (ECAR) was also analysed.  Acidification 
of culture medium is primarily a result of glycolytic turnover and concomitant lactate 
production, an alternative non-mitochondrial method of ATP production in cells 
(Dranka et al. 2011).  ECAR was found to be significantly higher in spheroids than 
2D cultures, at 7.6 ± 3.8 compared to 3.26 ± 1.63 mpH/min/µg protein (Figure 3.15).  
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Figure 3.14. OCR in C3A spheroids and 2D. A Mito Stress test was performed on 
10 day cultured spheroids and 2D C3A cells using Seahorse technology.  Raw OCR 
values (pmol O2/min/10
3 cells) were plotted against time (min). Data represent mean 
± SEM (n=3, 6 replicates).  
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Further respiratory parameters were calculated from the Mito Stress Test (Figure 
3.16).  Basal respiration in spheroids was found to be 7.9 ± 1.2 pmol O2/min/µg 
protein, compared to 11.8 ± 3.0 pmol O2/min/µg protein in 2D monolayer cultures.  
ATP production was 5.35 ± 0.5 O2/min/µg protein in spheroids and 10.2 ± 2.8 
O2/min/µg protein in 2D.  Proton leak was higher than 2D monolayer cultured cells at 
2.57 ± 1.1 O2/min/µg protein.  Non-mitochondrial respiration (NMR) was similar in 
both culture conditions.  The only significant difference in mitochondrial function 
observed between spheroids and monolayer cultures C3A cells was the maximal 
respiratory capacity and corresponding spare respiratory capacity (SRC), with 
spheroids having significantly lower values, for example SRC in spheroids was 2.35 
± 1.5 O2/min/µg protein compared to 13.2 ± 3.8 O2/min/µg protein in 2D.   
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Figure 3.15. ECAR in C3A spheroids and 2D. ECAR was measured in 10 day 
cultured spheroids and 2D C3A cells using Seahorse technology.  Basal ECAR 
values (mpH/min/103 cells) were plotted against culture condition.  Data represent 
mean ± SEM, *** p<0.001 (n=6, 6 replicates).  
 
  Chapter 3     
97 
 
 
 
  
%
 M
a
x
im
a
l 
re
s
p
ir
a
ti
o
n
B
as
al
A
TP
-li
nk
ed
P
ro
to
n 
le
ak
M
ax
im
al
S
R
C
N
M
R
C
ou
pl
in
g 
E
ff
ic
ie
nc
y 
(%
)
0
10
20
30
80
100
Spheroid
2D
**
*
Figure 3.16.  Spheroid mitochondrial function. A Mito Stress Test was performed 
on 10 day cultured spheroids and 2D C3A cells using Seahorse technology and 
mitochondrial respiratory parameters calculated and plotted as a percentage of 
maximal respiration. Basal respiration, ATP-linked respiration, proton leak, maximal 
respiration, spare capacity, non-mitochondrial respiration and coupling efficiency are 
plotted for each culture condition.  Data represent mean ± SEM, ** p<0.01, * p<0.05  
(n=3, 6 replicates).  
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3.4 Discussion 
After discovering that it was possible to recapitulate certain aspects of the liver 
microstructures in a 3D in vitro model it was then decided to investigate the liver-
specific functionality of C3A spheroids and compare this with a corresponding 2D 
model.   
The ability of hepatocytes to produce bile, excrete waste products and transport 
compounds is essential for their proper functioning.  Accumulation of a florescent 
bile substrate in bile canalicular structures in spheroids was confirmed, with little 
remaining within the cell, indicating that canalicular transporters in the spheroid were 
functional.  It was further confirmed that MRP2 and Pgp were indeed responsible for 
this transport by blocking these transporters.  CMFDA was not transported in 
monolayer cultured C3A cells, likely due to lack of expression of MRP2 and Pgp, 
improper polarisation of cells (shown in Section 2.3.4), or inactive transporters when 
cultured in 2D.  Since this work was carried out MRP2 function in HepG2 spheroids 
has been confirmed (Mueller et al. 2011; Ramaiahgari et al. 2014) indicating that 
this happens in multiple cell lines once cultured in 3D.   
The liver is well known to have functional zonation, as periportal and perivenous 
hepatocytes have different functions and therefore different expression markers 
(Bacon. B. R. et al. 2006).  This zonation is perhaps partially due to the oxygen and 
nutrient gradients throughout the liver sinusoid produced by relative distances to the 
vascularisation. It was revealed that C3A spheroids recapitulate some of the 
functional heterogeneity of the liver that occurs in vivo by confirming that both these 
periportal and perivenous markers were expressed in the spheroids.  CPS1 was 
expected to be expressed in areas of the liver lobule nearest to the oxygenated 
blood supply.  CPS1 was stained for and was clearly expressed in the peripheral 
regions on the spheroid, with a similar expression pattern to in vivo, indicating 
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spatiotemporal similarity of C3A spheroids with a human liver lobule (Koenig et al. 
2007).  To the knowledge of the author this functional heterogeneity has not been 
proven previously in an in vitro liver model.  The results suggest that C3A spheroids 
recapitulate functions from each zone in one spheroid, giving spheroids the potential 
to perform the zonated functions of the liver lobule. 
One of the main functions of the human liver is the homeostasis of numerous 
molecules and substances, including the metabolism and breakdown of compounds, 
detoxification of xenobiotics as well as the synthesis of substances (Bacon. B. R. et 
al. 2006; Lippincott. J. B 1993).  Many of the metabolic processes in the liver are 
performed by various phase I CYP enzymes, which are vital for efficient liver 
function (Koenig et al. 2007).  Hence, as an indicator of liver-specific functionality 
the CYP enzyme expression and activity were analysed in the spheroids.  CYP2E1 
and CYP3A4 were both found to be expressed in the C3A spheroids.  These two 
enzymes are responsible for the metabolism of numerous xenobiotics, including 
acetaminophen and diclofenac (James et al. 2003).  CYP expression had previously 
been confirmed in liver spheroids created from other cell types (Chang and Hughes-
Fulford 2009; Sainz et al. 2009; Tostoes et al. 2012) and this is now confirmed to be 
true for C3A spheroids.  The activity of CYP3A4 and CYP2D6 were further 
quantified.  Both enzymes were found to be functional in C3A spheroids over 17 
days in culture, with significantly higher metabolism than 2D cultured C3A cells.  
Interestingly, the levels of CYP activity appeared to be higher in C3A spheroids than 
that reported for 2D human hepatocytes, yet lower than hepatocyte spheroids (Bell 
et al. 2016; Hewitt et al. 2007).  In order to fully determine the metabolic capability of 
the model, phase II enzymes, such as UGT, could be analysed. 
It was additionally confirmed that the spheroids were able to synthesise and secrete 
albumin and urea, with higher values of albumin and urea produced in spheroids 
than the corresponding 2D model.  This indicates synthetic and metabolic function in 
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C3A liver spheroids as albumin and urea production are important physiological 
functions of hepatocytes in vivo (Bacon. B. R. et al. 2006; Cotran 2005; Khetani et 
al. 2015a), and builds on the evidence that cells cultured in spheroids have superior 
functionality to those cultured in 2D.  However, it has been suggested that 2D C3A 
cells produce urea without a completely functional urea-cycle through arginase II 
(Mavri-Damelin et al. 2008).  The expression of CPS1 in the spheroids indicates that 
parts of the urea cycle are present, however from the results presented in this 
chapter it cannot be confirmed that the other enzymes involved in the urea cycle are 
functional or that the synthesis of urea is through an active detoxification of 
ammonia through the urea cycle.  One possibility is that C3A cells cultured in 2D do 
not display zonated functions, and therefore might lack expression of periportal 
functions such as the urea cycle, whereas spheroid culture may overcome this 
limitation by expressing the enzymes necessary for the detoxification of ammonia 
through the urea cycle.  It was also found that the spheroids expressed the 
hepatocyte-specific marker keratin 18, this protein is only expressed in liver cells, 
with vital roles in maintaining cell integrity and structure.  This indicates that C3A 
spheroids are able to express proteins exclusively localised to hepatocytes, hence 
recapitulating the cells in a human liver.  Other groups have additionally analysed 
liver-specific functions in their C3A spheroids, revealing cholesterol and urea 
secretion (Fey and Wrzesinski 2012; Wrzesinski and Fey 2013).  The pattern of urea 
release from ‘Wrzesinski’s’ spheroids did not correlate with the results presented in 
this chapter, as they saw an increase over 45 days in culture unlike the rise and fall 
observed in the C3A cells presented here (Wrzesinski et al. 2013). 
Mitochondria are vitally important to the cell, producing energy through metabolism. 
ATP is produced by mitochondria via oxidative phosphorylation (OXPHOS) of 
nutrients, creating a proton gradient across the inner mitochondrial membrane as 
part of the ETC (Cooper 2000).  Toxic by-products of OXPHOS are oxygen free 
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radicals and ROS, which have the capability of damaging DNA, proteins, lipids and 
other molecules, potentially leading to oxidative stress and cellular dysfunction.  
Correct mitochondrial function is therefore essential to a cell’s phenotype and for 
efficient cell function and homeostasis.   
Mitochondria were present in abundance throughout the spheroid cytoplasm and 
looked viable in the electron microscopy images presented previously (see Section 
2.3.3).  Mitochondrial function was analysed in the spheroids under normal culture 
conditions and compared to 2D cultured C3A cells.  The basal respiration reflects 
the sum of all cellular processes consuming oxygen.  In C3A spheroids the basal 
respiration was comparable to that seen in 2D.  Respiration linked to ATP 
production from C3A spheroids had a similar value to 2D cultures, suggesting that 
the ATP demand of the cell is similar regardless of culture condition.  A decrease in 
the amount of ATP-linked respiration could mean a damaged electron transport 
chain.  Proton leak occurs when OXPHOS is incompletely coupled, with high values 
potentially indicating mitochondrial injury, however spheroids showed similar values 
for proton leak as monolayer cultures.  C3A spheroids had low levels of NMR which 
occurs from any other oxygen consuming process occurring within the cell, high 
levels could be due to increased ROS production (Divakaruni et al. 2014; Hill et al. 
2012).  Another important parameter is the coupling efficiency, the amount of ATP 
turnover compared to baseline levels, which was again comparable in C3A cells 
cultured in 2D or 3D.  The small differences in how C3A cells respired in 2D and 3D 
spheroids were generally not significant and overall the cells responded similarly 
regardless of culture condition.  An interesting observation was a significantly lower 
maximal respiration and SRC in spheroids compared to 2D monolayers.  Maximal 
respiration tells one the peak respiration that can occur within the cell, with the SRC 
being the difference between the basal and maximal respiration.  The SRC gives 
information about the ability of the cell to respond to increased energy demand, and 
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the C3A spheroids had fairly low reserve capacity.  This may indicate that the 
spheroids may be less able to cope with increased energy demand or stress than 
2D cultured cells.  Higher ECAR values were also observed in spheroids, potentially 
indicating a higher glycolytic capacity when C3A cells are cultured in 3D.  Overall, 
the analysis of mitochondrial function indicates that the spheroids were viable and 
functional with efficient energy production through OXPHOS as well as glycolysis 
and functional mitochondria, with minor differences between C3A cells cultured in 
2D or spheroid culture. 
The multiple functional differences observed between C3A cells cultured in 2D and 
3D could be due to a number of factors.  Wrzesinski et al. have shown metabolic 
changes induced by 3D cell culture.  Increased glucose metabolism, hence 
glycolysis, was observed in their spheroids, as well as reduced complex VI oxidative 
phosphorylation and reduced ATP synthase (Wrzesinski et al. 2014).  More recently 
significant proteome alterations in mitochondrial function, oxidative phosphorylation 
and the TCA cycle occur once hepatocytes were cultured in 2D, whereas spheroid 
cultures had a similar prolife as liver tissues (Bell et al. 2016).  This suggests that 
the bioenergetic profile of cells in 2D is unlike that of the in vivo liver, whereas 
spheroid culture behaves more alike liver tissue, and supports the data presented 
here.  Other cell types when cultured in 3D have shown a metabolic shift to increase 
glycolysis (Longati et al. 2013), similar to the results in C3A spheroids.  It has been 
suggested that an increase in metabolism acts as a way of intracellular and 
extracellular signalling (Jones and Bianchi 2015), which could be the cause of the 
differences in metabolism observed in 3D culture.  Without comparing the values 
obtained from C3A spheroids to those obtained in in vivo tissue it is hard to 
speculate as to whether or not these metabolic changes are advantageous or 
deleterious to the culture model.  Regardless, the results presented show 
improvements in many liver-specific functions in C3A spheroids when compared to 
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these cells under standard monolayer culture, suggesting that the cells in spheroids 
are becoming more like primary liver cells, hence it is possible that the changes in 
mitochondrial respiration and energy metabolism observed are an adaptation, or 
cause, of this differentiation of cells into a more liver-like phenotype. 
Since this work began, other research groups have looked at the effect of 3D cell 
culture on the phenotype of in vitro liver models and support the building evidence 
that liver functions are increased once cells are cultured in spheroids.  Multiple 
studies have now shown increases in albumin and urea synthesis, CYP expression 
and transporter function in liver spheroids when compared to 2D or sandwich culture 
using multiple different liver cell types (Chan et al. 2016; Ramaiahgari et al. 2014; 
Takahashi et al. 2015; Wang et al. 2015; Xia et al. 2016).   
Interestingly, C3A cells have been tested in microfluidics devices, and although 
some liver-specific functions have been elucidated, mainly albumin and urea 
production, there has been minimal direct comparisons with 2D cultures (Baudoin et 
al. 2011; Filippi et al. 2004),  Hence, there is insufficient evidence to show that 
microfluidics devices are in any way superior to 2D or spheroid cultures.  
Additionally these systems are practically difficult to maintain and low-throughput as 
well as being more costly that spheroid culture.  Therefore, C3A spheroids show 
promise as a simple 3D cell culture system with the added benefit of superior liver-
specific function compared to corresponding 2D cell models. 
 
3.5 Conclusion 
The disadvantages of liver cell lines, primarily the reduction of liver functionality, are 
often a justification to avoid the use of these cells during in vitro drug screening.  
Nonetheless there is growing evidence that improved cell culture condition can 
reverse the limitations of some liver cell lines, resulting in a functional, reproducible, 
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more cost-effective and high-throughput liver model.  C3A spheroids show 
enhanced liver-specific functions compared to the same cell type cultured in 2D, 
including active transporters, expression of hepatocyte-specific markers, CYP 
enzyme activity and albumin and urea synthesis.  Furthermore mitochondrial 
functionality and functional heterogeneity were revealed in the spheroid model.  The 
results presented in this chapter support the conclusion that when cultured in 
spheroids, cells display increased liver-like phenotype and function. 
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4.1 Introduction 
More predictive in vitro liver models are essential in order to decrease the number of 
toxic compounds being progressed into in vivo studies and clinical trials.  It is 
possible that the C3A spheroid model, with its numerous advantages over 2D cell 
culture, may be more predictive of compounds which cause DILI in humans.  This 
hypothesis was tested by performing a screen of hepatotoxins in C3A spheroids in 
order to determine the sensitivity of the model to compounds with a risk of DILI in 
humans. 
The majority of in vitro liver models concentrate on hepatocytes, or their 
immortalised alternatives (Godoy et al. 2013; Lippincott. J. B 1993), however NPC, 
such as LSEC, Kupffer cells and stellate cells, also have vital physiological roles in 
the liver and importantly, during liver injury and regeneration (Godoy et al. 2013; 
Kmiec 2001; Michalopoulos 2007).  There is some evidence to suggest that the 
inclusion of NPC in in vitro models has a role not only in maintaining the phenotype 
and function of hepatocytes, but the response of the liver to hepatotoxins (Edling et 
al. 2009; Kang et al. 2013; Ohno et al. 2009; West et al. 1986; Yagi et al. 1998).  
Therefore, it may be essential to include NPC for complete recapitulation of the liver 
in vitro and in order to improve the sensitivity of liver models to human hepatotoxins.  
Nonetheless, no study prior to the start of this work had elucidated the specific 
effects of different NPC on the ability of an in vitro liver model to detect DILI. 
As well as preclinical screening being extremely important, clinical tests are legally 
required before a compound can be marketed for use.  Current clinical DILI 
biomarkers however have multiple disadvantages including poor sensitivity, a delay 
in elevations in the serum and lack of organ specificity, to name a few (Antoine et al. 
2013; Antoine et al. 2012; Antoine et al. 2009a; Ozer et al. 2008; Zhou et al. 2013).  
Understandably, research is now focusing on novel biomarkers of DILI, such as 
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HMGB1, keratin 18 and miR-122, which have each been found to be more accurate 
at predicting the likelihood of survival and extent of injury than ALT (Antoine et al. 
2013; Antoine et al. 2012; Antoine et al. 2009b; Starkey Lewis et al. 2011; Zhang et 
al. 2010).  Surprisingly, circulating biomarkers are not routinely analysed during 
initial in vitro drug screening, with different criteria used in vitro to determine the 
likelihood of a compound being hepatotoxic.  This could be an inadequacy of the 
biomarkers, the in vitro models, or both.  Furthermore, despite building evidence in 
support of these novel biomarkers of DILI, there is still more research needed into 
their use in vitro.  Research into HMGB1, keratin 18 and miR-122 in preclinical liver 
models could further scientists’ understanding of their mechanisms of release and 
role during liver injury, as well as potentially aiding the sensitivity of in vitro models 
used for safety testing. 
In this chapter, the first aim was to determine the sensitivity of C3A spheroids to a 
panel of human hepatotoxins and compare this to corresponding 2D and 3D liver 
models.  Secondly, it was investigated whether including NPC in C3A spheroids 
would further improve the ability of the model to detect hepatotoxins.  Finally, there 
was an investigation into whether novel DILI biomarkers could be quantified from 
spheroid cultures and whether or not this analysis could enhance the predictive 
value of the model as well as giving additional insight into the type of cellular injury 
occurring after treatment with hepatotoxins.   
Hypothesis 1: Spheroids will be sensitive to a range of hepatotoxic compounds and 
will show increased susceptibility to this toxicity compared to 2D monolayer cells. 
Hypothesis 2: Spheroids co-cultured with NPC will have an enhanced susceptibility 
to hepatotoxins, detecting a higher number of DILI compounds than monoculture 
spheroids. 
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Hypothesis 3: The quantification of novel biomarkers in vitro will increase the 
sensitivity of the model and provide additional information as to the mechanism of 
cell death caused by hepatotoxins. 
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4.2 Materials and Methods 
L-glutamine, RPMI-1640, PBS and all drug compounds were purchased from Sigma 
Aldrich, Missouri, USA.  LSEC were purchased cryopreserved from ScienCell, 
Carlsbad, CA, USA.  THP-1 cells were purchased cryopreserved from The 
European Collection of Authenticated Cell Cultures, Salisbury, UK.  Cell Titer-Glo 
assay was purchased from Promega, Madison, USA.  M6 keratin 18 antibody was 
purchased from Peviva, Stockholm, Sweden.  Endothelial cell medium and bovine 
plasma fibronectin was purchased from Caltag Medsystems, Buckingham, UK.  
White 96-well flat-bottomed plates were purchased from Greiner Bio-One, 
Stonehouse, UK.  HMGB1 rabbit polyclonal antibody and CD31 antibody were 
purchased from Abcam, Cambridge, UK. 
4.2.1 Cell culture 
C3A cells were maintained and cultured in monolayers as previously described 
(Section 2.2.1).  LSEC were maintained in endothelial cell medium on fibronectin 
coated cell culture flasks.  THP1 cells were cultured in RPMI-1640 supplemented 
with 1 % L-glutamine and 1 % penicillin-streptomycin and all cells were cultured in 
standard conditions.  For 2D monolayer experiments cells were used at 100 % 
confluence. 
4.2.2 Spheroid formation and culture 
Spheroids were created using the LOT from 1000 C3A cells as described previously 
(Section 2.2.1).  LSEC co-culture spheroids were formed by seeding 850 C3A cells 
and 150 LSEC/well in 50 % supplemented EMEM/ 50 % endothelial cell medium 
(media optimised for maximal cell viability, data not shown), centrifuged at 1000 rpm 
and incubated for 72 hours to form spheroids.  THP1 co-culture spheroids were 
created by seeding 1000 THP1 cells/well onto 830 C3A cell spheroids in 50 % 
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supplemented EMEM/ 50 % supplemented RPMI-1640 (media optimised for 
maximal cell viability, data not shown) and allowing the cells to infiltrate throughout 
the spheroid for at least 24 hours (24 hours gave maximum cell infiltration, data not 
shown).  Tri-culture spheroids were created by infiltrating THP1 cells into LSEC co-
culture spheroids as above. 
4.2.3 Visualisation of compound penetration throughout spheroids 
Spheroids were treated with 3 µg/mL doxorubicin for 24 hours.  Spheroids were 
washed in PBS, fixed in 4 % PFA for 1 hour then incubated with Hoechst diluted 
1:5000 in 0.1 % Triton X-100 /1 % BSA in TBST for 1 hour.  Spheroids were imaged 
in 3D by LightSheet fluorescence microscopy (Zeiss LightSheet Z.1). 
4.2.4 Hepatotoxin treatment of spheroids 
Spheroids were treated at day 3 or day 10 of culture with hepatotoxic compounds 
diluted in 0.5 % DMSO in medium for 4 days with repeat dosing after 2 days.  2D 
monolayer C3A cells were treated with compounds for 24 hours.   
4.2.5 Cell viability analysis 
Cell viability was analysed using the Cell Titer-Glo assay (Promega) according to 
the manufacturer’s instructions.  100 µL of Cell Titer-Glo reagent was added to 
spheroids or monolayers in 100 µL media.  For spheroids the plates were then 
agitated using an orbital shaker at 55 rpm for 15 min to induce cell lysis.  100 µL 
lysate was transferred to a white 96-well flat-bottomed plate and the luminescence 
measured by a microplate reader (Thermo Scientific Varioskan Flash).  Media alone 
with Cell Titre-Glo reagent was used as a blank control and subtracted from sample 
values.  Cell viability was calculated as a percentage of untreated vehicle control 
samples.  Three replicates were used for each experiment (n=3).  A dose-response 
curve was plotted and IC50 and IC10 values determined from the curve or 
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extrapolated.  The likelihood of the compound causing DILI was predicted by 
calculating Cytotoxicity-based Safety Margin (SM) = IC
10 
/ C
max
 in order to account 
for compound exposure and compounds with a SM value below 20 were determined 
hepatotoxic (Bell et al. 2016; Richert et al. 2016; Sison-Young et al. 2016).  C
max 
values and IC10 values from InSphero human hepatocyte spheroid data were 
obtained from the collaboration with AstraZeneca. 
4.2.6 Visualisation of NPC in spheroids 
Immunofluorescent analysis of spheroids was performed as previously described 
(Section 2.2.7) in order to visualise NPC.  CD31 primary antibody was used at 1:50 
dilution to detect LSEC.  THP1 cells were pre-incubated with 5 µM CMFDA (cell 
tracker) for 30 min, then washed once in RPMI-1640 before seeding onto C3A 
spheroids.  
4.2.7 Preparation of cell lysates 
Cell lysates were prepared as previously described (Section 3.2.3). 
4.2.8 Bradford assay for quantification of protein content 
Bradford assays were performed as previously described (Section 3.2.4). 
4.2.9 Biomarker quantification from cell lysates by western blot 
Western blots were performed as previously described (3.2.5). Antibody 
concentrations were as follows: HMGB1 (1:1000), GAPDH (1:10000), M6 for ck18 
(1:500). Membranes were stripped using 2 % SDS 0.7 % β-mercaptoethanol, 12.5 
% 0.5 M Tris and re-probed using M6 for fk18 (1:5000) for 1 hour.  GAPDH was 
analysed to ensure even loading of samples. 
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4.2.10 Keratin 18 cell death quantification from spheroid supernatant by ELISA 
Spheroids were pooled (20 replicates) and supernatant separated from cell mass.  
Keratin 18 was quantified in supernatant using M65 and M30 ELISA kits as 
previously described (Section 2.2.5).   
4.2.11 miR-122 quantification from spheroid supernatant by PCR 
Spheroids were pooled (20 replicates) and supernatant separated from cell mass.  
miR-122 quantification was performed by Joanna Clarke, Department of Molecular 
and Clinical Pharmacology, University of Liverpool, as previously described (Starkey 
Lewis et al. 2011).  Briefly miR was firstly extracted and purified using a miRNeasy 
kit followed by RNeasy MinElute Cleanup Kit (Qiagen).  Reverse transcription and 
real-time quantitative PCR were then performed using Taqman. 
4.2.12 Statistical analysis 
Data are representative of at least three independent experiments (n=3) and 
expressed as mean ± SEM. Graphs and statistical analyses were performed using 
GraphPad Prism 5.  A Shapiro-Wilk normality test was performed on all data sets. 
Data which passed normality tests underwent analysis by a two-way ANOVA, those 
which did not underwent a non-parametric Kruskal-Wallis test.  Significance was 
determined from a p value < 0.05. **** p<0.0001, *** p< 0.001 ** p<0.01, * p< 0.05.  
Sensitivity was calculated as the number of true positives ÷ (number of true 
positives + number of false negatives).  Specificity was calculated as the number of 
true negatives ÷ (number of true negatives + number of false positives). 
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4.3 Results 
4.3.1 Drug penetration throughout the spheroids 
The first investigation was to confirm compound penetration and ascertain whether 
or not all the cells within the spheroids are being exposed to compounds added 
exogenously. A C3A spheroid, with a diameter of approximately 200 μm, was 
treated with doxorubicin and imaged using LightSheet microscopy in order to 
analyse compound penetration.  Doxorubicin was chosen as this is an 
autofluorescent chemotherapeutic compound and therefore its penetration 
throughout the spheroid could be easily visualised.  Separate images were taken 
throughout the z-plane of the spheroid to visualise throughout the entire spheroid 
core.  Figure 4.1 shows the spheroid after treatment with doxorubicin (green) for 24 
hours, with nuclei shown in blue.  Doxorubicin can be seen fluorescing throughout 
the spheroid core in the median section through the spheroid (Figure 4.1A), as well 
as throughout the periphery (Figure 4.1B), thus confirming that this compound is 
likely in contact with every cell in the spheroid and that the drug response observed 
is present within all cells. 
  
Figure 4.1. Drug penetration throughout the spheroid.  Spheroids were cultured 
by LOT, treated with 3 µg/ml doxorubicin (green) for 24 hours, fixed, stained with 
Hoechst (blue) to stain the nuclei and imaged by Zeiss LightSheet Z.1 microscope at 
40 × magnification.  (A) Represents a mid-section through the spheroid and; (B) a 
maximum projection image. Scale bars = 50 µm. 
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4.3.2 Sensitivity of C3A spheroids to human hepatotoxins compared to 2D 
C3A cells 
Cell viability was analysed after drug treatment in order to determine the 
toxicological effect of the drug on C3A spheroids.  Spheroids and C3A cells cultured 
in a 2D monolayer were first treated with varying concentrations of four hepatotoxic 
compounds, acetaminophen, diclofenac, fialuridine and trovafloxacin.  A 4 day 
repeat-dosing regimen could be used for spheroids, as their viability over this period 
was previously confirmed, however 2D cultures were given acute doses as these 
cells become over-confluent and lose viability once cultured for over 48 hours.  A 
dose-dependent reduction in cell viability, determined by measuring ATP levels, was 
observed in the spheroids in response to all four hepatotoxins (Figure 4.2, black 
circle).  Acetaminophen, diclofenac, trovafloxacin and fialuridine were all significantly 
more toxic to C3A spheroids than C3A monolayers, indicated by significantly lower 
cell viability (Figure 4.2).  IC50 values, the concentration at which a 50 % reduction in 
cell viability is observed, were calculated from this data and listed in Table 4.1.  
Acetaminophen had an IC50 value of 7212 µM in spheroids and 33,826 µM in 
monolayers. Spheroids were also significantly more sensitive to trovafloxacin, with 
an IC50 value of 65 µM in spheroids compared to 440 µM in 2D cultures, as well as 
fialuridine, which had an IC50 value of 251 µM in 3D culture and 380 µM in 2D (Table 
4.1).  In the monolayer cultures diclofenac did not have a toxic response at the 
concentrations used, although the IC50 value is reported to be around 763 µM in 
HepG2 monolayer cultures (Bort et al. 1999) and was found to be 295 µM in the 
C3A spheroids (Table 4.1).   
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Compound 
IC
50
 value in C3A 
spheroids (μM) 4 
day repeat 
dosing 
IC
50
 value in C3A 2D 
monolayer (μM) 24 hr 
acute dosing 
Acetaminophen 7212 ** 33,826 
Diclofenac 295 *** > 400 
Fialuridine 251 380 
Trovafloxacin 65 440 
Table 4.1.  The sensitivity of spheroids and 2D C3A cells to hepatotoxins. 
Spheroids and 2D C3A cells were treated with four hepatotoxins.  Cell viability was 
analysed and IC50 values calculated.  Data are represented as mean values, **** 
p<0.0001, *** p<0.001, ** p<0.01, (n=3 in triplicate). 
 
Figure 4.2.  Spheroids show a toxic response to hepatotoxins.  Spheroids and 
2D C3A cells were treated with (A) acetaminophen; (B) diclofenac; (C) fialuridine 
and (D) trovafloxacin.  Cell viability was analysed and plotted as a percentage of 
vehicle control.  Data are represented as mean ± SEM, **** p<0.0001, *** p<0.001, 
** p<0.01, * p<0.05 (n=3 in triplicate). 
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In order to determine whether culture time or spheroid size affected the response of 
the spheroids to hepatotoxins, this toxicological analysis was repeated on 10 day old 
spheroids.  Figure 4.3 shows that there was no significant difference between the 
toxicological response of the spheroids to acetaminophen, diclofenac, fialuridine or 
trovafloxacin at day 3 or day 10 of culture.   
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Figure 4.3.  Culture time does not affect spheroids response to hepatotoxins.  
Spheroids were cultured for 3 days or 10 days, and treated with (A) acetaminophen; 
(B) diclofenac; (C) fialuridine and (D) trovafloxacin.  Cell viability was analysed and 
plotted as a percentage of untreated control.  Data are represented as mean ± SEM 
(n=3 in triplicate). 
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Subsequently, a further eleven compounds were analysed in the C3A spheroids, 
eight of which are known to cause clinical liver injury and three which acted as DILI 
negative compounds.  These compounds were chosen due to their broad 
mechanisms of action, range of DILI symptoms and inability to be detected 
preclinically.  Table 4.2 provides information of each of the hepatotoxic compounds 
tested.  All DILI compounds caused a toxic response in C3A spheroids to some 
degree, confirmed by a dose-dependent decrease in cell viability (Figure 4.4 A-H).   
IC50 values were calculated for each compound and compared to values obtained 
from literature for a 2D C3A or HepG2 model, as well as 2D and sandwich cultured 
human hepatocyte models (Table 4.3).  Every compound other than amiodarone 
and pioglitazone had a lower IC50 value in spheroids than that reported for a 2D C3A 
or HepG2 cell model (Bort et al. 1999; Donato et al. 2008; Ju et al. 2015; Lin and 
Will 2012).  Interestingly, IC50 values for 9 out of 12 compounds were lower in 
spheroids than those reported in human hepatocyte cultures, with fialuridine, 
nefazodone, tolcapone, entacapone and perhexiline even lower than in sandwich 
cultured hepatocytes.  One of the negative DILI compounds was non-toxic to the 
spheroids at the concentrations tested, the other two had a similar effect in 
spheroids as reported for 2D cultures. 
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Compound DILI undetected in: Clinical DILI Proposed mechanism of action References 
Acetaminophen Clinical trials Fatal liver failure Reactive metabolite (Ju et al. 2015; Tujios and Fontana 2011) 
Diclofenac Clinical trials 
High concern DILI, acute or 
chronic liver disease 
Immunoallergic, mitochondrial 
dysfunction, reactive metabolite, 
transporter inhibition 
(Boelsterli 2003; Bort et al. 1999; Kia et al. 
2015; Tujios and Fontana 2011) 
Fialuridine Preclinical screening Fatal liver injury Mitochondrial dysfunction (Honkoop et al. 1997; McKenzie et al. 1995) 
Trovafloxacin Clinical trials Hepatotoxicity and liver failure Inflammatory stress (Beggs et al. 2014; Shaw et al. 2010) 
Ximelagatran Clinical trials 
Elevated DILI biomarkers and 
hepatotoxicity 
Unknown 
(Keisu and Andersson 2010; Schutzer et al. 
2004) 
Nefazodone Clinical trials 
Severe DILI, black box 
warning, fatal liver injury 
Toxic metabolites, transporter 
inhibition 
(Choi 2003; Kalgutkar et al. 2005; Kostrubsky 
et al. 2006; O'Brien et al. 2006) 
Bosentan Clinical trials 
Severe DILI, black box 
warning, rare 
Transporter inhibition 
(Eriksson et al. 2011; Fattinger et al. 2001; 
Lea et al. 2016) 
Amiodarone Clinical trials 
Severe DILI, black box 
warning, fatty liver disease, 
phospholipidosis 
Mitochondrial dysfunction, 
lysosomal dysfunction, toxic 
metabolite 
(Bandyopadhyay et al. 1990; Begriche et al. 
2011; Dake et al. 1985; Kia et al. 2015; Zahno 
et al. 2011) 
Troglitazone Clinical trials 
Severe DILI, acute liver 
failure, withdrawn 
Toxic metabolite, mitochondrial 
injury, lysosomal dysfunction, 
transporter inhibition 
(Kaplowitz 2005; Loi et al. 1999; Loi et al. 
1997; Smith 2003) 
Tolcapone Clinical trials 
Severe DILI, withdrawn, fatal 
acute liver injury 
Toxic metabolite, transporter 
inhibition 
(Borges 2003; Gebhardt 1992; Jorga et al. 
1999; Olanow 2000) 
Entacapone Clinical trials 
Elevated DILI biomarkers, 
hepatotoxicity 
Unknown (Fisher et al. 2002) 
Perhexiline Clinical trials Severe DILI, withdrawn 
Improper metabolism and 
excretion, transporter inhibition, 
lysosomal dysfunction 
(Amoah et al. 1986; Ashrafian et al. 2007; 
Fromenty and Pessayre 1997) 
Table 4.2. DILI compounds.  A range of hepatotoxins, their clinical manifestations and suggested mechanisms of action. 
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Figure 4.4.  Spheroids show a toxic response to a range of hepatotoxins. 
Spheroids were treated with (A-H) eight additional hepatotoxins and (I-K) three 
negative DILI controls.  Cell viability was analysed and plotted as a percentage of 
vehicle control. Data are represented as mean ± SEM (n=3 in triplicate). 
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Compound 
IC
50
 value in C3A 
spheroids (μM) 4 
day repeat 
dosing 
Published 
IC
50
 value for 
C3A/HepG2 
2D monolayer 
(μM) 
Published IC
50
 
value in human 
hepatocyte 2D/ 
sandwich (μM) 
Reference 
Acetaminophen 7212 22,800 20,000 / 3000 
(Ju et al. 2015; 
Richert et al. 2016) 
Diclofenac 295 763 400 / 200 
(Bort et al. 
1999; Richert et 
al. 2016) 
Fialuridine 206 > 400 > 1000 
(Richert et al. 
2016) 
Trovafloxacin 65 > 1000 > 200 / 200 
(Ramaiahgari et 
al. 2014; 
Richert et al. 
2016) 
Ximelagatran > 400 > 500 > 200 / 150 
(Kamalian et al. 
2015; Richert et 
al. 2016) 
Nefazodone 15 20 20 
(Lin and Will 
2012; Richert et 
al. 2016) 
Bosentan > 400 > 3000 > 200 
(Ramaiahgari et 
al. 2014) 
Amiodarone 98 >500 > 200 /  20 
(Donato et al. 
2008; Lin and 
Will 2012) 
Troglitazone 43 121 15 
(Lin and Will 
2012; Richert et 
al. 2016) 
Tolcapone 11 > 500 20 / 17 
(Kamalian et al. 
2015; Richert et 
al. 2016) 
Entacapone 22 > 500 200 / 22 
(Kamalian et al. 
2015) 
Perhexiline 8 10 12 
(Kamalian et al. 
2015; Richert et 
al. 2016) 
Buspirone 386 > 500 > 200 
(Donato et al. 
2008) 
Pioglitazone 145 > 100 > 200 
(Lin and Will 
2012; Richert et 
al. 2016) 
Metformin > 500 > 500 > 1000 
(Kamalian et al. 
2015; Richert et 
al. 2016) 
Table 4.3.  The sensitivity of spheroids to hepatotoxins.  Spheroids were treated 
with twelve known hepatotoxins and three negative DILI controls (red).  Cell viability 
was analysed IC50 values calculated.  2D monolayer IC50 values for C3A/ HepG2 or 
human hepatocytes were obtained from literature.  Data are represented as mean 
values. 
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4.3.3 Toxicological predictivity of C3A spheroids compared to human 
hepatocyte spheroids  
Human hepatocyte spheroid data was obtained from AstraZeneca.  The same 15 
compounds were tested using the same repeat-dosing protocol on InSphero primary 
human hepatocyte spheroids.  When comparing IC10 values C3A spheroids were 
more sensitive than InSphero spheroids to all but three hepatotoxins, 
acetaminophen, diclofenac and amiodarone (Table 4.4).  For example trovafloxacin 
had an IC10 values of 22 µM in C3A spheroids compared to 100 µM in InSphero 
spheroids, and fialuridine caused no toxicity whatsoever in the InSphero spheroids, 
whereas a decline in cell viability was detected in the C3A model.  The cytotoxicity 
safety margin (SM) was calculated from the highest non-toxic concentrations (IC10) 
and known exposure values (Cmax) as published previously (Mueller et al. 2015; 
Richert et al. 2016; Sison-Young et al. 2016) and an SM value lower than 20 
indicated a risk of DILI.  Table 4.4 lists the SM values for C3A or InSphero 
spheroids, with DILI risk indicated in green.  Using data from InSphero human 
hepatocyte spheroids, 8 out of 12 compounds were correctly detected as 
hepatotoxic.  C3A spheroids successfully detected 10 out of 12 compounds to have 
a risk of DILI, leaving only ximelegatran and amiodarone going undetected.  
However one of the non- DILI compounds were falsely detected as having a risk of 
DILI in C3A spheroids.  This corresponded to a sensitivity of 90.9 % and specificity 
of 66 % for C3A spheroids, and sensitivity of 88 % and specificity of 66 % for the 
InSphero spheroids.  
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Table 4.4.  The ability of C3A spheroids and human hepatocyte spheroids to 
predict DILI risk. Spheroids were treated with twelve known hepatotoxins and three 
negative controls (red).  Cell viability was analysed and IC10 values calculated.  DILI 
risk was predicted by calculating the Cytotoxicity-based Safety Margin (SM) = IC10 / 
Cmax and compounds with a SM value below 20 were determined hepatotoxic 
(indicated as green).  Cmax values were obtained from literature and InSphero human 
hepatocyte spheroid data obtained from AstraZeneca. Data are represented as 
mean values. 
 
 
 
 
Compound Cmax (µM) 
IC
10
 value (µM) SM (DILI risk detected 
when SM<20) 
InSphero 
spheroids 
C3A 
spheroids 
InSphero 
spheroids 
C3A 
spheroids 
Acetaminophen 139 300 1463 2.15 10.5 
Diclofenac 7.99 50 110 6.25 13.7 
Fialuridine 0.64 - 2 - 3.13 
Trovafloxacin 19.7 100 22 5 1.12 
Ximelagatran 0.30 30 7 100 23.3 
Nefazodone 4.26 30 2 7 0.47 
Bosentan 7.39 100 2 14 0.27 
Amiodarone 0.81 20 42 25 51.8 
Troglitazone 6.39 5 1 1 0.16 
Tolcapone 47.6 20 5 0.4 0.11 
Entacapone 4.34 100 5 23 1.15 
Perhexiline 2.16 2 0.5 1 0.23 
Buspirone 0.01 - 7 - 70 
Pioglitazone 2.95 30 2 10 0.67 
Metformin 7.75 - - - - 
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4.3.4 The location of NPC in co-culture spheroids 
The next aim was to create a NPC co-culture spheroid model.  LSEC were 
incorporated into the C3A spheroids at a ratio which most closely represented that 
seen in vivo, optimised to be 15 % LSEC, 85 % C3A cells.  Immunofluorescence 
confirmed the survival and location of endothelial cells in the co-cultured spheroids 
for 18 days (Figure 4.5) using an endothelial-specific marker CD31.  THP1 cells 
were infiltrated into the pre-formed C3A spheroids and were visualised to have 
migrated into the spheroid core and distributed throughout after a 24 hour incubation 
with C3A spheroids (Figure 4.6). 
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Figure 4.6.  THP-1 cell infiltration into spheroids.  Spheroids were created from 
850 C3A cells on liquid-overlay plates and cultured for 10 days.  THP-1 cells (green) 
were added to the spheroids and left to infiltrate for 24 hours.  Spheroids were 
stained for nuclei (blue) and F-actin (red) and imaged by confocal microscopy at  10 
× and 40 × and represented as maximum intensity projection images.  Scale bars = 
100 µm, 50 µm. 
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4.3.5 Sensitivity of NPC co-culture spheroids to human hepatotoxins 
Toxicological analysis was performed using the same panel of 15 compounds as 
previously on both co-culture and tri-culture spheroids (Table 4.2).  Both co-cultures 
responded in a similar manner to the hepatotoxic insult, and dose dependent toxicity 
was observed in all models (Figure 4.7A-L).  LSEC co-culture spheroids (red) were 
observed to be slightly more sensitive to the majority of hepatotoxins, 9 out of 12, 
compared to monoculture spheroids, however not significantly.  THP1 co-cultures 
(blue) and tri-cultures (green) also appeared to be more sensitive than both C3A 
and LSEC co-culture spheroids to the majority of hepatotoxins.  For example, 
acetaminophen, diclofenac, trovafloxacin and ximelegatran caused significantly 
more toxicity to tri-culture spheroids than C3A monoculture spheroids at one or 
more concentrations.  IC50 values for each compound were calculated as an 
indication of the sensitivities of each co-culture model (Table 4.5).   Acetaminophen, 
diclofenac, fialuridine, ximelegatran, bosentan and perhexiline had lower IC50 values 
in both all NPC co-culture models compared to C3A spheroids.  Troglitazone and 
tolcapone also had lower values in spheroids containing LSEC, and trovafloxacin 
had lower IC50 values in those incorporating THP1 cells.  For example, 
acetaminophen had an IC50 value of 7212 µM in monoculture spheroids, 4400 µM in 
LSEC co-culture spheroids, 3200 µM in THP1 co-culture spheroids and 1700 in tri-
culture spheroids (Table 4.5).  When analysing the non-DILI compounds, LSEC co-
culture spheroids were less sensitive to buspirone and pioglitazone than C3A 
spheroids, although THP1 co-culture spheroids appeared to be more sensitive to 
pioglitazone at high concentrations (Figure 4.7M-O and Table 4.5). 
The SM for each compound was then calculated in order to determine whether DILI 
would be detected in each co-culture model, and compared to previous values 
obtained from C3A spheroids and InSphero spheroids (Table 4.6).  All NPC co-
culture models correctly identified amiodarone to be hepatotoxic, however 
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ximelagatran was still determined to be safe in all spheroid models, despite the 
significantly increased sensitivity (Table 4.6).  Using this criteria these results 
determined a sensitivity of 91.6 % and a specificity of 66 % for LSEC and THP-1 co-
culture spheroids, and 90.9 % sensitvity for tri-culture spheroids.  
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Figure 4.5.  The addition of NPC leads to increased sensitivity to 
hepatotoxins.  Co-culture and tri-culture spheroids were treated with; (A-L) twelve 
hepatotoxins; and (M-O) three negative DILI controls.  Cell viability was analysed 
and plotted as a percentage of vehicle control. Data are represented as mean ± 
SEM, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05 compared to C3A 
monoculture spheroids (n=3 in triplicate). 
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Compound 
IC
50
 value (μM) 
C3A 
spheroids 
LSEC co-
culture 
spheroids  
THP1 co-
culture 
spheroids  
Tri-culture 
spheroids 
Acetaminophen 7212 4400 3200 1700 
Diclofenac 295 199 180 85 
Fialuridine 219 140 85 117 
Trovafloxacin 65 78 28 30 
Ximelagatran 1427 581 75 45 
Nefazodone 15 18 23 28 
Bosentan 373 7 52 30 
Amiodarone 98 89 55 113 
Troglitazone 43 28 44 32 
Tolcapone 11 9 18 19 
Entacapone 22 25 32 40 
Perhexiline 8 7.8 3.4 4.3 
Buspirone 386 430 330 270 
Pioglitazone 145 166 38 44 
Metformin > 500 > 500 > 500 > 500 
Table 4.5.  The sensitivity of NPC co-culture spheroids to hepatotoxins.  Co-
culture and tri-culture spheroids were treated with twelve hepatotoxins and three 
negative DILI controls (red).  Cell viability was analysed and IC50 values calculated.  
Data are compared against IC50 values obtained for C3A monoculture spheroids, 
green indicates a lower value than C3A spheroid control, pink indicates higher value.  
Data are represented as mean values. 
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Compound Cmax (µM) 
IC
10
 value (µM) for spheroids SM (DILI risk detected when SM<20) for spheroids 
InSphero  C3A  
LSEC co-
culture  
THP1 co-
culture  
Tri-culture InSphero C3A  
LSEC co-
culture  
THP1 co-
culture  
Tri-culture  
Acetaminophen 139 300 1463 234 287 400 2.15 10.5 1.68 2.06 2.8 
Diclofenac 7.99 50 110 13.4 52 22 6.25 13.7 1.68 6.51 2.7 
Fialuridine .64 - 2 2 7 15 - 3.13 3.13 10.9 23.4 
Trovafloxacin 19.7 100 22 31 12 7 5 1.12 1.57 0.61 0.35 
Ximelagatran .30 30 7 7 15 9 100 23.3 23.3 50 30 
Nefazodone 4.26 30 2 2.5 4 4 7 0.47 0.59 0.94 0.94 
Bosentan 7.39 100 2 4 7 7 14 0.27 0.54 0.95 0.95 
Amiodarone .81 20 42 2 4 9 25 51.8 6.71 4.94 11.1 
Troglitazone 6.39 5 1 0.5 2 3.5 1 0.16 0.08 0.31 0.55 
Tolcapone 47.6 20 5 3 10 12 0.4 0.11 0.06 0.21 0.25 
Entacapone 4.34 100 5 15 13 20 23 1.15 3.5 2.9 4.6 
Perhexiline 2.16 2 0.5 1.5 1.1 1.3 1 0.23 0.69 0.51 0.60 
Buspirone .01 - 7 10 59 32 - 70 100 590 3200 
Pioglitazone 2.95 30 2 29 6 32 10 0.67 9.8 2.0 10.8 
Metformin 7.75 - - - - - - - - - - 
Table 4.6.  Ability of co-culture spheroids to predict DILI risk.  Co-culture and tri-culture spheroids were treated with twelve hepatotoxins and three 
negative DILI controls (red).  Cell viability was analysed and IC10 values calculated.  DILI was predicted by calculating the Cytotoxicity-based Safety 
Margin (SM) = IC10 / Cmax and compounds with a SM value below 20 were determined hepatotoxic (indicated as green).  Cmax values were obtained from 
literature and InSphero human hepatocyte spheroid data obtained from the collaboration with AstraZeneca.  Data are represented as mean values. 
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4.3.6 Analysis of DILI biomarkers in spheroid lysates 
The next question asked was whether novel serum biomarkers could be analysed in 
the C3A spheroid in vitro model.  Spheroids were treated with acetaminophen, 
diclofenac and fialuridine, previously shown to cause toxicity in the C3A spheroids 
(see Figure 4.2).  HMGB1 was analysed by western blot in the spheroid and 
monolayer cell lysates after drug treatment.  The expression of HMGB1 in the cells 
didn’t appear to change regardless of drug type or dose (Figure 4.8).  Culture 
condition also had no effect on HMGB1 expression.   
Figure 4.8.  HMGB1 biomarker analysis in spheroid lysates.  Spheroids and 2D 
C3A cells were treated with hepatotoxins (A) acetaminophen, (B) diclofenac and (C) 
fialuridine, 20 spheroids pooled, lysed and HMGB1 analysed by western blot. Data  
represents one experiment of three repeats. 
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4.3.7 Analysis of keratin 18 in spheroid supernatant 
The release of apoptotic and necrotic forms of keratin 18 were then analysed from 
spheroid supernatant after treatment with four hepatotoxins previously shown to 
cause cell death in C3A spheroids (see Figure 4.2).  Apoptosis was determined 
using ck18 concentrations and necrosis determined by subtracting ck18 values from 
total keratin 18.  A dose dependent increase in apoptosis was observed after 
spheroids were treated with all four compounds (Figure 4.9A and B).  This 
correlated well with previous cell viability data (Figure 4.2).  Necrosis did not show 
the same correlation, as levels fluctuated from dose to dose for every compound.  
For fialuridine, although overall cell death was unchanged the levels of necrosis 
appeared to decrease as fialuridine concentration increased.  This was repeated on 
C3A cells cultured in 2D, giving slightly different results to spheroids.   Much smaller 
changes in apoptosis were observed after acetaminophen and diclofenac 
concentrations increased, and concentrations of necrosis followed no clear trend for 
any of the compounds (Figure 4.9A and B).  Overall, the levels of apoptosis and 
necrosis were similar whether cells were cultured in 2D or 3D, despite the previous 
observation of difference in sensitivity of the two models (Figure 4.2). 
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Figure 4.9.  Keratin 18 biomarker release from spheroids.  Spheroids and 2D C3A 
cells were treated with hepatotoxins (A) acetaminophen, (B) diclofenac, (C) fialuridine 
and (D) trovafloxacin, 20 spheroids pooled and supernatant analysed for keratin 18 by 
ELISA.  Apoptosis was calculated from ck18 quantification and necrosis calculated 
from ck18 subtracted from total keratin 18.  Data are represented as mean ± SEM 
(n=3 using 20 replicates) as a percentage of vehicle control. 
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Out of interest this analysis was repeated on supernatant from THP1 co-culture 
spheroids (Figure 4.10).  A similar pattern of apoptotic ck18 release was observed, 
showing a dose-dependent increase.  However, again necrosis did not correlate with 
the concentration of any of the drugs or overall cell viability from previous analysis 
(Figure 4.2).  The apoptosis observed from THP1 co-culture spheroids was also 
significantly higher than that in C3A spheroids, correlating with the increased toxicity 
previously observed in the co-culture model (Figure 4.7).  
miR-122 was analysed in the supernatant of spheroids treated with the same 
hepatotoxins, however negligible levels were detected in all of the samples (data not 
shown).  
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Figure 4.10.  Keratin 18 biomarker release from THP1 co-culture spheroids. 
THP1 co-culture spheroids were treated with hepatotoxins (A) acetaminophen, (B) 
diclofenac, (C) fialuridine and (D) trovafloxacin, 20 spheroids pooled and 
supernatant analysed for keratin 18 by ELISA.  Apoptosis was calculated from 
ck18 quantification and necrosis calculated from ck18 subtracted from total keratin 
18.  Data are represented as mean ± SEM (n=3 using 20 replicates) as a 
percentage of vehicle control. 
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4.4 Discussion  
Compounds can cause DILI by a multitude of different mechanisms.  For example, 
some hepatotoxins cause dysfunction of transporters or loss of structural integrity, 
such as diclofenac, nefazodone, bosentan, troglitazone and tolcapone (Fattinger et 
al. 2001; Kostrubsky et al. 2006; Smith 2003; Stricker 1992; Tujios and Fontana 
2011). Consequentially bile is not effectively secreted into the bile ducts and toxic 
substances can build-up in and around the hepatocytes (Fattinger et al. 2001; 
Kaplowitz 2005; Kostrubsky et al. 2006; Kullak-Ublick 2000-2013; Tujios and 
Fontana 2011).  As observed previously, C3A spheroids showed correct localisation 
of bile canalicular structures and transporter function, hence it could be predicted 
that any cholestatic compound interfering with this would be detected in the 
spheroids.   
On the other hand it is often the metabolite of a compound which causes damage to 
the liver, being directly hepatotoxic or forming adducts with liver proteins.  Examples 
of compounds with this as a suggested mechanism of toxicity include 
acetaminophen, diclofenac, nefazodone, amiodarone, perhexiline, tolcapone and 
troglitazone (Ashrafian et al. 2007; Jorga et al. 1999; Kalgutkar et al. 2005; 
Kaplowitz 2005; Smith 2003; Stricker 1992; Tujios and Fontana 2011; Zahno et al. 
2011).  It has been demonstrated that C3A spheroids display CYP enzyme activity 
with the ability to metabolise xenobiotic compounds (see Section 3.3.4), hence it is 
likely that drug metabolites would be formed in the spheroids and their toxic effects 
observed (Srivastava et al. 2010).   
Many compounds have been suggested to cause injury through damage of 
mitochondria such as diclofenac, fialuridine, amiodarone and troglitazone (Begriche 
et al. 2011; Boelsterli and Lim 2007; Honkoop et al. 1997; Smith 2003).  As the C3A 
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spheroids have functional mitochondria which can be analysed it detail, it is likely 
that disruption to mitochondrial respiration would be identified. 
Furthermore, certain compounds target certain zones of the liver, such as 
acetaminophen (Tujios and Fontana 2011).  Hence, the zonated function that was 
observed in the spheroid model may also be useful to the detection of toxins (Opie 
1904).  The C3A spheroids recapitulate functions from the periportal region and the 
perivenous region (as demonstrated in Section 3.3.2), herein it could be predicted 
that toxins affecting any area of the liver could be detected in this model.   
Many studies suggest that an immune response is involved, and accentuates the 
toxicity of many hepatotoxins.  Diclofenac and trovafloxacin are two compounds 
displaying evidence of immune or inflammatory-mediated toxicities (Shaw et al. 
2010; Stricker 1992).  In order for this damage to be detected, correct cell 
communications and signalling must be in place in an in vitro model, as well as the 
capability to alert or initiate an immune response. 
A final and vitally important parameter to consider is the longevity of the in vitro 
model.  Many hepatotoxins take a long time and often multiple exposures before 
toxicity ensues.  This study was able to adopt a 4 day dosing strategy, with repeat 
dosing on day 2 for spheroid cultures.  This was in order to better recapitulate the 
longer, repeated drug exposures experienced by patients but in a quick, simple, 
high-throughput drug screen.  Monolayer cells however were only treated for 24 
hours, as this is the typical dosing strategy for a 2D liver model and the cells 
become over-confluent and start to die after 48 hours in this culture condition.   
Each of the twelve hepatotoxic compounds caused toxicity in the C3A spheroids and 
all but one of the compounds was more toxic to spheroids than in corresponding 
HepG2/ C3A 2D models (Ju et al. 2015; Lin and Will 2012).  Furthermore 9 out of 12 
compounds were more toxic to C3A spheroids than 2D human hepatocyte cultures, 
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and 5 out of 12 more toxic to spheroids than hepatocyte sandwich cultures (Richert 
et al. 2016), with the remaining compounds showing similar sensitivity.  It is possible 
that these hepatotoxins would not have been identified to be toxic in the 2D in vitro 
liver models, yet the spheroid model clearly identified toxicity.  It is possible that the 
direct cell-cell contacts and increased liver-specific structures and functions of 
spheroids led to these toxins being able to exert their effects.  The lower enzyme 
activity, lack of transporter function, limited cell contacts and different mitochondrial 
function may be the reason these toxins were not detected in 2D.  Since these 
results were obtained, other researchers have found that their 3D cultures are more 
predictive of hepatotoxicity than monolayers, supporting the conclusion that 3D cell 
culture increases sensitivity to hepatotoxins (Gunness et al. 2013; Ramaiahgari et 
al. 2014).  Unfortunately not all of the compounds’ effects were directly compared to 
2D cultures and there was limited published information available about the toxicity 
of these compounds in C3A cells.  A direct experimental comparison of the two 
culture techniques using the same cell types and dosing strategy would provide 
confirmative evidence as to whether 3D cell culture increases the sensitivity of the 
model.  
Data obtained from commercially available InSphero primary human hepatocyte and 
Kupffer co-culture spheroids by AstraZeneca could be compared with data obtained 
from the C3A spheroids.  The same twelve hepatotoxins and three non-DILI 
compounds were analysed using an identical repeat dosing strategy and cell viability 
analysis as was carried out with the C3A spheroids.  In order to predict whether the 
spheroids detected the compounds to have a risk of DILI, a SM calculation was 
utilised, taking into account the highest non-toxic concentration (IC10) and compound 
exposure values (Cmax) (Mueller et al. 2015; Richert et al. 2016; Sison-Young et al. 
2016).  An SM value below 20 appeared to best distinguish hepatotoxic compounds 
from non-hepatotoxic compounds.  Despite being created from a hepatoma cell line, 
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the C3A spheroids detected toxicity in a similar number of compounds as the 
InSphero hepatocyte spheroids.  The C3A spheroids were able to correctly predict 
DILI in 10 out of 12 compounds tested compared to 8 out of 12 detected in 
InSphero, resulting in a sensitivity of 90.9 % and a specificity of 66 % for C3A 
spheroids, and a sensitivity of 88 % and a specificity of 66 % for the InSphero 
spheroids.  This could be due to the liver-specific functions in the C3A spheroids 
being upregulated and allowing the compounds to exert their mechanism of toxicity 
in this model.  Perhaps the C3A spheroids do not possess the appropriate 
mechanisms to prevent or repair damage cause by these toxins, accounting for the 
differences between toxicities observed in hepatocyte spheroids.  Although 
exposure was accounted for, the concentrations of each compound in spheroid 
culture may be significantly different from the Cmax in vivo, therefore the SM 
calculation may be considered irrelevant.  Furthermore using an SM value of 20, 
may not have been appropriate for the InSphero model.  Regardless, this sensitivity 
appears to be a huge improvement on the sensitivity reported for currently used in 
vitro systems (Olsen and Whalen 2009).  
Nevertheless, one of the non-DILI compounds, pioglitazone, was also determined to 
have a risk of DILI in the C3A spheroid model as well as the InSphero spheroids.  
Pioglitazone is not known to cause liver damage, but can damage the heart 
(Chinnam et al. 2012).  This false positive lowered the sensitivity and specificity of 
the spheroid models.  This lack of specificity may be a key limitation of the C3A 
spheroids, suggesting that the model cannot distinguish between hepatotoxic 
compounds and those toxic to other tissues.  Other cell lines show poor specificity to 
hepatotoxins when cultured in 2D (Atienzar et al. 2014).  It is difficult to accurately 
predict sensitivity and specificity with only a small number of positive and negative 
compounds and many of the compounds tested may indeed be toxic to other organs 
as well as the liver.   A further drug screen employing a larger panel of compounds 
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with more negative DILI compounds would help to more accurately determine the 
sensitivity and specificity of the C3A model to hepatotoxins.  Furthermore a negative 
control experiment, using a non-liver cell line cultured in 2D and spheroids, would 
identify whether spheroid culture heightens the sensitivity of multiple cell types to 
toxicity, indicating that this phenomenon is not liver-specific and is unrelated to the 
origin of the model. 
The next investigation was whether the presence of NPC increased the sensitivity of 
the spheroid model to hepatotoxins.  LSEC, cryopreserved after isolation from 
human liver, were chosen.  Endothelial cells are the second largest population of 
cells in the liver, with vital functions during liver homeostasis, as well as having a 
key role during liver damage and regeneration (Anderson 2015; Kmiec 2001).  
Secondly, it was decided that an immune cell should be included in the spheroids.  
THP1 cells were identified, a human monocytic cell line isolated from an acute 
monocytic leukaemia patient, as they display many of the properties and markers of 
human monocytes, with the ability to phagocytose, detect and respond to stress 
signals, release pro-inflammatory cytokines and differentiate into macrophages 
(Tsuchiya et al. 1980).  It was hypothesised that these NPC could create a more in 
vivo-like microenvironment in the spheroids and in turn respond to human 
hepatotoxins with heightened sensitivity. 
Firstly the presence of each cell type in the spheroids during the desired culture 
period was confirmed.  Secondly a toxicological analysis was performed.  A clear 
trend highlighted that the inclusion of LSEC in the model caused a small increase in 
the sensitivity of the model to hepatotoxins, the inclusion of THP1 cells increased 
this sensitivity further, and both cell types even further, which was reflected in the 
IC50 values obtained.  This led to a higher sensitivity of 91.6 % in the NPC co-culture 
models.  Amiodarone was correctly picked up using the co-culture spheroid models 
which went undetected in the C3A monoculture spheroids.  Suggested mechanisms 
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of amiodarone toxicity include mitochondrial and lysosomal dysfunction as well as 
toxic metabolite formation (Bandyopadhyay et al. 1990; Begriche et al. 2011; Dake 
et al. 1985; Zahno et al. 2011).  It is possible that the inclusion of NPC into the 
spheroid model created a more in vivo-like environment, with sensitive mitochondria 
and CYP enzyme activity, in which this toxin was able to exert its toxicological 
effects.  Moreover, despite not being identified as hepatotoxic, ximelagatran caused 
significantly more toxicity in spheroids cultured with THP1 monocyte cells.  The 
mechanism by which this compound causes DILI has yet to be specified, however 
from these results one could hypothesise that these immune cells aggravated 
ximelagatran toxicity in the spheroids, indicating a toxic mechanism involving the 
immune response or inflammation. 
Other research groups have analysed the ability of liver spheroids to detect 
hepatotoxic compounds.  Despite using the same cell type, Fey and Wrzesinski 
found higher IC50 values for acetaminophen, diclofenac and amiodarone in their C3A 
spheroids (Fey and Wrzesinski 2012).  This could be explained by the fact they used 
acute dosing, rather than a repeat-dosing strategy as used in this chapter.  There is 
now evidence that repeat dosing, as well as 3D cell culture, increases the sensitivity 
of a HepG2 model to hepatotoxins (Ramaiahgari et al. 2014).  Since performing the 
toxicological analysis presented here, another study tested the same panel of 
compounds using a 14 day repeat-dosing strategy and found their human 
hepatocyte co-culture spheroids to detect 75 % of hepatotoxins, indicating similar 
predictivity as the co-culture spheroid model in this chapter (Richert et al. 2016).  
Furthermore Bell et al. 2016 adopted longer dosing protocols of 7 or 28 days in their 
human hepatocyte co-culture spheroids, identifying 5/5 of their hepatotoxins to have 
a risk of DILI using their criteria  (Bell et al. 2016).  These 5 compounds were also 
correctly identified as being hepatotoxic in the C3A spheroid model.  A longer repeat 
dosing protocol could be implemented with the C3A spheroids, up 32 day drug 
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treatment - as it has been proven that C3A spheroids were viable and functional for 
this period.  This may increase their ability to detect toxins which cause DILI after 
longer and more numerous exposures.  It was additionally discovered that the age 
or culture time at which C3A spheroids were treated did not affect drug response, 
unlike hepatocyte spheroids (Ogihara et al. 2015), as both 3 day and 10 day old 
C3A spheroids produced similar dose-response curves and IC50 values.  This was 
perhaps due to the long-term stability of the C3A spheroid model.  
Further evidence has been published revealing that the inclusion of endothelial cells 
in in vitro liver models may have advantages.  Kang et al. 2013 show expression of 
hepatocyte differentiation markers and urea synthesis from rat hepatocytes after co-
culture with endothelial cells, with comparable results observed in liver cell lines 
once co-cultured (Kang et al. 2013; Ohno et al. 2009).  Co-cultures of vascular 
endothelial cells and C3A cells  have shown increased liver-specific function, 
including CYP expression and albumin synthesis, but conversely a decreased 
sensitivity to hepatotoxin acetaminophen (Nelson et al. 2015).  This increased 
function could be mitigated by signalling between the two cell types and an 
alteration in the phenotypes of these cells due to the creation of a more liver-like 
microenvironment.  Likewise, in vitro co-culture studies have found that Kupffer cells 
can modulate hepatocyte phenotype, including increases in liver-specific functions 
as well as responses to inflammatory stimuli which otherwise have no effect on the 
cells (West et al. 1986; Yagi et al. 1998).  Kupffer cells can also detect and respond 
to hepatocyte stress caused by hepatotoxins in vitro, potentially making a co-culture 
model with higher sensitivity to hepatotoxins (Kegel et al. 2015).  A model by Edling 
et al. 2009 showed that culturing immune cells with the liver cell line Huh-7 led to 
enhanced sensitivity to hepatotoxins (Edling et al. 2009).  The results presented in 
this chapter support this evidence that including NPC in liver models increases their 
sensitivity to a range of hepatotoxic compounds.  Further analysis could give insight 
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into the mechanism by which some of these hepatotoxins are working, potentially by 
damaging NPC, the structural integrity of the liver, or through immune-mediated 
mechanisms.  It would also be interesting to see the direct effects of the compounds 
on the NPC alone. 
One disadvantage of preclinical drug screening is that completely different analyses 
are used to detect liver damage in vitro than in a clinical situation.  The question was 
asked whether three novel biomarkers, HMGB1, keratin 18 and miR-122, could be 
analysed in an in vitro liver spheroid model and whether or not the measurement of 
these biomarkers would enhance the ability of the spheroid model to detect 
hepatotoxins by providing additional sensitivity and information about the toxicity 
occurring.  miR-122 could not be quantified from C3A spheroid supernatant.  It was 
previously thought that HepG2 cells did not express miR-122 (Murakami et al. 2005; 
Wu et al. 2009), however more recently miR-122 has been identified in HepG2 cells 
(Kia et al. 2015), suggesting that passage number could cause this gene deletion.  It 
is possible that the C3A cell line, a subclone of HepG2 cells, does not express this 
miR or perhaps the method used was not sensitive enough for in vitro detection of 
miR-122 and needs to be optimised for use with cell culture samples. 
Additionally, the analysis of HMGB1 in cell and spheroid lysates proved to be 
challenging and non-quantitative.  HMGB1 is released during cell death (Antoine et 
al. 2009b) therefore a reduction in expression intracellularly was expected at high 
drug concentrations; however the expression in the cell lysates was fairly consistent 
despite the compounds causing a reduction in cell viability.  It is not known exactly 
how these biomarkers are released from cells.  Clearly these markers must be 
studied further in order to understand how they are regulated, released from cells 
and at what time point they can be detected after initiation of cell damage.   Utilising 
a technique such as mass spectrometry imaging may provide a more sensitive 
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analysis of these two novel biomarkers in vitro, as well as providing quantitative 
information.   
The analysis of keratin 18 released from the spheroids into the supernatant was 
more informative.  All four compounds appeared to cause a dose-dependent 
increase in apoptosis in the spheroids.  Analysis of this novel biomarker therefore 
suggests that these compounds cause DILI primarily by increasing apoptosis.  On 
the other hand, this contradicts clinical evidence that acetaminophen causes 
necrosis which leads to liver damage (Hinson et al. 2010; James et al. 2003) and 
previously both ck18 and fk18 were found to increase after acetaminophen 
overdose (Antoine et al. 2013).  Additionally, the levels of this biomarker did not 
correlate with the levels of cell death observed, particularly as both 2D and 3D 
models released similar levels despite revealing increased cell death in spheroids.  
In light of this, despite providing mechanistic information as to the type of cell death 
occurring, this analysis did not improve the sensitivity of the model.  Hence relying 
on these biomarkers as a measure of toxicity from a range of different compounds 
may give misleading conclusions.  To summarise, more research is needed into 
these novel biomarkers before they can be relied upon for an accurate diagnosis of 
DILI in vitro or in the clinic. 
4.4.1 Conclusion 
C3A spheroids were found to be more sensitive to a small panel of hepatotoxins 
than a 2D model, with a similar sensitivity as a commercially available hepatocyte 
spheroid model.  The inclusion of NPC in the C3A spheroids increased the 
sensitivity of the model further, leading to a higher number of compounds being 
identified as having a hepatotoxic risk and supporting evidence than NPC have a 
vital role in DILI.  The analysis of novel biomarker keratin 18 provided information 
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about the mechanism of cell death caused by each hepatotoxin, however HMGB1 
and miR-122 could not be quantified in the C3A spheroid model.   
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5.1 Introduction 
Mitochondria are organelles which are vitally important to cell survival, whose 
primary role is to produce cellular energy through OXPHOS and the consequent 
production of ATP (Cooper 2000).  If mitochondria were to be damaged, not only 
would this lead to a reduction in cellular energy and function, but mitochondrial 
dysfunction could cause the production of ROS, damage DNA and proteins and 
inevitably lead to oxidative stress, cell death and potential organ damage.  50 % of 
hepatotoxic compounds are thought to have mitochondrial liability (Begriche et al. 
2011; Boelsterli and Lim 2007), with the direct consequence of some compounds 
causing disastrous failures in clinical trials due to undetected mitochondrial toxicity 
during preclinical screening (Honkoop et al. 1997).  By analysing the effect of a 
compound on mitochondrial function during preclinical trials, potentially dangerous 
toxins could be detected earlier in the drug discovery process. 
The basal mitochondrial functionality was previously determined from C3A cells 
(Section 3.3.6), and therefore this platform could be used to investigate the intricate 
differences in mitochondrial function caused by toxic compounds.  The analysis of 
mitochondrial stress in vitro could potentially highlight compounds with mitochondrial 
liabilities in humans.  Furthermore, this analysis may help to elucidate the 
mechanisms of action of numerous hepatotoxins with currently unconfirmed 
mechanisms of toxicity by revealing whether the toxin is interfering with cellular 
bioenergetics. 
In vitro experiments are most often performed on immortalised cells, which have 
adapted to withstand hypoxic and acidic conditions and display continued rapid 
growth.  Although under normal conditions these cell lines produce the majority of 
their energy through OXPHOS, they also have the increased ability to produce 
energy through glycolysis, as glucose (often in excessive concentrations in the 
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medium) is converted to pyruvate, yielding two ATP molecules (Diaz-Ruiz et al. 
2011; Marroquin et al. 2007).  Mitochondrial OXPHOS is therefore no longer 
essential for energy production (Dell' Antone 2012; Rodriguez-Enriquez et al. 2001), 
this phenomenon is known as the Crabtree effect.  This characteristic can result in 
compounds which cause mitochondrial damage going undetected in these model 
systems as the cells are able to continue to produce energy by an alternate 
mechanism resulting in the drug having little impact on cell viability (Marroquin et al. 
2007).   
One way to overcome this problem and allow immortalised cells to produce energy 
through functional mitochondrial ATP production is by removing the key substrate 
for glycolysis.   Once glucose is removed from culture medium and replaced with 
galactose, the cells are forced to undergo mitochondrial OXPHOS for energy 
production as the efficiency of glycolysis is vastly reduced (Marroquin et al. 2007; 
Reitzer et al. 1979).  This change in metabolism, or inhibition of the Crabtree effect, 
has been shown to occur within as little as 4 hours under galactose conditions 
(Kamalian et al. 2015).  Studies have also confirmed that this metabolic switch 
indeed raises the sensitivity of 2D cultured cells to known mitochondrial toxins, 
leading to an increased ability to detect mitochondrial liabilities in novel drug 
compounds (Kamalian et al. 2015; Marroquin et al. 2007).  Evidence suggests that 
C3A cells under normal cell culture conditions may be under the Crabtree effect, as 
similar immortalised cell lines display this feature (Kamalian et al. 2015; Marroquin 
et al. 2007; Rodriguez-Enriquez et al. 2001).  Furthermore, inhibition of the Crabtree 
effect has previously been possible in HepG2 cells (Kamalian et al. 2015; Marroquin 
et al. 2007).  C3A cells are able to grow in glucose deficient media (Nibourg et al. 
2012), hence evidence suggests that inhibition of the Crabtree effect using 
galactose conditions would be possible in these cells.   
  Chapter 5 
152 
 
C3A spheroids have displayed the ability to detect a wide range of hepatotoxic 
compounds, working by a range of different mechanisms.  In addition C3A cells 
possess different functional capabilities depending on whether cultured in 2D or 3D 
spheroids.  The first aim of this chapter was to elucidate whether changes in 
mitochondrial respiration could be detected after treatment with hepatotoxins, in 
order to confirm the mechanism of action of these compounds.  Secondly, the 
bioenergetic profile of C3A cells was investigated in 2D or spheroid culture and it 
was questioned whether it was possible to modify the bioenergetic profile of this 
spheroid model as an attempt to increase its mitochondrial susceptibility.   
Hypothesis 1: It will be possible to monitor changes in mitochondrial function 
caused by toxic compounds in the C3A spheroid model, which may help to 
determine the mechanism by which a compound is causing toxicity. 
Hypothesis 2: Control C3A cells will be under the Crabtree effect and by culturing 
in galactose conditions it will be possible to circumvent the Crabtree effect, 
subsequently rendering the model more sensitive to hepatotoxins with mitochondrial 
liabilities.   
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5.2 Materials and Methods 
All drug compounds and galactose were purchased from Sigma Aldrich, Missouri, 
USA.  DMEM no glucose and dialysed FBS were purchased from Thermo Scientific, 
Watham, USA.   
5.2.1 Spheroid formation and culture 
C3A cells were maintained and cultured in monolayers as previously described 
(Section 2.2.1).  Spheroids were created using the LOT from 1000 C3A cells as 
described previously (Section 2.2.1).  For monolayer experiments C3A cells were 
used at 100 % confluence. 
5.2.2 Culturing spheroids in galactose conditions 
DMEM no glucose was used to create the agarose for the plates, and spheroids 
were cultured in galactose media consisting of DMEM no glucose supplemented 
with 10 % dialysed FBS, 10 mM galactose, 1 % L-glutamine, 1 % sodium pyruvate, 
1 % penicillin-streptomycin.  
5.2.3 Compound treatment  
For experiments analysing the effect of hepatotoxins on mitochondrial function  and 
for the toxicological analysis in glucose and galactose conditions, spheroids were 
treated with hepatotoxic compounds using a 4 day repeat dosing strategy as 
previously described (Section 4.2.3).  For the experiments comparing the effects of 
hepatotoxins in glucose and galactose conditions on mitochondrial function, 
spheroids were treated with hepatotoxic compounds’ IC50 concentrations for a 24 
hour incubation period.  2D monolayer cells were also treated with hepatotoxic 
compounds for 24 hours.  For experiments using rotenone, spheroids were treated 
with rotenone in 0.5 % DMSO in galactose medium for either 2 hours or 24 hours.   
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5.2.5 Cell viability analysis 
Cell viability was analysed as previously described (Section 4.2.4).  Three replicates 
were used for each experiment.  A dose-response curve was plotted and IC50 values 
determined. 
5.2.6 Bradford assay for quantification of protein content 
Bradford assays were performed as previously described (Section 3.2.4). 
5.2.7 Analysis of mitochondrial stress by oxygen consumption analysis 
Cell Mito Stress Tests were performed on spheroids as previously described 
(Section 3.2.11), however for Crabtree investigations only rotenone was added to 
port A of the cartridge.  Data was analysed using a Seahorse XF Mito Stress Test 
Report Generator and data normalised to protein content.  6 replicates of spheroids 
or 2D monolayer wells were used for each experiment. 
5.2.8 Statistical analysis 
Data are representative of at least three independent experiments (n=3) and 
expressed as mean ± SEM. Graphs and statistical analyses were performed using 
GraphPad Prism 5.  A Shapiro-Wilk normality test was performed on all data sets. 
Data which passed normality tests underwent analysis by a two-way ANOVA, those 
which did not underwent a non-parametric Kruskal-Wallis test.  Significance was 
determined from a p value < 0.05. **** p<0.0001, *** p< 0.001 ** p<0.01, * p< 0.05. 
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5.3 Results 
5.3.1 Monitoring changes in mitochondrial function induced by hepatotoxins 
In order to investigate whether or not changes in mitochondrial function could be 
detected in C3A spheroids, a Cell Mito Stress Test was performed after drug 
treatment with several hepatotoxins under normal culture conditions.  Figure 5.1 
shows the OCR curve produced by spheroids treated with acetaminophen, 
diclofenac, fialuridine and trovafloxacin using the repeat-dosing protocol described 
in the previous chapter.  From this data it was concluded that both concentrations of 
trovafloxacin were too toxic to cells, as basal OCR values were very low and the 
spheroids did not respond to the Mito Stress Test.  Therefore data obtained for 
trovafloxacin was removed from further analysis in this experiment.  The values 
obtained after drug treatment were compared to untreated vehicle control spheroids 
to see how the compounds might be interfering with normal mitochondrial function 
(Figure 5.2).  None of the three hepatotoxins had a significant effect on any of the 
respiratory parameters in the spheroids, however small differences could be 
observed.  Basal respiration was seen to decrease in a dose-dependent manner in 
response to acetaminophen and fialuridine.  The amount of respiration linked to ATP 
production decreased in response to all toxins, to varying extents.  Proton leak was 
increased by diclofenac but decreased by high concentrations of fialuridine.  SRC 
increased dose-dependently in response to acetaminophen and diclofenac, as well 
as increasing in response to fialuridine.  All compounds caused a decrease in NMR 
and coupling efficiency compared to control spheroids, with fialuridine having the 
largest effect on NMR.  None of these differences were significantly different from 
control spheroids.  
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Figure 5.1.  The effect of hepatotoxins on OCR in spheroids.  Spheroids were 
treated with four hepatotoxins using a repeat-dosing strategy.  A Mito Stress Test 
was performed using Seahorse technology.  Raw OCR values (pmol O2/min/µg 
protein) were plotted against time (min) for each drug treatment.  Data represent 
mean ± SEM (n=3, 6 replicates).  
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Figure 5.2.  The effect of hepatotoxic compounds on mitochondrial function in 
spheroids.  Spheroids were treated with two different concentrations of four 
hepatotoxins using a repeat-dosing protocol.  A Mito Stress Test was performed 
using Seahorse technology and mitochondrial respiratory parameters calculated and 
plotted as a percentage of maximal respiration. Basal respiration, ATP-linked 
respiration, proton leak, maximal respiration, spare respiratory capacity, non-
mitochondrial respiration, coupling efficiency and basal ECAR are plotted for each 
drug treatment (A-H).  Data represent mean ± SEM normalised to untreated control 
values (n=3, 6 replicates). 
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It was next investigated how these results compared with the same compounds 
tested in 2D monolayer cultures (Figure 5.3).  Only small differences were observed 
for all respiratory parameters between 2D and spheroids, indicating that these 
compounds affected the mitochondria in both 3D and 2D cell cultures similarly, 
despite previously confirming increased toxicity in spheroids.  
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Figure 5.3.  The effect of hepatotoxic compounds on mitochondrial function in 
spheroids and 2D C3A cells.  Spheroids or 2D C3A cells were treated with two 
different concentrations of four hepatotoxins using a repeat-dosing protocol.  A Mito 
Stress Test was performed using Seahorse technology and mitochondrial respiratory 
parameters calculated and plotted as a percentage of maximal respiration. Basal 
respiration, ATP-linked respiration, proton leak, maximal respiration, spare 
respiratory capacity, non-mitochondrial respiration, coupling efficiency and basal 
ECAR are plotted for each culture condition and drug treatment (A-H).  Data 
represent mean ± SEM, (n=3, 6 replicates).  
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5.3.2 Circumventing the Crabtree effect in spheroids 
Firstly it was determined whether C3A spheroids or 2D C3A cells were displaying 
the Crabtree effect.  Subsequently, an investigation into whether or not the Crabtree 
effect could be circumvented was performed by culturing cells under galactose 
conditions.  Basal respiration was analysed in control (glucose) spheroids (Figure 
5.4A, black circle).  Mitochondrial OCR (indicative of OXPHOS rate) was 8.9 ± 3.1 
O2/min/µg protein and basal ECAR (indicative of glycolysis rate) was 6.1 ± 0.5 
mpH/min/µg protein in control spheroids (Dranka et al. 2011). The next part of the 
analysis involved treatment with rotenone, a mitochondrial complex I inhibitor.  
Spheroids cultured in glucose conditions saw a 4.5 O2/min/µg protein decrease in 
OCR after treatment with rotenone, corresponding to a 50 % decrease.  This 
suggests that rotenone successfully inhibited OXPHOS.  A 1.8 mpH/min/µg protein 
(30 %) increase in ECAR was observed after rotenone exposure (Figure 5.4A black 
circle), although not significant, indicating a small up-regulation of glycolysis.  These 
results indicate that the control glucose-cultured C3A spheroids were under the 
Crabtree effect to some extent, as once mitochondrial OXPHOS was reduced the 
cells compensated by increasing glycolytic capacity.  It was then investigated 
whether a metabolic shift could be induced in C3A spheroids.  Under galactose 
culture conditions basal mitochondrial OCR was similar to control spheroids at 8.7 ± 
3.3 O2/min/µg protein, however basal ECAR was lower in galactose conditions than 
control spheroids, at 4.6 ± 1.4 mpH/min/µg protein (Figure 5.4A, clear circle).  This 
indicates lower levels of basal glycolysis, hence a metabolic shift, under these 
conditions (Dranka et al. 2011).  Exposure to rotenone confirmed this alteration of 
energy metabolism in galactose conditions.  Again a decrease in OCR was 
observed as OXPHOS was successfully inhibited, with a 5.4 pmol O2/min/µg protein 
(62 %) drop.  However the corresponding increase in ECAR previously observed in 
control spheroids did not occur under galactose conditions.  A negligible 0.4 
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mpH/min/µg protein or 9 % increase in ECAR occurred after rotenone exposure in 
galactose-cultured C3A spheroids (Figure 5.4A, clear circle).  This strongly suggests 
that any Crabtree effects observed in control, glucose-cultured, spheroids were 
abolished by using galactose culture conditions, as glycolytic capacity is unable to 
be increased in response to a decrease in mitochondrial respiratory capacity. 
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Figure 5.4.  Effect of galactose conditions on mitochondrial OCR and ECAR.  
(A) Spheroids or (B) 2D C3A cells were acutely treated with rotenone after culture in 
glucose (black) or galactose (clear) conditions.  Raw OCR values were plotted 
against raw ECAR values before and after exposure to rotenone.   Data are 
represented as mean ± SEM, ** p<0.01, for galactose spheroids before and after 
exposure to rotenone (n=3 in triplicate). 
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This analysis was repeated in 2D C3A cells (Figure 5.4B).  For 2D C3A cells basal 
ECAR was lower than in spheroids when using glucose medium, as seen previously 
(Figure 3.14).  Control, glucose-cultured, 2D C3A cells had a basal OCR of 5.8 ± 1.0 
O2/min/µg protein and an ECAR of 1.3 ± 0.2 mpH/min/µg protein.  Once exposed to 
rotenone OCR decreased by 4.1 pmol O2/min/µg protein (70 %) and ECAR 
increased by 1.2 mpH/min/µg protein or 92 % (Figure 5.4B, black square).  It 
appears that control 2D C3A cells were also under the Crabtree effect, as glycolysis 
was upregulated in response to decreased OCR.  In fact a much larger increase in 
ECAR (92 %) compared to a 30 % increase was observed in 2D C3A cells, making 
the Crabtree effect more prominent in 2D cultured C3A cells.  2D C3A cells under 
galactose conditions responded similarly as when in spheroids, despite basal OCR 
and ECAR being higher than both 2D control and in spheroids, at 10.9 ± 3.5 pmol 
O2/min/µg protein and 2.1 ± 0.5 mpH/min/µg protein respectively (Figure 5.4B, clear 
square).  Once rotenone was added OCR decreased as expected, by 8.3 pmol 
O2/min/µg protein, (76 %) in galactose-cultured cells.  The increase in ECAR was 
again less in galactose conditions, only 23 %, 0.5 mpH/min/µg protein in 2D.  This 
again indicates that control C3A cells are under the Crabtree effect and using 
galactose culture conditions abolishes this phenomenon. 
Any differences in mitochondrial respiratory parameters were also elucidated in the 
two different conditions by performing a Mito Stress Test (Figure 5.5A).  The 
analysis of mitochondrial function revealed that spheroids cultured in galactose had 
slightly higher basal respiration, ATP-linked respiration, proton leak and maximal 
respiration than control spheroids, but lower NMR, SRC and coupling efficiency 
(Figure 5.5B). These differences however were not significant. 
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Next, the toxicological effect of rotenone on spheroids cultured in both conditions 
was determined.  Toxicity was observed in spheroids under both conditions in 
response to the complex I inhibitor.  A decrease in cell viability was observed as 
drug concentrations increased, with no significant difference in toxicological 
B 
Figure 5.5.  Effect of galactose conditions on mitochondrial function.  A Mito 
Stress Test was performed on spheroids cultured in control glucose (black) or 
galactose (clear) conditions using Seahorse technology. (A) Raw OCR values (pmol 
O2/min/µg protein) were plotted against time (min) for each culture condition; (B) 
Mitochondrial respiratory parameters were calculated and plotted as a percentage of 
maximal respiration. Basal respiration, ATP-linked respiration, proton leak, maximal 
respiration, spare capacity, non-mitochondrial respiration and coupling efficiency are 
plotted for each culture condition.  Data represent mean ± SEM (n=3, 6 replicates).  
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response under either condition (Figure 5.6A).  As little as 6.2 µM rotenone caused 
toxicity in both conditions after a 24 hour incubation with spheroids.  This 
toxicological analysis was repeated at lower concentrations of rotenone and a 
shorter incubation time, in order to separate any small differences between the two 
conditions (Figure 5.6B).  Indeed, when using a lower concentration and shorter 
incubation period, rotenone was less toxic to glucose-cultured spheroids (Figure 
5.6B, black circle), whereas galactose spheroids still suffered a larger reduction in 
cell viability (Figure 5.6B, clear circle), however these differences were not 
significant.   
This analysis was repeated on C3A cells cultured in 2D to elucidate whether culture 
condition altered the susceptibility of the cells to this mitotoxin.  Figure 5.7 shows the 
toxicity caused in both glucose and galactose conditions in 2D.  At the lower 
concentrations of rotenone a significant difference in sensitivity can be observed, 
with barely any toxicity detected in glucose-cultured C3A cells and a large reduction 
in cell viability in galactose-cultured cells (Figure 5.7B).  Table 5.3 compares IC50 
values calculated from each culture condition.  Correlating with the above data, 
galactose spheroids were more sensitive to rotenone, with a lower IC50 value of 0.65 
µM in galactose conditions compared to 4.3 µM in control spheroids.  Interestingly 
C3A cells had a different sensitivity to rotenone when cultured in 2D or 3D.  Control 
spheroids were significantly more sensitive to rotenone than control monolayers.  An 
IC50 value for glucose-cultured 2D C3A cells could not be calculated from the 2 hour 
incubation of rotenone as it did not cause enough toxicity.  However from the 24 
hour incubation the IC50 values were 3.2 µM and 4.7 µM for spheroids and 
monolayers respectively (Table 5.3). 
  Chapter 5 
165 
 
 
  
Rotenone (M)
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
0 20 40 60 80 100
0
25
50
75
100
Glucose spheroid
Galactose SP
**
**
Rotenone (M)
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
0 2 4 6 8 10
0
25
50
75
100
Glucose spheroid
Galactose spheroid
Rotenone (M)
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
0 2 4 6 8 10
0
25
50
75
100
Glucose spheroid
Galactose spheroid
A B 
Figure 5.6.  Galactose conditions increase the sensitivity of spheroids to 
mitotoxin rotenone.  Spheroids were treated with (A) 100 µM rotenone for 24 
hours or; (B) 10 µM rotenone for 2 hours, after culture in glucose or galactose 
conditions.  Cell viability was analysed and plotted as a percentage of untreated 
control.  Data are represented as mean ± SEM, ** p<0.01 (n=3 in triplicate). 
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Figure 5.7.  Galactose conditions increase the sensitivity of 2D C3A cells to 
mitotoxin rotenone.   2D C3A cells were treated with (A) 100 µM rotenone for 24 
hours or; (B) 10 µM rotenone for 2 hours, after culture in glucose or galactose 
conditions.  Cell viability was analysed and plotted as a percentage of untreated 
control.  Data are represented as mean ± SEM, ** p<0.01 (n=3 in triplicate). 
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Rotenone 
incubation 
time (hours) 
IC
50
 value in 
control 
spheroids 
(μM) 
IC
50
 value in 
galactose 
spheroids (μM) 
IC
50
 value in 
control 2D cells 
(μM) 
IC
50
 value in 
galactose 2D 
cells (μM) 
2 4.3 0.65 > 10 0.38 
24 3.2 *** 2.7 4.7 2.7 
 
Table 5.1.  Sensitivity of spheroids and 2D C3A cells to mitotoxin rotenone. 
Spheroids and 2D C3A cells were treated with rotenone for 2 hours after culture in 
control glucose conditions or galactose conditions.  Cell viability was analysed and 
IC50 values calculated.  Data are represented as mean values, *** p<0.001 control 
spheroids compared to control 2D (n=3 in triplicate). 
 
In order to visualise any differences in the number or location of mitochondria in 
glucose and galactose conditions, spheroids were stained with JC-1 and visualised 
by immunofluorescence.  Figure 5.8 shows the expression and location of 
mitochondria (red) in relation to nuclei (blue) in both culture conditions.  Numerous 
mitochondria can clearly be seen dispersed throughout the cell cytoplasm in both 
conditions with no clear difference in their localisation. 
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5.3.3 Toxicological analysis of spheroids circumventing the Crabtree effect 
Next the toxicity of the same four hepatotoxins were analysed under both glucose 
and galactose conditions.  Dose-response curves for each compound are shown in 
Figure 5.9 and IC50 values in Table 5.4.  Hepatotoxins caused toxicity in both the 
glucose and galactose-cultured spheroids.  Trovafloxacin appeared to cause cell 
death at lower concentrations in galactose-cultured spheroids, indicated by a lower 
IC50 value of 25 µM compared to 65 µM, however the top concentrations affected 
the spheroids similarly.   Diclofenac and acetaminophen appeared to be less toxic 
under galactose conditions, indicated by higher IC50 values for both.  Diclofenac 
caused significantly less cell death in galactose-cultured spheroids than control.  
Fialuridine was equally toxic to both models (Figure 5.9).   
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Figure 5.9.  Toxicological analysis of spheroids cultured in galactose 
conditions. Spheroids were treated with four hepatotoxins (A-D) using a repeat-
dosing protocol after culture in control glucose or galactose conditions.  Cell 
viability was analysed and plotted as a percentage of vehicle control.   Data are 
represented as mean ± SEM, ** p<0.01 (n=3 in triplicate).   
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This data was coupled with the effect of these compounds on mitochondrial 
respiration in both glucose and galactose conditions (Figure 5.10 and 5.11).  The 
OCR curve produced after treatment with each hepatotoxin is plotted in Figure 5.9.  
In order to see any changes in mitochondrial function that occur before toxicity, 
spheroids were treated with the IC50 concentrations of each compound for 24 hours.  
No significant differences were observed in the response of galactose-cultured 
spheroids compared to control spheroids.  Overall, basal respiration, respiration 
linked to ATP production, proton leak and maximal respiration were slightly higher in 
galactose conditions after treatment with all compounds and SRC and coupling 
efficiency were slightly lower.  NMR increased after treatment with trovafloxacin only 
(Figure 5.11).  The hepatotoxins therefore had no observable acute effect on 
glucose or galactose-cultured spheroids. 
 
 
 
Compound 
IC
50
 value in 
control spheroids 
(μM) 
IC
50
 value in 
galactose 
spheroids (μM) 
Acetaminophen 7212 9240 
Diclofenac 295 523 ** 
Trovafloxacin 65 25 
Fialuridine 219 200 
 
Table 5.2.  Sensitivity of spheroids cultured in galactose conditions.  
Spheroids were treated with four hepatotoxins using a repeat-dosing protocol 
after culture in control glucose or galactose conditions.  Cell viability was analysed 
and IC50 values calculated.  Data is compared against IC50 values obtained for 
C3A spheroids cultured in control glucose conditions.   Data are represented as 
mean values, ** p<0.01 (n=3 in triplicate). 
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Figure 5.10.  Effect of hepatotoxins on OCR in spheroids cultured in galactose 
conditions.  Spheroids were treated with IC50 concentrations of four hepatotoxins 
for 24 hours after culture in control glucose (filled circle) or galactose (clear circle) 
conditions.  A Mito Stress Test was performed using Seahorse technology.  Raw 
OCR values (pmol O2/min/µg protein) were plotted against time (min) for each drug 
treatment.  Data represent mean ± SEM (n=3, 6 replicates).  
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Figure 5.11.  Effect of hepatotoxic compounds on mitochondrial function in 
spheroids cultured in galactose conditions.  Spheroids were treated with IC50 
concentrations of four hepatotoxins for 24 hours after culture in control glucose 
conditions or galactose conditions.  A Mito Stress Test was performed using 
Seahorse technology and mitochondrial respiratory parameters calculated and 
plotted as a percentage of maximal respiration.  Basal respiration, ATP-linked 
respiration, proton leak, maximal respiration, spare respiratory capacity, non-
mitochondrial respiration, coupling efficiency and basal ECAR are plotted for each 
culture condition and drug treatment (A-H).  Data represent mean ± SEM 
normalised to values obtained from control glucose conditioned spheroids (n=3, 6 
replicates). 
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5.4 Discussion  
It was previously revealed that the liver-specific functionality and phenotype of C3A 
cells was different depending upon whether cultured in 2D and 3D, as well as 
differences in the sensitivity to numerous hepatotoxins, with overall more human-
relevant characteristics when cultured in spheroids.  In this chapter the aim was to 
investigate the bioenergetic profile of C3A cells in 2D and 3D in more detail, as well 
as explore whether or not the C3A spheroid model could be tailored for the detection 
of hepatotoxins causing injury through mitochondrial damage. 
Mitochondrial function was analysed in C3A spheroids after treatment with four 
hepatotoxins, in order to detect any subsequent signs of mitochondrial stress.  The 
same repeat-dosing protocol was used as in the previous chapter, to identify any 
changes the drug might cause after longer, repeated dosing, as some hepatotoxins 
have been shown to only cause mitochondrial damage after a longer, repeated 
exposure.  Changes in mitochondrial respiratory parameters could successfully be 
observed after exposure to hepatotoxins.  A dose-dependent reduction in basal 
respiration was detected after treatment with acetaminophen and fialuridine, 
potentially due to increased ATP demand, inhibited ETC or decreased substrate 
supply (Hill et al. 2012).  The same two compounds caused a decrease in 
respiration linked to ATP production, which may be due to damaged ETC, reduced 
ATP demand or low substrate availability (Hill et al. 2012).  Another indicator of 
mitochondrial damage is a decrease in maximal respiration, or SRC, potentially 
caused by a decreased number of mitochondria or poor ETC integrity.  A decrease 
in SRC results in the cells being less able to respond to oxidative stress or 
increased energy demand (Hill et al. 2012).  Surprisingly, SRC and maximal 
respiration increased after treatment with all hepatotoxins, perhaps as the cells 
compensate for the increased stress caused by the hepatotoxins.  NMR occurs from 
any other respiration occurring within the cell, mainly ROS production but also other 
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oxidases, interestingly levels decreased after hepatotoxin treatment (Hill et al. 
2012).  Every compound caused a decrease in coupling efficiency which could 
indicate mitochondrial damage due to electron transport being less efficiently linked 
to energy production (Brand and Nicholls 2011; Divakaruni et al. 2014; Hill et al. 
2012).  Hence, the ability to monitor changes in mitochondrial respiration using this 
method can provide more intricate information about the function of mitochondria 
and bioenergetics of an in vitro model. 
Despite observing these changes in mitochondrial respiration after drug treatment, 
the values were not significantly different to control spheroids.  Additionally, the 
effects on mitochondrial function within spheroid or 2D culture conditions were 
similar, despite previously showing that C3A spheroids were more sensitive to these 
hepatotoxins than 2D C3A cells.  Hence the primary mechanism of toxicity of these 
compounds is unlikely to be via mitochondrial dysfunction.  This is controversial, as 
acetaminophen, fialuridine and diclofenac have been previously stated to cause 
mitochondrial injuries (Boelsterli 2003; Honkoop et al. 1997; Kon et al. 2004; 
Moreno-Sanchez et al. 1999; Parmar et al. 1995).  However, it is possible that the 
high concentrations of drug compound and repeat-dosing strategy were not 
appropriate for analysing mitochondrial function, as this would have created a high 
percentage of cell death in the spheroids, therefore the cells analysed were possibly 
either very unhealthy from the drug treatment or resistant to toxicity.  For this 
reason, in later experiments spheroids were treated with IC50 concentrations for 24 
hours, allowing for any acute effects of the compounds on mitochondria to be 
detected before significant cell death ensues.   
The bioenergetic profile of C3A spheroids was next investigated.  It was confirmed 
that under normal culture conditions the spheroids appeared to be under the 
Crabtree effect to some extent, with the ability to up-regulate glycolytic activity, as a 
compensatory mechanism for the decrease in mitochondrial energy production 
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when under stress (Dranka et al. 2011; Marroquin et al. 2007).  It was further 
determined that one could circumvent the Crabtree effect by culturing the spheroids 
in galactose conditions.  The modified spheroids had lower glycolytic activity, due to 
the unavailability of glucose in the culture medium, and were unable to up-regulate 
this process even after OXPHOS inhibition with rotenone.  However, the differences 
between the two conditions were only small and non-significant, indicating that the 
control spheroids may in fact already rely heavily on mitochondria and OXPHOS for 
ATP production and only be capable of producing a small amount of energy via 
glycolysis, even when mitochondrial energy production is compromised.  This 
contrast with the results found with 2D C3A cells, which were able to up-regulate 
glycolysis to a much larger extent.  Perhaps this is because the cells in spheroids 
are not fully under the Crabtree effect, and 3D culture inhibits the ability of C3A cells 
to up-regulate glycolysis.  This could help to explain why 2D C3A cells are less 
sensitive to hepatotoxins (as seen in Chapter 4), as 2D cells are able to produce 
more energy via glycolysis and continue to survive despite toxic insult. 
Subsequently, the effect of rotenone on cell viability was analysed in spheroids 
under both conditions.  Previous research revealed that HepG2 cells cultured in 2D 
showed increased sensitivity to rotenone when cultured in galactose conditions, 
whereas control HepG2 cells were resistant to rotenone toxicity (Kamalian et al. 
2015; Marroquin et al. 2007).  However, the C3A spheroids were sensitive to 
rotenone, with only a small difference in toxicity between glucose and galactose-
cultured spheroids.  Spheroids were also more sensitive to rotenone than 2D C3A 
cells in control conditions, indicating that the original spheroid model was 
susceptible and able to detect mitochondrial toxicity.  This data provides evidence 
that the cells in the C3A spheroids are behaving more alike primary cells, using 
mitochondrial OXPHOS as their main energy production and as a result having 
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increased susceptibility to compounds which impair mitochondrial function 
(Marroquin et al. 2007). 
The response of the spheroids to four hepatotoxins was analysed to see whether 
the galactose culture conditions increased the sensitivity of the spheroid model 
(Beggs et al. 2014; Boelsterli 2003; Honkoop et al. 1997; James et al. 2003; Kon et 
al. 2004; Moreno-Sanchez et al. 1999; Parmar et al. 1995; Shaw et al. 2010).  The 
galactose-cultured spheroids were not significantly more sensitive to these 
hepatotoxins than control spheroids.  Additionally, mitochondrial respiration 
parameters were not significantly altered in response to the four hepatotoxins.  
These data indicate that the control C3A spheroid model already had maximum 
susceptibility to the four toxins tested.  This may be because these toxins are not 
targeting the mitochondria in the C3A spheroids and toxicity is caused through a 
different mechanism of action.  Inhibition of ATPase activity and mitochondrial 
permeability transition have been suggested as mechanisms of acetaminophen-
induced mitochondrial dysfunction (Kon et al. 2004; Parmar et al. 1995).  Diclofenac 
has been indicated to inhibit mitochondrial ATP synthesis and uncouple OXPHOS, 
however the results in this chapter do not support this conclusion (Bort et al. 1999; 
Moreno-Sanchez et al. 1999; Syed et al. 2016).  Fialuridine has been hypothesised 
to cause defects in mitochondrial DNA, resulting in an indirect inhibition of 
mitochondrial function (Tujios and Fontana, 2011).  Despite the fact these 
compounds have been suggested to cause hepatotoxicity through mitochondrial 
damage, it has not yet been proven and perhaps mitochondrial dysfunction is not 
their main mechanism of toxicity.   
Since conducting this research other groups have analysed respiratory parameters 
in C3A cells using a Seahorse technology.  Bavli et al. were similarly able to detect 
mitochondrial toxicity induced by rotenone, as well as showing a clear effect of 
hepatotoxin troglitazone on mitochondrial respiratory parameters before toxicity is 
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observed (Bavli et al. 2016).  This indicates that the analytical method used in this 
chapter is indeed capable of detecting mitochondrial toxicity in C3A cells, supporting 
the evidence that the hepatotoxins tested are not directly toxic to mitochondria.  
However it is possible that the mechanism of mitochondrial injury caused by the 
hepatotoxins tested is not detectable using the analysis carried out in this work.  
There is a downside to using galactose to alter energy metabolism.  Culturing cells 
for prolonged periods in galactose conditions has been shown to have a deleterious 
effect on the cells.  Cells cultured in galactose have been shown to have increased 
mitophagy and mitochondrial degradation due to the up-regulated OXPHOS (Dombi 
et al. 2016; Melser et al. 2013; Van Laar et al. 2011).   
5.4.1. Conclusion  
In summary, the analysis of mitochondrial stress is possible in a C3A spheroid 
model and intricate changes in mitochondrial function can be identified.  The C3A 
cell line’s bioenergetic profile differs depending upon culture condition in that cells in 
2D are under the Crabtree effect to a higher degree, whereas spheroids rely more 
heavily on OXPHOS.  This results in the C3A spheroid model being susceptible to 
mitochondrial toxins without the need to culture in galactose conditions.  It was 
identified that acetaminophen, diclofenac, fialuridine and trovafloxacin do not cause 
any detectable mitochondrial injury in the C3A liver spheroid model.  The ability of 
the model to analyse intricate mitochondrial liabilities could reduce harm caused by 
mitochondrial toxins in clinical trials by detecting these dangerous chemicals earlier 
in the drug development process.  
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6.1 Introduction 
As explained throughout this thesis, the overall aim was to develop a novel in vitro 
liver model in the hope of improving its likeness to the human liver in order to 
investigate DILI.  The development of a more in vivo-like human-relevant liver model 
could potentially increase the sensitivity of the drug screening process.  This 
research should contribute to reducing costs, producing safer medicines and 
consequently minimizing the numbers of adverse effects seen in patients by 
preventing compounds with hepatotoxic liabilities making it to clinical trials.   
In this thesis, a 3D liver spheroid model was successfully developed utilising C3A 
cells and numerous important parameters were characterised, many of which had 
not been previously investigated.  Once the structure and viability of the spheroids 
had been thoroughly interrogated and the models likeness to in vivo liver tissue 
discovered, it was further proven that the C3A spheroids were capable of performing 
numerous liver-specific functions.  The enhanced structure and function of the liver 
spheroids resulted in high sensitivity to liver toxins.  Moreover the effect of including 
NPC in the spheroid model was elucidated, which in fact further increased the 
sensitivity of the model to hepatotoxins.  Finally the bioenergetic profile of C3A 
spheroids was confirmed, revealing an increased likeness of C3A cells to primary 
cells once cultured in 2D.  Changes in mitochondrial respiration and biomarker 
release could be detected in response to drug compounds, allowing the mechanism 
of action of hepatotoxins to be probed in detail.  This chapter will discuss the 
implications of this research and the ongoing efforts to enhance the understanding 
of the mechanisms of DILI and improve the detection of hepatotoxins preclinically. 
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6.2 Enhancements in the preclinical investigation of DILI 
At the beginning of this project, exciting advancements were taking place in 
preclinical screening.  Researchers were investigating the potential of novel, 
complex in vitro systems, fuelled by the ever increasing failures during drug trials.  
Simple 2D monoculture cell models were becoming outdated, unable to detect up to 
40 % of hepatotoxic compounds and costing companies precious time and money 
(Xu et al. 2008) and with improvements in tissue culture and engineering, novel 
techniques were becoming more easily available.  Figure 6.1 depicts some of the 
most common systems in which DILI is investigated.  
  Figure 6. 1. Advancements in liver models.  Numerous liver models are available 
for the investigation of DILI, these models range from the closest resemblance to 
humans with highest complexity to the most ethically accepted and easy to 
manipulate systems.  With advancements in 3D cell culture, spheroid models have 
now been optimised and validated for use in drug safety screening, with numerous 
advantages over older in vitro models. 
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Clinical research into human DILI is essential, furthermore, animal studies are 
legally required to be performed on two separate species before a chemical can be 
tested in patients (Krewski et al. 2010).  However, it is clear that in vitro models are 
absolutely crucial in order to detect human hepatotoxicity before entering clinical 
trials.  These liver models tend to be human-relevant, inexpensive and with little 
limitation as to what experiments can be carried out.  However, in the past, in vitro 
liver models have lacked complexity, resulting in systems which do not recapitulate 
human liver structure or function and consequently poorly predict hepatotoxicity (Xu 
et al. 2008). 
Researchers have attempted numerous techniques in order to try and improve liver 
models, for instance investigating multiple different cell types such as primary 
hepatocytes, modified cell lines, stem cells, co-cultures as well as culturing with 
ECM or scaffolds (Godoy et al. 2013).  For example, sandwich culture of 
hepatocytes can prolong their function and produce secondary structures.  However, 
these models still have disadvantages, they do not represent a human liver, and 
have problems with variability and impracticalities performing the techniques (Godoy 
et al. 2013; van Zijl and Mikulits 2010).  One of the most significant changes to in 
vitro drug testing was undoubtedly the emergence of 3D models.  Spheroids, 
bioreactors and scaffolds have been used for many years in embryonic research 
and cancer therapeutics and more recently adapted in other areas of drug research 
(van Zijl and Mikulits 2010).  Numerous research groups are now investigating the 
use of 3D liver models for drug testing, aiming to create organ-like structures in 
order to detect toxicity of novel drug compounds.  3D liver cell culture has proven on 
numerous occasions to display more in vivo-like structural and functional 
components when compared to monolayer cultures, correlating with an increased 
sensitivity to toxicants (Bell et al. 2016; Godoy et al. 2013; Ramaiahgari et al. 2014; 
Tostoes et al. 2012) 
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Spheroids appear to have become the one of most popular novel in vitro liver 
models, with multiple companies, such as InSphero and Organovo, now offering 
pre-formed spheroids to be shipped directly for drug screening purposes.  With the 
advantages of being easier to create and manipulate than more complex novel cell 
culture techniques, spheroids are an attractive model to bridge the gap between the 
very simple and overly complex liver models.  Furthermore, spheroids created from 
liver cell lines have the benefits of being more widely available and with less ethical 
implications than using liver slices or primary cells.  These improvements are 
mirrored in the ability of liver spheroids to detect human hepatotoxins (Bell et al. 
2016; Ramaiahgari et al. 2014; Richert et al. 2016; Tostoes et al. 2012).  Hence, 
liver spheroids have immense potential for investigating DILI.  
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6.3 Potential of the C3A liver spheroid model for the investigation of DILI 
How does the C3A spheroid model compare to other in vitro liver models? With 
increasingly complex cell culture models emerging, how do C3A spheroids fit into 
the drug screening process?  Figure 6.2 depicts the important stages in the 
development of a novel drug compound.  In vitro models are used in the drug 
development process to investigate the efficacy of a lead compound, as well as 
determine its kinetics and safety in humans.  It is impossible to choose one perfect 
model for drug screening; one can however choose an appropriate model, or 
combination, in order to answer a specific research question.   
 
Figure 6.2. The drug development process.  The development of a novel 
therapeutic compound firstly involves the discovery of a novel drug compound.  This 
involved the identification of a lead compound with efficacy for the target of interest 
using high-throughput screening and analysing physicochemical properties.  The 
next stage, lead optimisation, consists of in vitro and in vivo testing of these 
compounds to ensure safety and efficacy of the compound.  Finally, clinical trials are 
performed before the drug can be marketed for clinical use.  Spheroids could 
potentially be utilised at multiple stages of the drug development process. 
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For preclinical drug screening, an initial simple but effective screen is required to 
identify lead compounds.  This drug screen must ideally be fast, high-throughput, 
inexpensive, reproducible, readily available and easy to analyse.  The spheroid 
model developed in this thesis can be created in 72 hours, in 96-well plate format, 
from an inexpensive and reproducible cell line, with easy end-point analysis.  
Automated production and dosing of C3A spheroids is possible, and has been 
performed at AstraZeneca, further increasing the ease of use of this model.  The 
biology of the C3A spheroids has been validated, with key parameters elucidated 
including 32 day lifespan, cell viability, proliferation rate, cell number, diameter, 3D 
cell morphology and secondary structures.  Furthermore, the analysis of liver-
specific functions of C3A spheroids revealed an increased likeness to in vivo 
functionality.  In addition to this, C3A spheroids display a sensitivity of 90.9 % and 
specificity of 66 %, higher than that observed in established in vitro models (Olsen 
and Whalen 2009; Olson et al. 2000b).  This evidence suggests the potential of a 
C3A spheroid model to detect hepatotoxins and improve upon the sensitivity of 2D 
culture models.  Hence, C3A spheroids are a promising, novel, human-relevant in 
vitro model for high-throughput drug screening. 
 
In addition, spheroids could be used further down the drug safety process.  The C3A 
spheroid model can be cultured for at least 32 days, allowing for longer and 
repeated drug exposures, with the potential of analysing sub-acute or delayed drug 
effects.  For a more in-depth analysis the spheroid model could be utilised to 
investigate the mechanism by which compounds are causing toxicity by analysing 
novel biomarkers of DILI, mitochondrial function, transporter inhibition or the effect 
of the compound on NPC.  There is even the potential to use more complex 
spheroids to model liver diseases and examine the efficacy of therapeutic 
compounds. 
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6.4 Future potential for in vitro liver models 
In the future, in vitro liver models are likely to become more advanced.  Multi-
compartmental microfluidics devices are now freely available, allowing the flow of 
media from one cell model to another, replicating the interaction of multiple different 
cell types, tissues or organs of the human body.  This could involve compartments 
containing different NPC, allowing the circulation of soluble factors between the 
different cell types, or indeed the interaction of multiple organ systems with the liver 
compartment.  Liver spheroids could be incorporated into a multi-compartmental 
model in order to recapitulate a human liver more precisely than 2D cultured cells.  
Studies have attempted to combine 3D spheroids with flow and the combination of 
these two techniques could further improve liver-specific functions and result in 
increased sensitivity to hepatotoxins, once practical difficulties are overcome (Esch 
et al. 2015; Lee et al. 2013; Tostoes et al. 2012).  Novel 3D models have the ability 
to recreate complex structures incorporating multiple cell types and ECM due to the 
enhancements in chemical engineering and 3D printing.  The production of an entire 
in vitro liver sinusoid structure is now possible, with a capillary compartment 
supplying a flow of oxygen and nutrients, a 3D mass of hepatocytes and NPC in the 
sinusoid themselves, secondary structures and a bile compartment to remove waste 
products produced by the hepatocytes (Choi et al. 2016; Toh et al. 2009; Williams D 
et al. 2012).  Furthermore, in order to overcome some of the practical difficulties of 
using specialist in vitro models, these systems are likely to become more 
automated, with continuous monitoring of important parameters as well as 
automated sample collection or imaging in order to become more user friendly and 
produce higher volumes of data (Bhatia and Ingber 2014).  The analysis of these 
systems is likely to also become more specialised, with technologies such as high-
content screening becoming available and entirely automated analysis of end-
points, the quantity of data obtained from these drug screens is ever increasing and 
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these analyses have the potential to have a higher predictivity than in vivo models 
(Ballard et al. 2016; Garside et al. 2014; Persson et al. 2014). 
 
The possibility of replacing animal models with more human-relevant 3D models has 
been discussed, in order to improve on the 50 % of human hepatotoxins detected in 
animal studies (Olsen and Whalen 2009).  In vivo experimentation will always 
receive criticism due to the unethical nature of causing harm to animals.  
Furthermore the vast genetic and environmental differences beckons the question 
as to whether these animal models are relevant to human toxicity (Krewski et al. 
2010).  Complex human-relevant in vitro liver models have immense potential to be 
used to analyse drug efficacy, ADME (adsorption, drug distribution, metabolism, 
excretion) and side effects, all of which could help determine a safe and efficacious 
dose for clinical trials (Ballard et al. 2016; Bhatia and Ingber 2014; Khetani et al. 
2015a; Persson et al. 2014).  The advantage of microfluidics offers more realistic 
thermodynamic properties of the model, allowing estimations of compounds 
exposures (Bhatia and Ingber 2014; Choucha Snouber et al. 2013; Dash et al. 2013; 
Esch et al. 2015; Khetani et al. 2015a; Rashidi et al. 2016).   Furthermore, complex 
liver models could be used to investigate drug toxicity more intricately, with the 
possibility to model interactions between multiple organ systems and investigate the 
mechanisms of drug pharmacology and toxicity in detail (Bhatia and Ingber 2014; 
Khetani et al. 2015a).  Therefore, although abolishing in vivo studies completely is 
unlikely, many animal-based assays could be replaced with an alternative in vitro 
test system.  In the future these specialised liver models may have a vital role 
throughout the drug development process. 
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